#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=In Vivo Imaging of Translocator Protein, a Marker of Activated Microglia, in Alcohol Dependence
#Text=Neuroinflammation may be a critical component of the neurobiology of alcohol use disorders, yet the exact nature of this relationship is not well understood.
1-1	0-2	In	_	
1-2	3-7	Vivo	_	
1-3	8-15	Imaging	_	
1-4	16-18	of	_	
1-5	19-31	Translocator	_	
1-6	32-39	Protein	_	
1-7	39-40	,	_	
1-8	41-42	a	_	
1-9	43-49	Marker	_	
1-10	50-52	of	_	
1-11	53-62	Activated	_	
1-12	63-72	Microglia	_	
1-13	72-73	,	_	
1-14	74-76	in	_	
1-15	77-84	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-16	85-95	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-17	96-113	Neuroinflammation	_	
1-18	114-117	may	_	
1-19	118-120	be	_	
1-20	121-122	a	_	
1-21	123-131	critical	_	
1-22	132-141	component	_	
1-23	142-144	of	_	
1-24	145-148	the	_	
1-25	149-161	neurobiology	_	
1-26	162-164	of	_	
1-27	165-172	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
1-28	173-176	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
1-29	177-186	disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
1-30	186-187	,	_	
1-31	188-191	yet	_	
1-32	192-195	the	_	
1-33	196-201	exact	_	
1-34	202-208	nature	_	
1-35	209-211	of	_	
1-36	212-216	this	_	
1-37	217-229	relationship	_	
1-38	230-232	is	_	
1-39	233-236	not	_	
1-40	237-241	well	_	
1-41	242-252	understood	_	
1-42	252-253	.	_	

#Text=This work compared the brain and peripheral immune profile of alcohol dependent subjects and controls.
2-1	254-258	This	_	
2-2	259-263	work	_	
2-3	264-272	compared	_	
2-4	273-276	the	_	
2-5	277-282	brain	_	
2-6	283-286	and	_	
2-7	287-297	peripheral	_	
2-8	298-304	immune	_	
2-9	305-312	profile	_	
2-10	313-315	of	_	
2-11	316-323	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
2-12	324-333	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
2-13	334-342	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
2-14	343-346	and	_	
2-15	347-355	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
2-16	355-356	.	_	

#Text=Brain levels of 18-kDa translocator protein (TSPO), a marker of microglial activation and neuroinflammation, were measured with [11C]PBR28 positron emission tomography imaging in 15 healthy controls and 15 alcohol dependent subjects.
3-1	357-362	Brain	_	
3-2	363-369	levels	_	
3-3	370-372	of	_	
3-4	373-375	18	_	
3-5	375-376	-	_	
3-6	376-379	kDa	_	
3-7	380-392	translocator	_	
3-8	393-400	protein	_	
3-9	401-402	(	_	
3-10	402-406	TSPO	_	
3-11	406-407	)	_	
3-12	407-408	,	_	
3-13	409-410	a	_	
3-14	411-417	marker	_	
3-15	418-420	of	_	
3-16	421-431	microglial	_	
3-17	432-442	activation	_	
3-18	443-446	and	_	
3-19	447-464	neuroinflammation	_	
3-20	464-465	,	_	
3-21	466-470	were	_	
3-22	471-479	measured	_	
3-23	480-484	with	_	
3-24	485-486	[	_	
3-25	486-489	11C	_	
3-26	489-490	]	_	
3-27	490-495	PBR28	_	
3-28	496-504	positron	_	
3-29	505-513	emission	_	
3-30	514-524	tomography	_	
3-31	525-532	imaging	_	
3-32	533-535	in	_	
3-33	536-538	15	_	
3-34	539-546	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-35	547-555	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-36	556-559	and	_	
3-37	560-562	15	_	
3-38	563-570	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]	
3-39	571-580	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]	
3-40	581-589	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]	
3-41	589-590	.	_	

#Text=Alcohol dependent subjects were imaged 1-4 days (n=14) or 24 days (n=1) after their last drink.
4-1	591-598	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]	
4-2	599-608	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]	
4-3	609-617	subjects	_	
4-4	618-622	were	_	
4-5	623-629	imaged	_	
4-6	630-631	1	_	
4-7	631-632	-	_	
4-8	632-633	4	_	
4-9	634-638	days	_	
4-10	639-640	(	_	
4-11	640-641	n	_	
4-12	641-642	=	_	
4-13	642-644	14	_	
4-14	644-645	)	_	
4-15	646-648	or	_	
4-16	649-651	24	_	
4-17	652-656	days	_	
4-18	657-658	(	_	
4-19	658-659	n	_	
4-20	659-660	=	_	
4-21	660-661	1	_	
4-22	661-662	)	_	
4-23	663-668	after	_	
4-24	669-674	their	_	
4-25	675-679	last	_	
4-26	680-685	drink	_	
4-27	685-686	.	_	

#Text=Linear mixed modeling of partial volume corrected [11C]PBR28 data revealed a main effect of alcohol dependence (p=0.034), corresponding to 10% lower TSPO levels in alcohol dependent subjects.
5-1	687-693	Linear	_	
5-2	694-699	mixed	_	
5-3	700-708	modeling	_	
5-4	709-711	of	_	
5-5	712-719	partial	_	
5-6	720-726	volume	_	
5-7	727-736	corrected	_	
5-8	737-738	[	_	
5-9	738-741	11C	_	
5-10	741-742	]	_	
5-11	742-747	PBR28	_	
5-12	748-752	data	_	
5-13	753-761	revealed	_	
5-14	762-763	a	_	
5-15	764-768	main	_	
5-16	769-775	effect	_	
5-17	776-778	of	_	
5-18	779-786	alcohol	_	
5-19	787-797	dependence	_	
5-20	798-799	(	_	
5-21	799-800	p	_	
5-22	800-801	=	_	
5-23	801-806	0.034	_	
5-24	806-807	)	_	
5-25	807-808	,	_	
5-26	809-822	corresponding	_	
5-27	823-825	to	_	
5-28	826-829	10%	_	
5-29	830-835	lower	_	
5-30	836-840	TSPO	_	
5-31	841-847	levels	_	
5-32	848-850	in	_	
5-33	851-858	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]	
5-34	859-868	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]	
5-35	869-877	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]	
5-36	877-878	.	_	

#Text=Within this group, exploratory analyses found a negative association of TSPO levels in hippocampus and striatum with alcohol dependence severity (p<0.035).
6-1	879-885	Within	_	
6-2	886-890	this	_	
6-3	891-896	group	_	
6-4	896-897	,	_	
6-5	898-909	exploratory	_	
6-6	910-918	analyses	_	
6-7	919-924	found	_	
6-8	925-926	a	_	
6-9	927-935	negative	_	
6-10	936-947	association	_	
6-11	948-950	of	_	
6-12	951-955	TSPO	_	
6-13	956-962	levels	_	
6-14	963-965	in	_	
6-15	966-977	hippocampus	_	
6-16	978-981	and	_	
6-17	982-990	striatum	_	
6-18	991-995	with	_	
6-19	996-1003	alcohol	_	
6-20	1004-1014	dependence	_	
6-21	1015-1023	severity	_	
6-22	1024-1025	(	_	
6-23	1025-1026	p	_	
6-24	1026-1027	<	_	
6-25	1027-1032	0.035	_	
6-26	1032-1033	)	_	
6-27	1033-1034	.	_	

#Text=Peripheral immune response was assessed in a subset of subjects by measuring cytokine expression from monocytes cultured both in the presence and absence of lipopolysaccharide.
7-1	1035-1045	Peripheral	_	
7-2	1046-1052	immune	_	
7-3	1053-1061	response	_	
7-4	1062-1065	was	_	
7-5	1066-1074	assessed	_	
7-6	1075-1077	in	_	
7-7	1078-1079	a	_	
7-8	1080-1086	subset	_	
7-9	1087-1089	of	_	
7-10	1090-1098	subjects	_	
7-11	1099-1101	by	_	
7-12	1102-1111	measuring	_	
7-13	1112-1120	cytokine	_	
7-14	1121-1131	expression	_	
7-15	1132-1136	from	_	
7-16	1137-1146	monocytes	_	
7-17	1147-1155	cultured	_	
7-18	1156-1160	both	_	
7-19	1161-1163	in	_	
7-20	1164-1167	the	_	
7-21	1168-1176	presence	_	
7-22	1177-1180	and	_	
7-23	1181-1188	absence	_	
7-24	1189-1191	of	_	
7-25	1192-1210	lipopolysaccharide	_	
7-26	1210-1211	.	_	

#Text=Peripheral monocyte response to lipopolysaccharide stimulation was lower in alcohol dependent subjects compared to controls for the pro-inflammatory cytokines IL-6 and IL-8.
8-1	1212-1222	Peripheral	_	
8-2	1223-1231	monocyte	_	
8-3	1232-1240	response	_	
8-4	1241-1243	to	_	
8-5	1244-1262	lipopolysaccharide	_	
8-6	1263-1274	stimulation	_	
8-7	1275-1278	was	_	
8-8	1279-1284	lower	_	
8-9	1285-1287	in	_	
8-10	1288-1295	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]	
8-11	1296-1305	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]	
8-12	1306-1314	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]	
8-13	1315-1323	compared	_	
8-14	1324-1326	to	_	
8-15	1327-1335	controls	_	
8-16	1336-1339	for	_	
8-17	1340-1343	the	_	
8-18	1344-1360	pro-inflammatory	_	
8-19	1361-1370	cytokines	_	
8-20	1371-1373	IL	_	
8-21	1373-1374	-	_	
8-22	1374-1375	6	_	
8-23	1376-1379	and	_	
8-24	1380-1382	IL	_	
8-25	1382-1383	-	_	
8-26	1383-1384	8	_	
8-27	1384-1385	.	_	

#Text=Thus, alcohol dependent individuals exhibited less activated microglia in brain and a blunted peripheral pro-inflammatory response compared to controls.
9-1	1386-1390	Thus	_	
9-2	1390-1391	,	_	
9-3	1392-1399	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]	
9-4	1400-1409	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]	
9-5	1410-1421	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]	
9-6	1422-1431	exhibited	_	
9-7	1432-1436	less	_	
9-8	1437-1446	activated	_	
9-9	1447-1456	microglia	_	
9-10	1457-1459	in	_	
9-11	1460-1465	brain	_	
9-12	1466-1469	and	_	
9-13	1470-1471	a	_	
9-14	1472-1479	blunted	_	
9-15	1480-1490	peripheral	_	
9-16	1491-1507	pro-inflammatory	_	
9-17	1508-1516	response	_	
9-18	1517-1525	compared	_	
9-19	1526-1528	to	_	
9-20	1529-1537	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
9-21	1537-1538	.	_	

#Text=These findings suggest a role for pharmaceuticals tuning the neuroimmune system as therapeutics for alcohol dependence.
10-1	1539-1544	These	_	
10-2	1545-1553	findings	_	
10-3	1554-1561	suggest	_	
10-4	1562-1563	a	_	
10-5	1564-1568	role	_	
10-6	1569-1572	for	_	
10-7	1573-1588	pharmaceuticals	_	
10-8	1589-1595	tuning	_	
10-9	1596-1599	the	_	
10-10	1600-1611	neuroimmune	_	
10-11	1612-1618	system	_	
10-12	1619-1621	as	_	
10-13	1622-1634	therapeutics	_	
10-14	1635-1638	for	_	
10-15	1639-1646	alcohol	_	
10-16	1647-1657	dependence	_	
10-17	1657-1658	.	_	

#Text=Introduction
#Text=Alcohol abuse is a leading cause of preventable death, and can cause or detrimentally affect over 200 health conditions.
11-1	1659-1671	Introduction	_	
11-2	1672-1679	Alcohol	_	
11-3	1680-1685	abuse	_	
11-4	1686-1688	is	_	
11-5	1689-1690	a	_	
11-6	1691-1698	leading	_	
11-7	1699-1704	cause	_	
11-8	1705-1707	of	_	
11-9	1708-1719	preventable	_	
11-10	1720-1725	death	_	
11-11	1725-1726	,	_	
11-12	1727-1730	and	_	
11-13	1731-1734	can	_	
11-14	1735-1740	cause	_	
11-15	1741-1743	or	_	
11-16	1744-1757	detrimentally	_	
11-17	1758-1764	affect	_	
11-18	1765-1769	over	_	
11-19	1770-1773	200	_	
11-20	1774-1780	health	_	
11-21	1781-1791	conditions	_	
11-22	1791-1792	.	_	

#Text=Many of these conditions, including alcoholic liver disease, sepsis, and diminished immunity, can be classified as alcohol-attributed immunodeficiencies.
12-1	1793-1797	Many	_	
12-2	1798-1800	of	_	
12-3	1801-1806	these	_	
12-4	1807-1817	conditions	_	
12-5	1817-1818	,	_	
12-6	1819-1828	including	_	
12-7	1829-1838	alcoholic	_	
12-8	1839-1844	liver	_	
12-9	1845-1852	disease	_	
12-10	1852-1853	,	_	
12-11	1854-1860	sepsis	_	
12-12	1860-1861	,	_	
12-13	1862-1865	and	_	
12-14	1866-1876	diminished	_	
12-15	1877-1885	immunity	_	
12-16	1885-1886	,	_	
12-17	1887-1890	can	_	
12-18	1891-1893	be	_	
12-19	1894-1904	classified	_	
12-20	1905-1907	as	_	
12-21	1908-1926	alcohol-attributed	_	
12-22	1927-1945	immunodeficiencies	_	
12-23	1945-1946	.	_	

#Text=Other changes to innate immune function caused by alcohol dependence include increased blood levels of peripheral immune signaling proteins such as cytokines.
13-1	1947-1952	Other	_	
13-2	1953-1960	changes	_	
13-3	1961-1963	to	_	
13-4	1964-1970	innate	_	
13-5	1971-1977	immune	_	
13-6	1978-1986	function	_	
13-7	1987-1993	caused	_	
13-8	1994-1996	by	_	
13-9	1997-2004	alcohol	_	
13-10	2005-2015	dependence	_	
13-11	2016-2023	include	_	
13-12	2024-2033	increased	_	
13-13	2034-2039	blood	_	
13-14	2040-2046	levels	_	
13-15	2047-2049	of	_	
13-16	2050-2060	peripheral	_	
13-17	2061-2067	immune	_	
13-18	2068-2077	signaling	_	
13-19	2078-2086	proteins	_	
13-20	2087-2091	such	_	
13-21	2092-2094	as	_	
13-22	2095-2104	cytokines	_	
13-23	2104-2105	.	_	

#Text=These observations provide clear evidence that alcohol dependence broadly alters the function of the peripheral immune system.
14-1	2106-2111	These	_	
14-2	2112-2124	observations	_	
14-3	2125-2132	provide	_	
14-4	2133-2138	clear	_	
14-5	2139-2147	evidence	_	
14-6	2148-2152	that	_	
14-7	2153-2160	alcohol	_	
14-8	2161-2171	dependence	_	
14-9	2172-2179	broadly	_	
14-10	2180-2186	alters	_	
14-11	2187-2190	the	_	
14-12	2191-2199	function	_	
14-13	2200-2202	of	_	
14-14	2203-2206	the	_	
14-15	2207-2217	peripheral	_	
14-16	2218-2224	immune	_	
14-17	2225-2231	system	_	
14-18	2231-2232	.	_	

#Text=Alcohol dependence also damages the brain, causing gray matter atrophy, neurodegeneration, and a variety of cognitive impairments.
15-1	2233-2240	Alcohol	_	
15-2	2241-2251	dependence	_	
15-3	2252-2256	also	_	
15-4	2257-2264	damages	_	
15-5	2265-2268	the	_	
15-6	2269-2274	brain	_	
15-7	2274-2275	,	_	
15-8	2276-2283	causing	_	
15-9	2284-2288	gray	_	
15-10	2289-2295	matter	_	
15-11	2296-2303	atrophy	_	
15-12	2303-2304	,	_	
15-13	2305-2322	neurodegeneration	_	
15-14	2322-2323	,	_	
15-15	2324-2327	and	_	
15-16	2328-2329	a	_	
15-17	2330-2337	variety	_	
15-18	2338-2340	of	_	
15-19	2341-2350	cognitive	_	
15-20	2351-2362	impairments	_	
15-21	2362-2363	.	_	

#Text=There may be an important link between brain changes and immune changes induced by alcohol dependence.
16-1	2364-2369	There	_	
16-2	2370-2373	may	_	
16-3	2374-2376	be	_	
16-4	2377-2379	an	_	
16-5	2380-2389	important	_	
16-6	2390-2394	link	_	
16-7	2395-2402	between	_	
16-8	2403-2408	brain	_	
16-9	2409-2416	changes	_	
16-10	2417-2420	and	_	
16-11	2421-2427	immune	_	
16-12	2428-2435	changes	_	
16-13	2436-2443	induced	_	
16-14	2444-2446	by	_	
16-15	2447-2454	alcohol	_	
16-16	2455-2465	dependence	_	
16-17	2465-2466	.	_	

#Text=The effects of alcohol on the neuroimmune system have been a topic of much recent preclinical research (see  for review).
17-1	2467-2470	The	_	
17-2	2471-2478	effects	_	
17-3	2479-2481	of	_	
17-4	2482-2489	alcohol	_	
17-5	2490-2492	on	_	
17-6	2493-2496	the	_	
17-7	2497-2508	neuroimmune	_	
17-8	2509-2515	system	_	
17-9	2516-2520	have	_	
17-10	2521-2525	been	_	
17-11	2526-2527	a	_	
17-12	2528-2533	topic	_	
17-13	2534-2536	of	_	
17-14	2537-2541	much	_	
17-15	2542-2548	recent	_	
17-16	2549-2560	preclinical	_	
17-17	2561-2569	research	_	
17-18	2570-2571	(	_	
17-19	2571-2574	see	_	
17-20	2576-2579	for	_	
17-21	2580-2586	review	_	
17-22	2586-2587	)	_	
17-23	2587-2588	.	_	

#Text=Yet, possible associations between clinical alcohol dependence and the brain’s neuroimmune system are poorly understood.
18-1	2589-2592	Yet	_	
18-2	2592-2593	,	_	
18-3	2594-2602	possible	_	
18-4	2603-2615	associations	_	
18-5	2616-2623	between	_	
18-6	2624-2632	clinical	_	
18-7	2633-2640	alcohol	_	
18-8	2641-2651	dependence	_	
18-9	2652-2655	and	_	
18-10	2656-2659	the	_	
18-11	2660-2665	brain	_	
18-12	2665-2666	’	_	
18-13	2666-2667	s	_	
18-14	2668-2679	neuroimmune	_	
18-15	2680-2686	system	_	
18-16	2687-2690	are	_	
18-17	2691-2697	poorly	_	
18-18	2698-2708	understood	_	
18-19	2708-2709	.	_	

#Text=Microglia are brain cells that are resident macrophages of the central nervous system critical to the brain’s immune function.
19-1	2710-2719	Microglia	_	
19-2	2720-2723	are	_	
19-3	2724-2729	brain	_	
19-4	2730-2735	cells	_	
19-5	2736-2740	that	_	
19-6	2741-2744	are	_	
19-7	2745-2753	resident	_	
19-8	2754-2765	macrophages	_	
19-9	2766-2768	of	_	
19-10	2769-2772	the	_	
19-11	2773-2780	central	_	
19-12	2781-2788	nervous	_	
19-13	2789-2795	system	_	
19-14	2796-2804	critical	_	
19-15	2805-2807	to	_	
19-16	2808-2811	the	_	
19-17	2812-2817	brain	_	
19-18	2817-2818	’	_	
19-19	2818-2819	s	_	
19-20	2820-2826	immune	_	
19-21	2827-2835	function	_	
19-22	2835-2836	.	_	

#Text=Under normal conditions, microglia exist in a ‘resting’ state that is regulated closely by interactions with neurons.
20-1	2837-2842	Under	_	
20-2	2843-2849	normal	_	
20-3	2850-2860	conditions	_	
20-4	2860-2861	,	_	
20-5	2862-2871	microglia	_	
20-6	2872-2877	exist	_	
20-7	2878-2880	in	_	
20-8	2881-2882	a	_	
20-9	2883-2884	‘	_	
20-10	2884-2891	resting	_	
20-11	2891-2892	’	_	
20-12	2893-2898	state	_	
20-13	2899-2903	that	_	
20-14	2904-2906	is	_	
20-15	2907-2916	regulated	_	
20-16	2917-2924	closely	_	
20-17	2925-2927	by	_	
20-18	2928-2940	interactions	_	
20-19	2941-2945	with	_	
20-20	2946-2953	neurons	_	
20-21	2953-2954	.	_	

#Text=However, microglia become activated by signals indicating the presence of tissue damage or pathogens.
21-1	2955-2962	However	_	
21-2	2962-2963	,	_	
21-3	2964-2973	microglia	_	
21-4	2974-2980	become	_	
21-5	2981-2990	activated	_	
21-6	2991-2993	by	_	
21-7	2994-3001	signals	_	
21-8	3002-3012	indicating	_	
21-9	3013-3016	the	_	
21-10	3017-3025	presence	_	
21-11	3026-3028	of	_	
21-12	3029-3035	tissue	_	
21-13	3036-3042	damage	_	
21-14	3043-3045	or	_	
21-15	3046-3055	pathogens	_	
21-16	3055-3056	.	_	

#Text=This microglial activation is a key process in the initiation and maintenance of neuroinflammation.
22-1	3057-3061	This	_	
22-2	3062-3072	microglial	_	
22-3	3073-3083	activation	_	
22-4	3084-3086	is	_	
22-5	3087-3088	a	_	
22-6	3089-3092	key	_	
22-7	3093-3100	process	_	
22-8	3101-3103	in	_	
22-9	3104-3107	the	_	
22-10	3108-3118	initiation	_	
22-11	3119-3122	and	_	
22-12	3123-3134	maintenance	_	
22-13	3135-3137	of	_	
22-14	3138-3155	neuroinflammation	_	
22-15	3155-3156	.	_	

#Text=Although activated microglia serve necessary repair functions, excessive microglial activation may lead to the release of substances such as inflammatory cytokines, reactive oxygen species, nitric oxide, and glutamate that can cause neuronal dysfunction and death.
23-1	3157-3165	Although	_	
23-2	3166-3175	activated	_	
23-3	3176-3185	microglia	_	
23-4	3186-3191	serve	_	
23-5	3192-3201	necessary	_	
23-6	3202-3208	repair	_	
23-7	3209-3218	functions	_	
23-8	3218-3219	,	_	
23-9	3220-3229	excessive	_	
23-10	3230-3240	microglial	_	
23-11	3241-3251	activation	_	
23-12	3252-3255	may	_	
23-13	3256-3260	lead	_	
23-14	3261-3263	to	_	
23-15	3264-3267	the	_	
23-16	3268-3275	release	_	
23-17	3276-3278	of	_	
23-18	3279-3289	substances	_	
23-19	3290-3294	such	_	
23-20	3295-3297	as	_	
23-21	3298-3310	inflammatory	_	
23-22	3311-3320	cytokines	_	
23-23	3320-3321	,	_	
23-24	3322-3330	reactive	_	
23-25	3331-3337	oxygen	_	
23-26	3338-3345	species	_	
23-27	3345-3346	,	_	
23-28	3347-3353	nitric	_	
23-29	3354-3359	oxide	_	
23-30	3359-3360	,	_	
23-31	3361-3364	and	_	
23-32	3365-3374	glutamate	_	
23-33	3375-3379	that	_	
23-34	3380-3383	can	_	
23-35	3384-3389	cause	_	
23-36	3390-3398	neuronal	_	
23-37	3399-3410	dysfunction	_	
23-38	3411-3414	and	_	
23-39	3415-3420	death	_	
23-40	3420-3421	.	_	

#Text=The type of microglial activation depends in part on the type of molecular signal: pro-inflammatory cytokines such as tissue necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) lead to a pro-inflammatory phenotype which can contribute to neuronal loss, while exposure to anti-inflammatory cytokines induces a neuroprotective phenotype in microglia.
24-1	3422-3425	The	_	
24-2	3426-3430	type	_	
24-3	3431-3433	of	_	
24-4	3434-3444	microglial	_	
24-5	3445-3455	activation	_	
24-6	3456-3463	depends	_	
24-7	3464-3466	in	_	
24-8	3467-3471	part	_	
24-9	3472-3474	on	_	
24-10	3475-3478	the	_	
24-11	3479-3483	type	_	
24-12	3484-3486	of	_	
24-13	3487-3496	molecular	_	
24-14	3497-3503	signal	_	
24-15	3503-3504	:	_	
24-16	3505-3521	pro-inflammatory	_	
24-17	3522-3531	cytokines	_	
24-18	3532-3536	such	_	
24-19	3537-3539	as	_	
24-20	3540-3546	tissue	_	
24-21	3547-3555	necrosis	_	
24-22	3556-3564	factor-α	_	
24-23	3565-3566	(	_	
24-24	3566-3571	TNF-α	_	
24-25	3571-3572	)	_	
24-26	3573-3576	and	_	
24-27	3577-3588	interleukin	_	
24-28	3588-3589	-	_	
24-29	3589-3591	1β	_	
24-30	3592-3593	(	_	
24-31	3593-3595	IL	_	
24-32	3595-3596	-	_	
24-33	3596-3598	1β	_	
24-34	3598-3599	)	_	
24-35	3600-3604	lead	_	
24-36	3605-3607	to	_	
24-37	3608-3609	a	_	
24-38	3610-3626	pro-inflammatory	_	
24-39	3627-3636	phenotype	_	
24-40	3637-3642	which	_	
24-41	3643-3646	can	_	
24-42	3647-3657	contribute	_	
24-43	3658-3660	to	_	
24-44	3661-3669	neuronal	_	
24-45	3670-3674	loss	_	
24-46	3674-3675	,	_	
24-47	3676-3681	while	_	
24-48	3682-3690	exposure	_	
24-49	3691-3693	to	_	
24-50	3694-3711	anti-inflammatory	_	
24-51	3712-3721	cytokines	_	
24-52	3722-3729	induces	_	
24-53	3730-3731	a	_	
24-54	3732-3747	neuroprotective	_	
24-55	3748-3757	phenotype	_	
24-56	3758-3760	in	_	
24-57	3761-3770	microglia	_	
24-58	3770-3771	.	_	

#Text=Preclinical studies indicate that an initial alcohol binge activates microglia into a neuroprotective state.
25-1	3772-3783	Preclinical	_	
25-2	3784-3791	studies	_	
25-3	3792-3800	indicate	_	
25-4	3801-3805	that	_	
25-5	3806-3808	an	_	
25-6	3809-3816	initial	_	
25-7	3817-3824	alcohol	_	
25-8	3825-3830	binge	_	
25-9	3831-3840	activates	_	
25-10	3841-3850	microglia	_	
25-11	3851-3855	into	_	
25-12	3856-3857	a	_	
25-13	3858-3873	neuroprotective	_	
25-14	3874-3879	state	_	
25-15	3879-3880	.	_	

#Text=An initial activation may “prime” microglia for subsequent alcohol doses, resulting in a classically activated proinflammatory state.
26-1	3881-3883	An	_	
26-2	3884-3891	initial	_	
26-3	3892-3902	activation	_	
26-4	3903-3906	may	_	
26-5	3907-3908	“	_	
26-6	3908-3913	prime	_	
26-7	3913-3914	”	_	
26-8	3915-3924	microglia	_	
26-9	3925-3928	for	_	
26-10	3929-3939	subsequent	_	
26-11	3940-3947	alcohol	_	
26-12	3948-3953	doses	_	
26-13	3953-3954	,	_	
26-14	3955-3964	resulting	_	
26-15	3965-3967	in	_	
26-16	3968-3969	a	_	
26-17	3970-3981	classically	_	
26-18	3982-3991	activated	_	
26-19	3992-4007	proinflammatory	_	
26-20	4008-4013	state	_	
26-21	4013-4014	.	_	

#Text=When this proinflammatory state becomes chronic, such as during a sustained alcohol binge, neurodegeneration and diminished neural function may occur.
27-1	4015-4019	When	_	
27-2	4020-4024	this	_	
27-3	4025-4040	proinflammatory	_	
27-4	4041-4046	state	_	
27-5	4047-4054	becomes	_	
27-6	4055-4062	chronic	_	
27-7	4062-4063	,	_	
27-8	4064-4068	such	_	
27-9	4069-4071	as	_	
27-10	4072-4078	during	_	
27-11	4079-4080	a	_	
27-12	4081-4090	sustained	_	
27-13	4091-4098	alcohol	_	
27-14	4099-4104	binge	_	
27-15	4104-4105	,	_	
27-16	4106-4123	neurodegeneration	_	
27-17	4124-4127	and	_	
27-18	4128-4138	diminished	_	
27-19	4139-4145	neural	_	
27-20	4146-4154	function	_	
27-21	4155-4158	may	_	
27-22	4159-4164	occur	_	
27-23	4164-4165	.	_	

#Text=Thus, microglial activation represents a potential mechanism through which alcohol interferes with neuronal function, ultimately leading to neurodegeneration.
28-1	4166-4170	Thus	_	
28-2	4170-4171	,	_	
28-3	4172-4182	microglial	_	
28-4	4183-4193	activation	_	
28-5	4194-4204	represents	_	
28-6	4205-4206	a	_	
28-7	4207-4216	potential	_	
28-8	4217-4226	mechanism	_	
28-9	4227-4234	through	_	
28-10	4235-4240	which	_	
28-11	4241-4248	alcohol	_	
28-12	4249-4259	interferes	_	
28-13	4260-4264	with	_	
28-14	4265-4273	neuronal	_	
28-15	4274-4282	function	_	
28-16	4282-4283	,	_	
28-17	4284-4294	ultimately	_	
28-18	4295-4302	leading	_	
28-19	4303-4305	to	_	
28-20	4306-4323	neurodegeneration	_	
28-21	4323-4324	.	_	

#Text=For this reason, therapies targeting microglia and neuroimmune function are of great interest for treating alcohol dependence.
29-1	4325-4328	For	_	
29-2	4329-4333	this	_	
29-3	4334-4340	reason	_	
29-4	4340-4341	,	_	
29-5	4342-4351	therapies	_	
29-6	4352-4361	targeting	_	
29-7	4362-4371	microglia	_	
29-8	4372-4375	and	_	
29-9	4376-4387	neuroimmune	_	
29-10	4388-4396	function	_	
29-11	4397-4400	are	_	
29-12	4401-4403	of	_	
29-13	4404-4409	great	_	
29-14	4410-4418	interest	_	
29-15	4419-4422	for	_	
29-16	4423-4431	treating	_	
29-17	4432-4439	alcohol	_	
29-18	4440-4450	dependence	_	
29-19	4450-4451	.	_	

#Text=Positron Emission Tomography (PET) imaging can be used to measure levels of activated microglia in vivo using radioligands, such as [11C]PBR28, that bind to the 18-kDa translocator protein (TSPO).
30-1	4452-4460	Positron	_	
30-2	4461-4469	Emission	_	
30-3	4470-4480	Tomography	_	
30-4	4481-4482	(	_	
30-5	4482-4485	PET	_	
30-6	4485-4486	)	_	
30-7	4487-4494	imaging	_	
30-8	4495-4498	can	_	
30-9	4499-4501	be	_	
30-10	4502-4506	used	_	
30-11	4507-4509	to	_	
30-12	4510-4517	measure	_	
30-13	4518-4524	levels	_	
30-14	4525-4527	of	_	
30-15	4528-4537	activated	_	
30-16	4538-4547	microglia	_	
30-17	4548-4550	in	_	
30-18	4551-4555	vivo	_	
30-19	4556-4561	using	_	
30-20	4562-4574	radioligands	_	
30-21	4574-4575	,	_	
30-22	4576-4580	such	_	
30-23	4581-4583	as	_	
30-24	4584-4585	[	_	
30-25	4585-4588	11C	_	
30-26	4588-4589	]	_	
30-27	4589-4594	PBR28	_	
30-28	4594-4595	,	_	
30-29	4596-4600	that	_	
30-30	4601-4605	bind	_	
30-31	4606-4608	to	_	
30-32	4609-4612	the	_	
30-33	4613-4615	18	_	
30-34	4615-4616	-	_	
30-35	4616-4619	kDa	_	
30-36	4620-4632	translocator	_	
30-37	4633-4640	protein	_	
30-38	4641-4642	(	_	
30-39	4642-4646	TSPO	_	
30-40	4646-4647	)	_	
30-41	4647-4648	.	_	

#Text=TSPO is a protein expressed on the outer mitochondrial membrane of microglia.
31-1	4649-4653	TSPO	_	
31-2	4654-4656	is	_	
31-3	4657-4658	a	_	
31-4	4659-4666	protein	_	
31-5	4667-4676	expressed	_	
31-6	4677-4679	on	_	
31-7	4680-4683	the	_	
31-8	4684-4689	outer	_	
31-9	4690-4703	mitochondrial	_	
31-10	4704-4712	membrane	_	
31-11	4713-4715	of	_	
31-12	4716-4725	microglia	_	
31-13	4725-4726	.	_	

#Text=Microglial activation increases TSPO levels, evidenced by multiple reports of a tight relationship between immunohistochemical measures of microglial activation and TSPO levels.
32-1	4727-4737	Microglial	_	
32-2	4738-4748	activation	_	
32-3	4749-4758	increases	_	
32-4	4759-4763	TSPO	_	
32-5	4764-4770	levels	_	
32-6	4770-4771	,	_	
32-7	4772-4781	evidenced	_	
32-8	4782-4784	by	_	
32-9	4785-4793	multiple	_	
32-10	4794-4801	reports	_	
32-11	4802-4804	of	_	
32-12	4805-4806	a	_	
32-13	4807-4812	tight	_	
32-14	4813-4825	relationship	_	
32-15	4826-4833	between	_	
32-16	4834-4853	immunohistochemical	_	
32-17	4854-4862	measures	_	
32-18	4863-4865	of	_	
32-19	4866-4876	microglial	_	
32-20	4877-4887	activation	_	
32-21	4888-4891	and	_	
32-22	4892-4896	TSPO	_	
32-23	4897-4903	levels	_	
32-24	4903-4904	.	_	

#Text=TSPO imaging is therefore thought to provide an in vivo marker of activated microglia levels in brain.
33-1	4905-4909	TSPO	_	
33-2	4910-4917	imaging	_	
33-3	4918-4920	is	_	
33-4	4921-4930	therefore	_	
33-5	4931-4938	thought	_	
33-6	4939-4941	to	_	
33-7	4942-4949	provide	_	
33-8	4950-4952	an	_	
33-9	4953-4955	in	_	
33-10	4956-4960	vivo	_	
33-11	4961-4967	marker	_	
33-12	4968-4970	of	_	
33-13	4971-4980	activated	_	
33-14	4981-4990	microglia	_	
33-15	4991-4997	levels	_	
33-16	4998-5000	in	_	
33-17	5001-5006	brain	_	
33-18	5006-5007	.	_	

#Text=PET imaging of TSPO has been used to investigate clinical neuropathologies such as Alzheimer’s disease, multiple sclerosis, and temporal lobe epilepsy.
34-1	5008-5011	PET	_	
34-2	5012-5019	imaging	_	
34-3	5020-5022	of	_	
34-4	5023-5027	TSPO	_	
34-5	5028-5031	has	_	
34-6	5032-5036	been	_	
34-7	5037-5041	used	_	
34-8	5042-5044	to	_	
34-9	5045-5056	investigate	_	
34-10	5057-5065	clinical	_	
34-11	5066-5082	neuropathologies	_	
34-12	5083-5087	such	_	
34-13	5088-5090	as	_	
34-14	5091-5100	Alzheimer	_	
34-15	5100-5101	’	_	
34-16	5101-5102	s	_	
34-17	5103-5110	disease	_	
34-18	5110-5111	,	_	
34-19	5112-5120	multiple	_	
34-20	5121-5130	sclerosis	_	
34-21	5130-5131	,	_	
34-22	5132-5135	and	_	
34-23	5136-5144	temporal	_	
34-24	5145-5149	lobe	_	
34-25	5150-5158	epilepsy	_	
34-26	5158-5159	.	_	

#Text=To our knowledge, PET imaging of TSPO has not yet been used to study clinical alcohol dependence.
35-1	5160-5162	To	_	
35-2	5163-5166	our	_	
35-3	5167-5176	knowledge	_	
35-4	5176-5177	,	_	
35-5	5178-5181	PET	_	
35-6	5182-5189	imaging	_	
35-7	5190-5192	of	_	
35-8	5193-5197	TSPO	_	
35-9	5198-5201	has	_	
35-10	5202-5205	not	_	
35-11	5206-5209	yet	_	
35-12	5210-5214	been	_	
35-13	5215-5219	used	_	
35-14	5220-5222	to	_	
35-15	5223-5228	study	_	
35-16	5229-5237	clinical	_	
35-17	5238-5245	alcohol	_	
35-18	5246-5256	dependence	_	
35-19	5256-5257	.	_	

#Text=The primary goal of this work was to measure TSPO levels in the brains of individuals with alcohol dependence compared to healthy controls.
36-1	5258-5261	The	_	
36-2	5262-5269	primary	_	
36-3	5270-5274	goal	_	
36-4	5275-5277	of	_	
36-5	5278-5282	this	_	
36-6	5283-5287	work	_	
36-7	5288-5291	was	_	
36-8	5292-5294	to	_	
36-9	5295-5302	measure	_	
36-10	5303-5307	TSPO	_	
36-11	5308-5314	levels	_	
36-12	5315-5317	in	_	
36-13	5318-5321	the	_	
36-14	5322-5328	brains	_	
36-15	5329-5331	of	_	
36-16	5332-5343	individuals	_	
36-17	5344-5348	with	_	
36-18	5349-5356	alcohol	_	
36-19	5357-5367	dependence	_	
36-20	5368-5376	compared	_	
36-21	5377-5379	to	_	
36-22	5380-5387	healthy	_	
36-23	5388-5396	controls	_	
36-24	5396-5397	.	_	

#Text=We hypothesized that alcohol dependence would be associated with higher TSPO levels in brain based on preclinical and post mortem data.
37-1	5398-5400	We	_	
37-2	5401-5413	hypothesized	_	
37-3	5414-5418	that	_	
37-4	5419-5426	alcohol	_	
37-5	5427-5437	dependence	_	
37-6	5438-5443	would	_	
37-7	5444-5446	be	_	
37-8	5447-5457	associated	_	
37-9	5458-5462	with	_	
37-10	5463-5469	higher	_	
37-11	5470-5474	TSPO	_	
37-12	5475-5481	levels	_	
37-13	5482-5484	in	_	
37-14	5485-5490	brain	_	
37-15	5491-5496	based	_	
37-16	5497-5499	on	_	
37-17	5500-5511	preclinical	_	
37-18	5512-5515	and	_	
37-19	5516-5520	post	_	
37-20	5521-5527	mortem	_	
37-21	5528-5532	data	_	
37-22	5532-5533	.	_	

#Text=In particular, the frontal-striatal and frontal-cerebellar circuits are heavily implicated in neurodegeneration associated with heavy alcohol use, while the hippocampus is implicated in dysregulated neuroimmune function.
38-1	5534-5536	In	_	
38-2	5537-5547	particular	_	
38-3	5547-5548	,	_	
38-4	5549-5552	the	_	
38-5	5553-5569	frontal-striatal	_	
38-6	5570-5573	and	_	
38-7	5574-5592	frontal-cerebellar	_	
38-8	5593-5601	circuits	_	
38-9	5602-5605	are	_	
38-10	5606-5613	heavily	_	
38-11	5614-5624	implicated	_	
38-12	5625-5627	in	_	
38-13	5628-5645	neurodegeneration	_	
38-14	5646-5656	associated	_	
38-15	5657-5661	with	_	
38-16	5662-5667	heavy	_	
38-17	5668-5675	alcohol	_	
38-18	5676-5679	use	_	
38-19	5679-5680	,	_	
38-20	5681-5686	while	_	
38-21	5687-5690	the	_	
38-22	5691-5702	hippocampus	_	
38-23	5703-5705	is	_	
38-24	5706-5716	implicated	_	
38-25	5717-5719	in	_	
38-26	5720-5732	dysregulated	_	
38-27	5733-5744	neuroimmune	_	
38-28	5745-5753	function	_	
38-29	5753-5754	.	_	

#Text=Thus our analysis focused on these four regions of frontal cortex, striatum, cerebellum, and hippocampus.
39-1	5755-5759	Thus	_	
39-2	5760-5763	our	_	
39-3	5764-5772	analysis	_	
39-4	5773-5780	focused	_	
39-5	5781-5783	on	_	
39-6	5784-5789	these	_	
39-7	5790-5794	four	_	
39-8	5795-5802	regions	_	
39-9	5803-5805	of	_	
39-10	5806-5813	frontal	_	
39-11	5814-5820	cortex	_	
39-12	5820-5821	,	_	
39-13	5822-5830	striatum	_	
39-14	5830-5831	,	_	
39-15	5832-5842	cerebellum	_	
39-16	5842-5843	,	_	
39-17	5844-5847	and	_	
39-18	5848-5859	hippocampus	_	
39-19	5859-5860	.	_	

#Text=To accomplish this goal, [11C]PBR28 PET scans were acquired in 15 alcohol dependent subjects and 15 healthy controls matched for age, sex, and rs6971 single nucleotide polymorphism (SNP) genotype, which affects the affinity of [11C]PBR28 for TSPO.
40-1	5861-5863	To	_	
40-2	5864-5874	accomplish	_	
40-3	5875-5879	this	_	
40-4	5880-5884	goal	_	
40-5	5884-5885	,	_	
40-6	5886-5887	[	_	
40-7	5887-5890	11C	_	
40-8	5890-5891	]	_	
40-9	5891-5896	PBR28	_	
40-10	5897-5900	PET	_	
40-11	5901-5906	scans	_	
40-12	5907-5911	were	_	
40-13	5912-5920	acquired	_	
40-14	5921-5923	in	_	
40-15	5924-5926	15	_	
40-16	5927-5934	alcohol	_	
40-17	5935-5944	dependent	_	
40-18	5945-5953	subjects	_	
40-19	5954-5957	and	_	
40-20	5958-5960	15	_	
40-21	5961-5968	healthy	_	
40-22	5969-5977	controls	_	
40-23	5978-5985	matched	_	
40-24	5986-5989	for	_	
40-25	5990-5993	age	_	
40-26	5993-5994	,	_	
40-27	5995-5998	sex	_	
40-28	5998-5999	,	_	
40-29	6000-6003	and	_	
40-30	6004-6010	rs6971	_	
40-31	6011-6017	single	_	
40-32	6018-6028	nucleotide	_	
40-33	6029-6041	polymorphism	_	
40-34	6042-6043	(	_	
40-35	6043-6046	SNP	_	
40-36	6046-6047	)	_	
40-37	6048-6056	genotype	_	
40-38	6056-6057	,	_	
40-39	6058-6063	which	_	
40-40	6064-6071	affects	_	
40-41	6072-6075	the	_	
40-42	6076-6084	affinity	_	
40-43	6085-6087	of	_	
40-44	6088-6089	[	_	
40-45	6089-6092	11C	_	
40-46	6092-6093	]	_	
40-47	6093-6098	PBR28	_	
40-48	6099-6102	for	_	
40-49	6103-6107	TSPO	_	
40-50	6107-6108	.	_	

#Text=A secondary aim was to assess peripheral innate immune response in a subset of these subjects.
41-1	6109-6110	A	_	
41-2	6111-6120	secondary	_	
41-3	6121-6124	aim	_	
41-4	6125-6128	was	_	
41-5	6129-6131	to	_	
41-6	6132-6138	assess	_	
41-7	6139-6149	peripheral	_	
41-8	6150-6156	innate	_	
41-9	6157-6163	immune	_	
41-10	6164-6172	response	_	
41-11	6173-6175	in	_	
41-12	6176-6177	a	_	
41-13	6178-6184	subset	_	
41-14	6185-6187	of	_	
41-15	6188-6193	these	_	
41-16	6194-6202	subjects	_	
41-17	6202-6203	.	_	

#Text=To accomplish this goal, venous monocytes were stimulated with lipopolysaccharide (LPS, also known as endotoxin) to robustly trigger “classic” monocyte activation, and changes in inflammatory cytokine levels in LPS-incubated samples were measured.
42-1	6204-6206	To	_	
42-2	6207-6217	accomplish	_	
42-3	6218-6222	this	_	
42-4	6223-6227	goal	_	
42-5	6227-6228	,	_	
42-6	6229-6235	venous	_	
42-7	6236-6245	monocytes	_	
42-8	6246-6250	were	_	
42-9	6251-6261	stimulated	_	
42-10	6262-6266	with	_	
42-11	6267-6285	lipopolysaccharide	_	
42-12	6286-6287	(	_	
42-13	6287-6290	LPS	_	
42-14	6290-6291	,	_	
42-15	6292-6296	also	_	
42-16	6297-6302	known	_	
42-17	6303-6305	as	_	
42-18	6306-6315	endotoxin	_	
42-19	6315-6316	)	_	
42-20	6317-6319	to	_	
42-21	6320-6328	robustly	_	
42-22	6329-6336	trigger	_	
42-23	6337-6338	“	_	
42-24	6338-6345	classic	_	
42-25	6345-6346	”	_	
42-26	6347-6355	monocyte	_	
42-27	6356-6366	activation	_	
42-28	6366-6367	,	_	
42-29	6368-6371	and	_	
42-30	6372-6379	changes	_	
42-31	6380-6382	in	_	
42-32	6383-6395	inflammatory	_	
42-33	6396-6404	cytokine	_	
42-34	6405-6411	levels	_	
42-35	6412-6414	in	_	
42-36	6415-6428	LPS-incubated	_	
42-37	6429-6436	samples	_	
42-38	6437-6441	were	_	
42-39	6442-6450	measured	_	
42-40	6450-6451	.	_	

#Text=While baseline cytokine levels in periphery are higher in alcohol dependence compared to healthy controls, previous studies reported a reduced cytokine response in periphery to inflammatory insult in alcohol dependence.
43-1	6452-6457	While	_	
43-2	6458-6466	baseline	_	
43-3	6467-6475	cytokine	_	
43-4	6476-6482	levels	_	
43-5	6483-6485	in	_	
43-6	6486-6495	periphery	_	
43-7	6496-6499	are	_	
43-8	6500-6506	higher	_	
43-9	6507-6509	in	_	
43-10	6510-6517	alcohol	_	
43-11	6518-6528	dependence	_	
43-12	6529-6537	compared	_	
43-13	6538-6540	to	_	
43-14	6541-6548	healthy	_	
43-15	6549-6557	controls	_	
43-16	6557-6558	,	_	
43-17	6559-6567	previous	_	
43-18	6568-6575	studies	_	
43-19	6576-6584	reported	_	
43-20	6585-6586	a	_	
43-21	6587-6594	reduced	_	
43-22	6595-6603	cytokine	_	
43-23	6604-6612	response	_	
43-24	6613-6615	in	_	
43-25	6616-6625	periphery	_	
43-26	6626-6628	to	_	
43-27	6629-6641	inflammatory	_	
43-28	6642-6648	insult	_	
43-29	6649-6651	in	_	
43-30	6652-6659	alcohol	_	
43-31	6660-6670	dependence	_	
43-32	6670-6671	.	_	

#Text=Thus we hypothesized a similar blunted pro-inflammatory cytokine response of peripheral monocytes to LPS for alcohol dependent subjects relative to healthy controls.
44-1	6672-6676	Thus	_	
44-2	6677-6679	we	_	
44-3	6680-6692	hypothesized	_	
44-4	6693-6694	a	_	
44-5	6695-6702	similar	_	
44-6	6703-6710	blunted	_	
44-7	6711-6727	pro-inflammatory	_	
44-8	6728-6736	cytokine	_	
44-9	6737-6745	response	_	
44-10	6746-6748	of	_	
44-11	6749-6759	peripheral	_	
44-12	6760-6769	monocytes	_	
44-13	6770-6772	to	_	
44-14	6773-6776	LPS	_	
44-15	6777-6780	for	_	
44-16	6781-6788	alcohol	_	
44-17	6789-6798	dependent	_	
44-18	6799-6807	subjects	_	
44-19	6808-6816	relative	_	
44-20	6817-6819	to	_	
44-21	6820-6827	healthy	_	
44-22	6828-6836	controls	_	
44-23	6836-6837	.	_	

#Text=Taken together, these experiments provide an important in vivo assessment of innate immune function during clinical alcohol dependence in both brain and peripheral circulatory monocytes.
45-1	6838-6843	Taken	_	
45-2	6844-6852	together	_	
45-3	6852-6853	,	_	
45-4	6854-6859	these	_	
45-5	6860-6871	experiments	_	
45-6	6872-6879	provide	_	
45-7	6880-6882	an	_	
45-8	6883-6892	important	_	
45-9	6893-6895	in	_	
45-10	6896-6900	vivo	_	
45-11	6901-6911	assessment	_	
45-12	6912-6914	of	_	
45-13	6915-6921	innate	_	
45-14	6922-6928	immune	_	
45-15	6929-6937	function	_	
45-16	6938-6944	during	_	
45-17	6945-6953	clinical	_	
45-18	6954-6961	alcohol	_	
45-19	6962-6972	dependence	_	
45-20	6973-6975	in	_	
45-21	6976-6980	both	_	
45-22	6981-6986	brain	_	
45-23	6987-6990	and	_	
45-24	6991-7001	peripheral	_	
45-25	7002-7013	circulatory	_	
45-26	7014-7023	monocytes	_	
45-27	7023-7024	.	_	

#Text=Methods
#Text=Subjects
#Text=Fifteen alcohol dependent subjects (11 men, 4 women) and fifteen healthy control subjects (11 men, 4 women) matched for age, sex, and single nucleotide polymorphism (SNP) rs6971 genotype were recruited from the local population to participate in one [11C]PBR28 PET scan including arterial blood sampling and one magnetic resonance imaging (MRI) scan.
46-1	7025-7032	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
46-2	7033-7041	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-3	7042-7049	Fifteen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-4	7050-7057	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[11]	
46-5	7058-7067	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[11]	
46-6	7068-7076	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[11]	
46-7	7077-7078	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-8	7078-7080	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-9	7081-7084	men	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-10	7084-7085	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-11	7086-7087	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-12	7088-7093	women	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-13	7093-7094	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-14	7095-7098	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-15	7099-7106	fifteen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-16	7107-7114	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
46-17	7115-7122	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
46-18	7123-7131	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
46-19	7132-7133	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-20	7133-7135	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-21	7136-7139	men	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-22	7139-7140	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-23	7141-7142	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-24	7143-7148	women	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-25	7148-7149	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-26	7150-7157	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-27	7158-7161	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-28	7162-7165	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-29	7165-7166	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-30	7167-7170	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-31	7170-7171	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-32	7172-7175	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-33	7176-7182	single	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-34	7183-7193	nucleotide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-35	7194-7206	polymorphism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-36	7207-7208	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-37	7208-7211	SNP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-38	7211-7212	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-39	7213-7219	rs6971	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-40	7220-7228	genotype	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-41	7229-7233	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-42	7234-7243	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-43	7244-7248	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-44	7249-7252	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-45	7253-7258	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-46	7259-7269	population	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-47	7270-7272	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-48	7273-7284	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-49	7285-7287	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-50	7288-7291	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-51	7292-7293	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-52	7293-7296	11C	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-53	7296-7297	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-54	7297-7302	PBR28	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
46-55	7303-7306	PET	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[14]	
46-56	7307-7311	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[14]	
46-57	7312-7321	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-58	7322-7330	arterial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-59	7331-7336	blood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-60	7337-7345	sampling	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-61	7346-7349	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-62	7350-7353	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
46-63	7354-7362	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
46-64	7363-7372	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
46-65	7373-7380	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
46-66	7381-7382	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
46-67	7382-7385	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
46-68	7385-7386	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
46-69	7387-7391	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[15]	
46-70	7391-7392	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Prior to scanning, all subjects were genotyped for the rs6971 SNP as previously described.
47-1	7393-7398	Prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-2	7399-7401	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-3	7402-7410	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-4	7410-7411	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-5	7412-7415	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-6	7416-7424	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-7	7425-7429	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-8	7430-7439	genotyped	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-9	7440-7443	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-10	7444-7447	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-11	7448-7454	rs6971	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-12	7455-7458	SNP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-13	7459-7461	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-14	7462-7472	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-15	7473-7482	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
47-16	7482-7483	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=This polymorphism affects the affinity of [11C]PBR28 for the TSPO site.
48-1	7484-7488	This	_	
48-2	7489-7501	polymorphism	_	
48-3	7502-7509	affects	_	
48-4	7510-7513	the	_	
48-5	7514-7522	affinity	_	
48-6	7523-7525	of	_	
48-7	7526-7527	[	_	
48-8	7527-7530	11C	_	
48-9	7530-7531	]	_	
48-10	7531-7536	PBR28	_	
48-11	7537-7540	for	_	
48-12	7541-7544	the	_	
48-13	7545-7549	TSPO	_	
48-14	7550-7554	site	_	
48-15	7554-7555	.	_	

#Text=T/T homozygotes (Low Affinity Binders) were excluded from the study.
49-1	7556-7557	T	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-2	7557-7558	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-3	7558-7559	T	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-4	7560-7571	homozygotes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-5	7572-7573	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-6	7573-7576	Low	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-7	7577-7585	Affinity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-8	7586-7593	Binders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-9	7593-7594	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-10	7595-7599	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-11	7600-7608	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-12	7609-7613	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-13	7614-7617	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-14	7618-7623	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
49-15	7623-7624	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Alcohol dependent subjects met DSM-IV criteria for alcohol dependence with no axis I disorder other than nicotine dependence, with no current or past significant medical or neurological disorders and no psychotropic medication use over the previous month.
50-1	7625-7632	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[19]	
50-2	7633-7642	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[19]	
50-3	7643-7651	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[19]	
50-4	7652-7655	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-5	7656-7662	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-6	7663-7671	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-7	7672-7675	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-8	7676-7683	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[20]	
50-9	7684-7694	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[20]	
50-10	7695-7699	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-11	7700-7702	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-12	7703-7707	axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-13	7708-7709	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-14	7710-7718	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-15	7719-7724	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-16	7725-7729	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-17	7730-7738	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-18	7739-7749	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-19	7749-7750	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-20	7751-7755	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-21	7756-7758	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-22	7759-7766	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-23	7767-7769	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-24	7770-7774	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-25	7775-7786	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-26	7787-7794	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-27	7795-7797	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-28	7798-7810	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-29	7811-7820	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-30	7821-7824	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-31	7825-7827	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-32	7828-7840	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-33	7841-7851	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-34	7852-7855	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-35	7856-7860	over	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-36	7861-7864	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-37	7865-7873	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-38	7874-7879	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
50-39	7879-7880	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Cigarette use was evaluated by self report.
51-1	7881-7890	Cigarette	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
51-2	7891-7894	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
51-3	7895-7898	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
51-4	7899-7908	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
51-5	7909-7911	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
51-6	7912-7916	self	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
51-7	7917-7923	report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
51-8	7923-7924	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=Subjects with prior alcohol detoxifications using benzodiazepines were not eligible, since they would be more likely to require benzodiazepines during detoxification and these drugs are active at the TSPO site.
52-1	7925-7933	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-2	7934-7938	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-3	7939-7944	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-4	7945-7952	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-5	7953-7968	detoxifications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-6	7969-7974	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-7	7975-7990	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-8	7991-7995	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-9	7996-7999	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-10	8000-8008	eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-11	8008-8009	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-12	8010-8015	since	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-13	8016-8020	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-14	8021-8026	would	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-15	8027-8029	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-16	8030-8034	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-17	8035-8041	likely	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-18	8042-8044	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-19	8045-8052	require	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-20	8053-8068	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-21	8069-8075	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-22	8076-8090	detoxification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-23	8091-8094	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-24	8095-8100	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-25	8101-8106	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-26	8107-8110	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-27	8111-8117	active	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-28	8118-8120	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-29	8121-8124	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-30	8125-8129	TSPO	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-31	8130-8134	site	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
52-32	8134-8135	.	_	

#Text=During screening, alcohol dependence severity was evaluated with the Alcohol Dependence Scale, alcohol craving was surveyed with the Alcohol Craving Questionnaire, and alcohol use over the previous month was collected with the Timeline Follow-Back (TLFB).
53-1	8136-8142	During	_	
53-2	8143-8152	screening	_	
53-3	8152-8153	,	_	
53-4	8154-8161	alcohol	_	
53-5	8162-8172	dependence	_	
53-6	8173-8181	severity	_	
53-7	8182-8185	was	_	
53-8	8186-8195	evaluated	_	
53-9	8196-8200	with	_	
53-10	8201-8204	the	_	
53-11	8205-8212	Alcohol	http://www.case.edu/ProvCaRe/provcare#Scale[23]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[24]	
53-12	8213-8223	Dependence	http://www.case.edu/ProvCaRe/provcare#Scale[23]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[24]	
53-13	8224-8229	Scale	http://www.case.edu/ProvCaRe/provcare#Scale[23]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[24]	
53-14	8229-8230	,	_	
53-15	8231-8238	alcohol	_	
53-16	8239-8246	craving	_	
53-17	8247-8250	was	_	
53-18	8251-8259	surveyed	_	
53-19	8260-8264	with	_	
53-20	8265-8268	the	_	
53-21	8269-8276	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[25]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[26]	
53-22	8277-8284	Craving	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[25]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[26]	
53-23	8285-8298	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[25]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[26]	
53-24	8298-8299	,	_	
53-25	8300-8303	and	_	
53-26	8304-8311	alcohol	_	
53-27	8312-8315	use	_	
53-28	8316-8320	over	_	
53-29	8321-8324	the	_	
53-30	8325-8333	previous	_	
53-31	8334-8339	month	_	
53-32	8340-8343	was	_	
53-33	8344-8353	collected	_	
53-34	8354-8358	with	_	
53-35	8359-8362	the	_	
53-36	8363-8371	Timeline	http://www.case.edu/ProvCaRe/provcare#Questionnaire[27]	
53-37	8372-8383	Follow-Back	http://www.case.edu/ProvCaRe/provcare#Questionnaire[27]	
53-38	8384-8385	(	http://www.case.edu/ProvCaRe/provcare#Questionnaire[27]	
53-39	8385-8389	TLFB	http://www.case.edu/ProvCaRe/provcare#Questionnaire[27]	
53-40	8389-8390	)	http://www.case.edu/ProvCaRe/provcare#Questionnaire[27]	
53-41	8390-8391	.	_	

#Text=Alcohol dependent subjects were admitted to the Connecticut Mental Health Center Clinical Neuroscience Unit and imaged at 1-4 days (n=14) or 24 days (n=1) after their last drink.
54-1	8392-8399	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[29]	
54-2	8400-8409	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[29]	
54-3	8410-8418	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[29]	
54-4	8419-8423	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-5	8424-8432	admitted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-6	8433-8435	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-7	8436-8439	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-8	8440-8451	Connecticut	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-9	8452-8458	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-10	8459-8465	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-11	8466-8472	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-12	8473-8481	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-13	8482-8494	Neuroscience	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-14	8495-8499	Unit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-15	8500-8503	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-16	8504-8510	imaged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-17	8511-8513	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-18	8514-8515	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-19	8515-8516	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-20	8516-8517	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-21	8518-8522	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-22	8523-8524	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-23	8524-8525	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-24	8525-8526	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-25	8526-8528	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-26	8528-8529	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-27	8530-8532	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-28	8533-8535	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-29	8536-8540	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-30	8541-8542	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-31	8542-8543	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-32	8543-8544	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-33	8544-8545	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-34	8545-8546	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-35	8547-8552	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-36	8553-8558	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-37	8559-8563	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-38	8564-8569	drink	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	
54-39	8569-8570	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[28]	

#Text=This time frame was selected to most closely examine microglia in alcohol dependence in the absence of alcohol but before major brain changes occur following alcohol abstinence.
55-1	8571-8575	This	_	
55-2	8576-8580	time	_	
55-3	8581-8586	frame	_	
55-4	8587-8590	was	_	
55-5	8591-8599	selected	_	
55-6	8600-8602	to	_	
55-7	8603-8607	most	_	
55-8	8608-8615	closely	_	
55-9	8616-8623	examine	_	
55-10	8624-8633	microglia	_	
55-11	8634-8636	in	_	
55-12	8637-8644	alcohol	_	
55-13	8645-8655	dependence	_	
55-14	8656-8658	in	_	
55-15	8659-8662	the	_	
55-16	8663-8670	absence	_	
55-17	8671-8673	of	_	
55-18	8674-8681	alcohol	_	
55-19	8682-8685	but	_	
55-20	8686-8692	before	_	
55-21	8693-8698	major	_	
55-22	8699-8704	brain	_	
55-23	8705-8712	changes	_	
55-24	8713-8718	occur	_	
55-25	8719-8728	following	_	
55-26	8729-8736	alcohol	_	
55-27	8737-8747	abstinence	_	
55-28	8747-8748	.	_	

#Text=While on the unit, the Clinical Institute Withdrawal Assessment was administered every 6 hours until scores were stably 0.
56-1	8749-8754	While	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-2	8755-8757	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-3	8758-8761	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-4	8762-8766	unit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-5	8766-8767	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-6	8768-8771	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-7	8772-8780	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-8	8781-8790	Institute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-9	8791-8801	Withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-10	8802-8812	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-11	8813-8816	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-12	8817-8829	administered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-13	8830-8835	every	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-14	8836-8837	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-15	8838-8843	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-16	8844-8849	until	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-17	8850-8856	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-18	8857-8861	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-19	8862-8868	stably	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-20	8869-8870	0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
56-21	8870-8871	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	

#Text=None of the subjects in this study required benzodiazepine treatment.
57-1	8872-8876	None	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-2	8877-8879	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-3	8880-8883	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-4	8884-8892	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-5	8893-8895	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-6	8896-8900	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-7	8901-8906	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-8	8907-8915	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-9	8916-8930	benzodiazepine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-10	8931-8940	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
57-11	8940-8941	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	

#Text=Healthy controls had no history of significant major medical disorders or head trauma and did not meet DSM-IV criteria for current or past psychiatric or substance abuse diagnosis other than nicotine use.
58-1	8942-8949	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[33]	
58-2	8950-8958	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[33]	
58-3	8959-8962	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-4	8963-8965	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-5	8966-8973	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-6	8974-8976	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-7	8977-8988	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-8	8989-8994	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-9	8995-9002	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-10	9003-9012	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-11	9013-9015	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-12	9016-9020	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-13	9021-9027	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-14	9028-9031	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-15	9032-9035	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-16	9036-9039	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-17	9040-9044	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-18	9045-9051	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-19	9052-9060	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-20	9061-9064	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-21	9065-9072	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-22	9073-9075	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-23	9076-9080	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-24	9081-9092	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-25	9093-9095	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-26	9096-9105	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-27	9106-9111	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-28	9112-9121	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-29	9122-9127	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-30	9128-9132	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-31	9133-9141	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-32	9142-9145	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	
58-33	9145-9146	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]	

#Text=In addition, control subjects reported drinking fewer than eight alcoholic drinks per week.
59-1	9147-9149	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-2	9150-9158	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-3	9158-9159	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-4	9160-9167	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[35]	
59-5	9168-9176	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[35]	
59-6	9177-9185	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-7	9186-9194	drinking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-8	9195-9200	fewer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-9	9201-9205	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-10	9206-9211	eight	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-11	9212-9221	alcoholic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-12	9222-9228	drinks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-13	9229-9232	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-14	9233-9237	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-15	9237-9238	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	

#Text=For all female subjects, negative pregnancy tests were established during screening and prior to radiotracer administration on the day of the scans.
60-1	9239-9242	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-2	9243-9246	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-3	9247-9253	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-4	9254-9262	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-5	9262-9263	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-6	9264-9272	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-7	9273-9282	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-8	9283-9288	tests	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-9	9289-9293	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-10	9294-9305	established	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-11	9306-9312	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-12	9313-9322	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-13	9323-9326	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-14	9327-9332	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-15	9333-9335	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-16	9336-9347	radiotracer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-17	9348-9362	administration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-18	9363-9365	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-19	9366-9369	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-20	9370-9373	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-21	9374-9376	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-22	9377-9380	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-23	9381-9386	scans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-24	9386-9387	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	

#Text=All procedures were approved by the Yale University School of Medicine Human Investigation Committee and the Radiation Safety Committee.
61-1	9388-9391	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-2	9392-9402	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-3	9403-9407	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-4	9408-9416	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-5	9417-9419	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-6	9420-9423	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-7	9424-9428	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-8	9429-9439	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-9	9440-9446	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-10	9447-9449	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-11	9450-9458	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-12	9459-9464	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-13	9465-9478	Investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-14	9479-9488	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-15	9489-9492	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-16	9493-9496	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-17	9497-9506	Radiation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-18	9507-9513	Safety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-19	9514-9523	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	
61-20	9523-9524	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]	

#Text=Written informed consent, approved by the Yale University School of Medicine Human Investigation Committee, was obtained from all subjects prior to participation in this study.
62-1	9525-9532	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-2	9533-9541	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-3	9542-9549	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-4	9549-9550	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-5	9551-9559	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-6	9560-9562	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-7	9563-9566	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-8	9567-9571	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-9	9572-9582	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-10	9583-9589	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-11	9590-9592	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-12	9593-9601	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-13	9602-9607	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-14	9608-9621	Investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-15	9622-9631	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-16	9631-9632	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-17	9633-9636	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-18	9637-9645	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-19	9646-9650	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-20	9651-9654	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-21	9655-9663	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-22	9664-9669	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-23	9670-9672	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-24	9673-9686	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-25	9687-9689	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-26	9690-9694	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-27	9695-9700	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
62-28	9700-9701	.	_	

#Text=Imaging Data Acquisition
#Text=[11C]PBR28 was produced as previously described, resulting in high specific activities of 294±188 MBq/nmol.
63-1	9702-9709	Imaging	_	
63-2	9710-9714	Data	_	
63-3	9715-9726	Acquisition	_	
63-4	9727-9728	[	_	
63-5	9728-9731	11C	_	
63-6	9731-9732	]	_	
63-7	9732-9737	PBR28	_	
63-8	9738-9741	was	_	
63-9	9742-9750	produced	_	
63-10	9751-9753	as	_	
63-11	9754-9764	previously	_	
63-12	9765-9774	described	_	
63-13	9774-9775	,	_	
63-14	9776-9785	resulting	_	
63-15	9786-9788	in	_	
63-16	9789-9793	high	_	
63-17	9794-9802	specific	_	
63-18	9803-9813	activities	_	
63-19	9814-9816	of	_	
63-20	9817-9820	294	_	
63-21	9820-9821	±	_	
63-22	9821-9824	188	_	
63-23	9825-9828	MBq	_	
63-24	9828-9829	/	_	
63-25	9829-9833	nmol	_	
63-26	9833-9834	.	_	

#Text=PET data were acquired with a High Resolution Research Tomograph (HRRT; Siemens), and head motion data were acquired with an optical motion-tracking tool (Vicra, NDI Systems).
64-1	9835-9838	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-2	9839-9843	data	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-3	9844-9848	were	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-4	9849-9857	acquired	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-5	9858-9862	with	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-6	9863-9864	a	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-7	9865-9869	High	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-8	9870-9880	Resolution	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-9	9881-9889	Research	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-10	9890-9899	Tomograph	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-11	9900-9901	(	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-12	9901-9905	HRRT	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-13	9905-9906	;	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-14	9907-9914	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-15	9914-9915	)	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[39]	
64-16	9915-9916	,	_	
64-17	9917-9920	and	_	
64-18	9921-9925	head	_	
64-19	9926-9932	motion	_	
64-20	9933-9937	data	_	
64-21	9938-9942	were	_	
64-22	9943-9951	acquired	_	
64-23	9952-9956	with	_	
64-24	9957-9959	an	_	
64-25	9960-9967	optical	_	
64-26	9968-9983	motion-tracking	_	
64-27	9984-9988	tool	_	
64-28	9989-9990	(	_	
64-29	9990-9995	Vicra	_	
64-30	9995-9996	,	_	
64-31	9997-10000	NDI	_	
64-32	10001-10008	Systems	_	
64-33	10008-10009	)	_	
64-34	10009-10010	.	_	

#Text=PET imaging sessions began with acquisition of a 6 min 137Cs transmission scan for attenuation correction of the emission data.
65-1	10011-10014	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[40]	
65-2	10015-10022	imaging	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[40]	
65-3	10023-10031	sessions	_	
65-4	10032-10037	began	_	
65-5	10038-10042	with	_	
65-6	10043-10054	acquisition	_	
65-7	10055-10057	of	_	
65-8	10058-10059	a	_	
65-9	10060-10061	6	_	
65-10	10062-10065	min	_	
65-11	10066-10071	137Cs	_	
65-12	10072-10084	transmission	_	
65-13	10085-10089	scan	_	
65-14	10090-10093	for	_	
65-15	10094-10105	attenuation	_	
65-16	10106-10116	correction	_	
65-17	10117-10119	of	_	
65-18	10120-10123	the	_	
65-19	10124-10132	emission	_	
65-20	10133-10137	data	_	
65-21	10137-10138	.	_	

#Text=PET data acquisition began simultaneously with administration of 551±174 MBq [11C]PBR28 as a slow bolus over 1 min, with data acquisition lasting 120 min.
66-1	10139-10142	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[41]	
66-2	10143-10147	data	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[41]	
66-3	10148-10159	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[41]	
66-4	10160-10165	began	_	
66-5	10166-10180	simultaneously	_	
66-6	10181-10185	with	_	
66-7	10186-10200	administration	_	
66-8	10201-10203	of	_	
66-9	10204-10207	551	_	
66-10	10207-10208	±	_	
66-11	10208-10211	174	_	
66-12	10212-10215	MBq	_	
66-13	10216-10217	[	_	
66-14	10217-10220	11C	_	
66-15	10220-10221	]	_	
66-16	10221-10226	PBR28	_	
66-17	10227-10229	as	_	
66-18	10230-10231	a	_	
66-19	10232-10236	slow	_	
66-20	10237-10242	bolus	_	
66-21	10243-10247	over	_	
66-22	10248-10249	1	_	
66-23	10250-10253	min	_	
66-24	10253-10254	,	_	
66-25	10255-10259	with	_	
66-26	10260-10264	data	_	
66-27	10265-10276	acquisition	_	
66-28	10277-10284	lasting	_	
66-29	10285-10288	120	_	
66-30	10289-10292	min	_	
66-31	10292-10293	.	_	

#Text=The metabolite-corrected arterial input function was measured as previously described.
67-1	10294-10297	The	_	
67-2	10298-10318	metabolite-corrected	_	
67-3	10319-10327	arterial	_	
67-4	10328-10333	input	_	
67-5	10334-10342	function	_	
67-6	10343-10346	was	_	
67-7	10347-10355	measured	_	
67-8	10356-10358	as	_	
67-9	10359-10369	previously	_	
67-10	10370-10379	described	_	
67-11	10379-10380	.	_	

#Text=Magnetic resonance image (MRI) data were acquired for anatomical localization of [11C]PBR28 uptake.
68-1	10381-10389	Magnetic	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[42]	
68-2	10390-10399	resonance	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[42]	
68-3	10400-10405	image	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[42]	
68-4	10406-10407	(	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[42]	
68-5	10407-10410	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[42]	
68-6	10410-10411	)	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[42]	
68-7	10412-10416	data	_	
68-8	10417-10421	were	_	
68-9	10422-10430	acquired	_	
68-10	10431-10434	for	_	
68-11	10435-10445	anatomical	_	
68-12	10446-10458	localization	_	
68-13	10459-10461	of	_	
68-14	10462-10463	[	_	
68-15	10463-10466	11C	_	
68-16	10466-10467	]	_	
68-17	10467-10472	PBR28	_	
68-18	10473-10479	uptake	_	
68-19	10479-10480	.	_	

#Text=MR data were acquired with a 3T Trio Scanner (Siemens Medical Systems, Erlangen, Germany) with a weighted gradient-echo (MPRAGE) sequence featuring the following parameters: (TE=3.3 ms; TI=1,100 ms, TF=2,500 ms, FA=7°) giving 1 mm3 isotropic resolution.
69-1	10481-10483	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[43]	
69-2	10484-10488	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[43]	
69-3	10489-10493	were	_	
69-4	10494-10502	acquired	_	
69-5	10503-10507	with	_	
69-6	10508-10509	a	_	
69-7	10510-10512	3T	_	
69-8	10513-10517	Trio	_	
69-9	10518-10525	Scanner	_	
69-10	10526-10527	(	_	
69-11	10527-10534	Siemens	_	
69-12	10535-10542	Medical	_	
69-13	10543-10550	Systems	_	
69-14	10550-10551	,	_	
69-15	10552-10560	Erlangen	_	
69-16	10560-10561	,	_	
69-17	10562-10569	Germany	_	
69-18	10569-10570	)	_	
69-19	10571-10575	with	_	
69-20	10576-10577	a	_	
69-21	10578-10586	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[44]	
69-22	10587-10600	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[44]	
69-23	10601-10602	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[44]	
69-24	10602-10608	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[44]	
69-25	10608-10609	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[44]	
69-26	10610-10618	sequence	_	
69-27	10619-10628	featuring	_	
69-28	10629-10632	the	_	
69-29	10633-10642	following	_	
69-30	10643-10653	parameters	_	
69-31	10653-10654	:	_	
69-32	10655-10656	(	_	
69-33	10656-10658	TE	_	
69-34	10658-10659	=	_	
69-35	10659-10662	3.3	_	
69-36	10663-10665	ms	_	
69-37	10665-10666	;	_	
69-38	10667-10669	TI	_	
69-39	10669-10670	=	_	
69-40	10670-10675	1,100	_	
69-41	10676-10678	ms	_	
69-42	10678-10679	,	_	
69-43	10680-10682	TF	_	
69-44	10682-10683	=	_	
69-45	10683-10688	2,500	_	
69-46	10689-10691	ms	_	
69-47	10691-10692	,	_	
69-48	10693-10695	FA	_	
69-49	10695-10696	=	_	
69-50	10696-10697	7	_	
69-51	10697-10698	°	_	
69-52	10698-10699	)	_	
69-53	10700-10706	giving	_	
69-54	10707-10708	1	_	
69-55	10709-10712	mm3	_	
69-56	10713-10722	isotropic	_	
69-57	10723-10733	resolution	_	
69-58	10733-10734	.	_	

#Text=Imaging Data Processing and Analysis
#Text=Dynamic list-mode PET data were histogrammed into discrete time frames up to 5 min and reconstructed with the MOLAR algorithm.
70-1	10735-10742	Imaging	_	
70-2	10743-10747	Data	_	
70-3	10748-10758	Processing	_	
70-4	10759-10762	and	_	
70-5	10763-10771	Analysis	_	
70-6	10772-10779	Dynamic	_	
70-7	10780-10789	list-mode	_	
70-8	10790-10793	PET	_	
70-9	10794-10798	data	_	
70-10	10799-10803	were	_	
70-11	10804-10816	histogrammed	_	
70-12	10817-10821	into	_	
70-13	10822-10830	discrete	_	
70-14	10831-10835	time	_	
70-15	10836-10842	frames	_	
70-16	10843-10845	up	_	
70-17	10846-10848	to	_	
70-18	10849-10850	5	_	
70-19	10851-10854	min	_	
70-20	10855-10858	and	_	
70-21	10859-10872	reconstructed	_	
70-22	10873-10877	with	_	
70-23	10878-10881	the	_	
70-24	10882-10887	MOLAR	_	
70-25	10888-10897	algorithm	_	
70-26	10897-10898	.	_	

#Text=To transform PET data into MR space, a summed image of the first 10 min of PET data was registered to the subject-specific T1-weighted MRI using a mutual information algorithm with six degrees of freedom (FLIRT, FSL 3.2; Analysis Group; FMRIB, Oxford, UK).
71-1	10899-10901	To	_	
71-2	10902-10911	transform	_	
71-3	10912-10915	PET	_	
71-4	10916-10920	data	_	
71-5	10921-10925	into	_	
71-6	10926-10928	MR	_	
71-7	10929-10934	space	_	
71-8	10934-10935	,	_	
71-9	10936-10937	a	_	
71-10	10938-10944	summed	_	
71-11	10945-10950	image	_	
71-12	10951-10953	of	_	
71-13	10954-10957	the	_	
71-14	10958-10963	first	_	
71-15	10964-10966	10	_	
71-16	10967-10970	min	_	
71-17	10971-10973	of	_	
71-18	10974-10977	PET	_	
71-19	10978-10982	data	_	
71-20	10983-10986	was	_	
71-21	10987-10997	registered	_	
71-22	10998-11000	to	_	
71-23	11001-11004	the	_	
71-24	11005-11021	subject-specific	_	
71-25	11022-11024	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
71-26	11024-11025	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
71-27	11025-11033	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
71-28	11034-11037	MRI	_	
71-29	11038-11043	using	_	
71-30	11044-11045	a	_	
71-31	11046-11052	mutual	_	
71-32	11053-11064	information	_	
71-33	11065-11074	algorithm	_	
71-34	11075-11079	with	_	
71-35	11080-11083	six	_	
71-36	11084-11091	degrees	_	
71-37	11092-11094	of	_	
71-38	11095-11102	freedom	_	
71-39	11103-11104	(	_	
71-40	11104-11109	FLIRT	_	
71-41	11109-11110	,	_	
71-42	11111-11114	FSL	_	
71-43	11115-11118	3.2	_	
71-44	11118-11119	;	_	
71-45	11120-11128	Analysis	_	
71-46	11129-11134	Group	_	
71-47	11134-11135	;	_	
71-48	11136-11141	FMRIB	_	
71-49	11141-11142	,	_	
71-50	11143-11149	Oxford	_	
71-51	11149-11150	,	_	
71-52	11151-11153	UK	_	
71-53	11153-11154	)	_	
71-54	11154-11155	.	_	

#Text=The native MRI was then co-registered to the Montreal Neurological Institute (MNI) template space with a nonlinear transformation algorithm (BioImage Suite; http://www.bioimagesuite.com) for Region of Interest (ROI) definition.
72-1	11156-11159	The	_	
72-2	11160-11166	native	_	
72-3	11167-11170	MRI	_	
72-4	11171-11174	was	_	
72-5	11175-11179	then	_	
72-6	11180-11193	co-registered	_	
72-7	11194-11196	to	_	
72-8	11197-11200	the	_	
72-9	11201-11209	Montreal	_	
72-10	11210-11222	Neurological	_	
72-11	11223-11232	Institute	_	
72-12	11233-11234	(	_	
72-13	11234-11237	MNI	_	
72-14	11237-11238	)	_	
72-15	11239-11247	template	_	
72-16	11248-11253	space	_	
72-17	11254-11258	with	_	
72-18	11259-11260	a	_	
72-19	11261-11270	nonlinear	_	
72-20	11271-11285	transformation	_	
72-21	11286-11295	algorithm	_	
72-22	11296-11297	(	_	
72-23	11297-11305	BioImage	_	
72-24	11306-11311	Suite	_	
72-25	11311-11312	;	_	
72-26	11313-11317	http	_	
72-27	11317-11318	:	_	
72-28	11318-11319	/	_	
72-29	11319-11320	/	_	
72-30	11320-11341	www.bioimagesuite.com	_	
72-31	11341-11342	)	_	
72-32	11343-11346	for	_	
72-33	11347-11353	Region	_	
72-34	11354-11356	of	_	
72-35	11357-11365	Interest	_	
72-36	11366-11367	(	_	
72-37	11367-11370	ROI	_	
72-38	11370-11371	)	_	
72-39	11372-11382	definition	_	
72-40	11382-11383	.	_	

#Text=The dynamic PET data were corrected for partial volume effects with previously published methods using SPM12-segmented tissue masks.
73-1	11384-11387	The	_	
73-2	11388-11395	dynamic	_	
73-3	11396-11399	PET	_	
73-4	11400-11404	data	_	
73-5	11405-11409	were	_	
73-6	11410-11419	corrected	_	
73-7	11420-11423	for	_	
73-8	11424-11431	partial	_	
73-9	11432-11438	volume	_	
73-10	11439-11446	effects	_	
73-11	11447-11451	with	_	
73-12	11452-11462	previously	_	
73-13	11463-11472	published	_	
73-14	11473-11480	methods	_	
73-15	11481-11486	using	_	
73-16	11487-11492	SPM12	_	
73-17	11492-11493	-	_	
73-18	11493-11502	segmented	_	
73-19	11503-11509	tissue	_	
73-20	11510-11515	masks	_	
73-21	11515-11516	.	_	

#Text=The time-activity curves of radioactivity concentration in tissue were extracted from the regions of cerebellum, frontal cortex, hippocampus, and striatum, since these are important regions affected by alcohol-induced neurodegeneration and dysregulated neuroimmune function.
74-1	11517-11520	The	_	
74-2	11521-11534	time-activity	_	
74-3	11535-11541	curves	_	
74-4	11542-11544	of	_	
74-5	11545-11558	radioactivity	_	
74-6	11559-11572	concentration	_	
74-7	11573-11575	in	_	
74-8	11576-11582	tissue	_	
74-9	11583-11587	were	_	
74-10	11588-11597	extracted	_	
74-11	11598-11602	from	_	
74-12	11603-11606	the	_	
74-13	11607-11614	regions	_	
74-14	11615-11617	of	_	
74-15	11618-11628	cerebellum	_	
74-16	11628-11629	,	_	
74-17	11630-11637	frontal	_	
74-18	11638-11644	cortex	_	
74-19	11644-11645	,	_	
74-20	11646-11657	hippocampus	_	
74-21	11657-11658	,	_	
74-22	11659-11662	and	_	
74-23	11663-11671	striatum	_	
74-24	11671-11672	,	_	
74-25	11673-11678	since	_	
74-26	11679-11684	these	_	
74-27	11685-11688	are	_	
74-28	11689-11698	important	_	
74-29	11699-11706	regions	_	
74-30	11707-11715	affected	_	
74-31	11716-11718	by	_	
74-32	11719-11734	alcohol-induced	_	
74-33	11735-11752	neurodegeneration	_	
74-34	11753-11756	and	_	
74-35	11757-11769	dysregulated	_	
74-36	11770-11781	neuroimmune	_	
74-37	11782-11790	function	_	
74-38	11790-11791	.	_	

#Text=For PET data, the primary outcome measure of this study was the total distribution volume (VT), which is the ratio at equilibrium of [11C]PBR28 concentration in tissue to [11C]PBR28 concentration in arterial plasma.
75-1	11792-11795	For	_	
75-2	11796-11799	PET	_	
75-3	11800-11804	data	_	
75-4	11804-11805	,	_	
75-5	11806-11809	the	_	
75-6	11810-11817	primary	_	
75-7	11818-11825	outcome	_	
75-8	11826-11833	measure	_	
75-9	11834-11836	of	_	
75-10	11837-11841	this	_	
75-11	11842-11847	study	_	
75-12	11848-11851	was	_	
75-13	11852-11855	the	_	
75-14	11856-11861	total	_	
75-15	11862-11874	distribution	_	
75-16	11875-11881	volume	_	
75-17	11882-11883	(	_	
75-18	11883-11885	VT	_	
75-19	11885-11886	)	_	
75-20	11886-11887	,	_	
75-21	11888-11893	which	_	
75-22	11894-11896	is	_	
75-23	11897-11900	the	_	
75-24	11901-11906	ratio	_	
75-25	11907-11909	at	_	
75-26	11910-11921	equilibrium	_	
75-27	11922-11924	of	_	
75-28	11925-11926	[	_	
75-29	11926-11929	11C	_	
75-30	11929-11930	]	_	
75-31	11930-11935	PBR28	_	
75-32	11936-11949	concentration	_	
75-33	11950-11952	in	_	
75-34	11953-11959	tissue	_	
75-35	11960-11962	to	_	
75-36	11963-11964	[	_	
75-37	11964-11967	11C	_	
75-38	11967-11968	]	_	
75-39	11968-11973	PBR28	_	
75-40	11974-11987	concentration	_	
75-41	11988-11990	in	_	
75-42	11991-11999	arterial	_	
75-43	12000-12006	plasma	_	
75-44	12006-12007	.	_	

#Text=The VT is indirectly proportional to the number of TSPO sites available for [11C]PBR28 binding.
76-1	12008-12011	The	_	
76-2	12012-12014	VT	_	
76-3	12015-12017	is	_	
76-4	12018-12028	indirectly	_	
76-5	12029-12041	proportional	_	
76-6	12042-12044	to	_	
76-7	12045-12048	the	_	
76-8	12049-12055	number	_	
76-9	12056-12058	of	_	
76-10	12059-12063	TSPO	_	
76-11	12064-12069	sites	_	
76-12	12070-12079	available	_	
76-13	12080-12083	for	_	
76-14	12084-12085	[	_	
76-15	12085-12088	11C	_	
76-16	12088-12089	]	_	
76-17	12089-12094	PBR28	_	
76-18	12095-12102	binding	_	
76-19	12102-12103	.	_	

#Text=Multilinear analysis (MA1;) with t*=30 min was used to estimate VT as previously validated.
77-1	12104-12115	Multilinear	_	
77-2	12116-12124	analysis	_	
77-3	12125-12126	(	_	
77-4	12126-12129	MA1	_	
77-5	12129-12130	;	_	
77-6	12130-12131	)	_	
77-7	12132-12136	with	_	
77-8	12137-12138	t	_	
77-9	12138-12139	*	_	
77-10	12139-12140	=	_	
77-11	12140-12142	30	_	
77-12	12143-12146	min	_	
77-13	12147-12150	was	_	
77-14	12151-12155	used	_	
77-15	12156-12158	to	_	
77-16	12159-12167	estimate	_	
77-17	12168-12170	VT	_	
77-18	12171-12173	as	_	
77-19	12174-12184	previously	_	
77-20	12185-12194	validated	_	
77-21	12194-12195	.	_	

#Text=For visualization purposes, voxel-wise parametric images were also calculated with an algorithm constraining the MA1 parameters to reduce noise following spatial smoothing with an 8 mm FWHM Gaussian kernel.
78-1	12196-12199	For	_	
78-2	12200-12213	visualization	_	
78-3	12214-12222	purposes	_	
78-4	12222-12223	,	_	
78-5	12224-12234	voxel-wise	_	
78-6	12235-12245	parametric	_	
78-7	12246-12252	images	_	
78-8	12253-12257	were	_	
78-9	12258-12262	also	_	
78-10	12263-12273	calculated	_	
78-11	12274-12278	with	_	
78-12	12279-12281	an	_	
78-13	12282-12291	algorithm	_	
78-14	12292-12304	constraining	_	
78-15	12305-12308	the	_	
78-16	12309-12312	MA1	_	
78-17	12313-12323	parameters	_	
78-18	12324-12326	to	_	
78-19	12327-12333	reduce	_	
78-20	12334-12339	noise	_	
78-21	12340-12349	following	_	
78-22	12350-12357	spatial	_	
78-23	12358-12367	smoothing	_	
78-24	12368-12372	with	_	
78-25	12373-12375	an	_	
78-26	12376-12377	8	_	
78-27	12378-12380	mm	_	
78-28	12381-12385	FWHM	_	
78-29	12386-12394	Gaussian	_	
78-30	12395-12401	kernel	_	
78-31	12401-12402	.	_	

#Text=Endotoxin Stimulation of Peripheral Monocytes
#Text=Briefly, venous blood samples were acquired on the day of the PET scan for 11 alcohol dependent subjects and 9 healthy controls.
79-1	12403-12412	Endotoxin	_	
79-2	12413-12424	Stimulation	_	
79-3	12425-12427	of	_	
79-4	12428-12438	Peripheral	_	
79-5	12439-12448	Monocytes	_	
79-6	12449-12456	Briefly	_	
79-7	12456-12457	,	_	
79-8	12458-12464	venous	_	
79-9	12465-12470	blood	_	
79-10	12471-12478	samples	_	
79-11	12479-12483	were	_	
79-12	12484-12492	acquired	_	
79-13	12493-12495	on	_	
79-14	12496-12499	the	_	
79-15	12500-12503	day	_	
79-16	12504-12506	of	_	
79-17	12507-12510	the	_	
79-18	12511-12514	PET	_	
79-19	12515-12519	scan	_	
79-20	12520-12523	for	_	
79-21	12524-12526	11	_	
79-22	12527-12534	alcohol	_	
79-23	12535-12544	dependent	_	
79-24	12545-12553	subjects	_	
79-25	12554-12557	and	_	
79-26	12558-12559	9	_	
79-27	12560-12567	healthy	_	
79-28	12568-12576	controls	_	
79-29	12576-12577	.	_	

#Text=Peripheral blood mononuclear cells (PBMCs) were isolated and placed in culture medium RPMI-1640.
80-1	12578-12588	Peripheral	_	
80-2	12589-12594	blood	_	
80-3	12595-12606	mononuclear	_	
80-4	12607-12612	cells	_	
80-5	12613-12614	(	_	
80-6	12614-12619	PBMCs	_	
80-7	12619-12620	)	_	
80-8	12621-12625	were	_	
80-9	12626-12634	isolated	_	
80-10	12635-12638	and	_	
80-11	12639-12645	placed	_	
80-12	12646-12648	in	_	
80-13	12649-12656	culture	_	
80-14	12657-12663	medium	_	
80-15	12664-12668	RPMI	_	
80-16	12668-12669	-	_	
80-17	12669-12673	1640	_	
80-18	12673-12674	.	_	

#Text=After initial incubation over 1 h, cells were stimulated with either 10 ng/mL lipopolysaccharide (LPS) or 50 μL phosphate buffered saline (PBS), and further incubated for an additional 24 h.
81-1	12675-12680	After	_	
81-2	12681-12688	initial	_	
81-3	12689-12699	incubation	_	
81-4	12700-12704	over	_	
81-5	12705-12706	1	_	
81-6	12707-12708	h	_	
81-7	12708-12709	,	_	
81-8	12710-12715	cells	_	
81-9	12716-12720	were	_	
81-10	12721-12731	stimulated	_	
81-11	12732-12736	with	_	
81-12	12737-12743	either	_	
81-13	12744-12746	10	_	
81-14	12747-12749	ng	_	
81-15	12749-12750	/	_	
81-16	12750-12752	mL	_	
81-17	12753-12771	lipopolysaccharide	_	
81-18	12772-12773	(	_	
81-19	12773-12776	LPS	_	
81-20	12776-12777	)	_	
81-21	12778-12780	or	_	
81-22	12781-12783	50	_	
81-23	12784-12786	μL	_	
81-24	12787-12796	phosphate	_	
81-25	12797-12805	buffered	_	
81-26	12806-12812	saline	_	
81-27	12813-12814	(	_	
81-28	12814-12817	PBS	_	
81-29	12817-12818	)	_	
81-30	12818-12819	,	_	
81-31	12820-12823	and	_	
81-32	12824-12831	further	_	
81-33	12832-12841	incubated	_	
81-34	12842-12845	for	_	
81-35	12846-12848	an	_	
81-36	12849-12859	additional	_	
81-37	12860-12862	24	_	
81-38	12863-12864	h	_	
81-39	12864-12865	.	_	

#Text=Cytokine concentrations were assayed with MILLIPLEX panel assay, and fold-change in cytokine expression for each cytokine within each subject was reported as the ratio of average cytokine concentration in LPS-stimulated samples to average cytokine concentration in PBS-added (non-stimulated) samples.
82-1	12866-12874	Cytokine	_	
82-2	12875-12889	concentrations	_	
82-3	12890-12894	were	_	
82-4	12895-12902	assayed	_	
82-5	12903-12907	with	_	
82-6	12908-12917	MILLIPLEX	_	
82-7	12918-12923	panel	_	
82-8	12924-12929	assay	_	
82-9	12929-12930	,	_	
82-10	12931-12934	and	_	
82-11	12935-12946	fold-change	_	
82-12	12947-12949	in	_	
82-13	12950-12958	cytokine	_	
82-14	12959-12969	expression	_	
82-15	12970-12973	for	_	
82-16	12974-12978	each	_	
82-17	12979-12987	cytokine	_	
82-18	12988-12994	within	_	
82-19	12995-12999	each	_	
82-20	13000-13007	subject	_	
82-21	13008-13011	was	_	
82-22	13012-13020	reported	_	
82-23	13021-13023	as	_	
82-24	13024-13027	the	_	
82-25	13028-13033	ratio	_	
82-26	13034-13036	of	_	
82-27	13037-13044	average	_	
82-28	13045-13053	cytokine	_	
82-29	13054-13067	concentration	_	
82-30	13068-13070	in	_	
82-31	13071-13085	LPS-stimulated	_	
82-32	13086-13093	samples	_	
82-33	13094-13096	to	_	
82-34	13097-13104	average	_	
82-35	13105-13113	cytokine	_	
82-36	13114-13127	concentration	_	
82-37	13128-13130	in	_	
82-38	13131-13140	PBS-added	_	
82-39	13141-13142	(	_	
82-40	13142-13156	non-stimulated	_	
82-41	13156-13157	)	_	
82-42	13158-13165	samples	_	
82-43	13165-13166	.	_	

#Text=A detailed description of these methods is available in Supplementary Methods.
83-1	13167-13168	A	_	
83-2	13169-13177	detailed	_	
83-3	13178-13189	description	_	
83-4	13190-13192	of	_	
83-5	13193-13198	these	_	
83-6	13199-13206	methods	_	
83-7	13207-13209	is	_	
83-8	13210-13219	available	_	
83-9	13220-13222	in	_	
83-10	13223-13236	Supplementary	_	
83-11	13237-13244	Methods	_	
83-12	13244-13245	.	_	

#Text=Statistics
#Text=[11C]PBR28 VT values were statistically analyzed with a linear mixed modeling approach.
84-1	13246-13256	Statistics	_	
84-2	13257-13258	[	_	
84-3	13258-13261	11C	_	
84-4	13261-13262	]	_	
84-5	13262-13267	PBR28	_	
84-6	13268-13270	VT	_	
84-7	13271-13277	values	_	
84-8	13278-13282	were	_	
84-9	13283-13296	statistically	_	
84-10	13297-13305	analyzed	_	
84-11	13306-13310	with	_	
84-12	13311-13312	a	_	
84-13	13313-13319	linear	_	
84-14	13320-13325	mixed	_	
84-15	13326-13334	modeling	_	
84-16	13335-13343	approach	_	
84-17	13343-13344	.	_	

#Text=To test the null hypothesis of no difference in [11C]PBR28 VT between the alcohol dependent and healthy control groups, a model was constructed with rs6971 genotype as a fixed factor, group as a between-subjects factor and region as a within-subjects factor.
85-1	13345-13347	To	_	
85-2	13348-13352	test	_	
85-3	13353-13356	the	_	
85-4	13357-13361	null	_	
85-5	13362-13372	hypothesis	_	
85-6	13373-13375	of	_	
85-7	13376-13378	no	_	
85-8	13379-13389	difference	_	
85-9	13390-13392	in	_	
85-10	13393-13394	[	_	
85-11	13394-13397	11C	_	
85-12	13397-13398	]	_	
85-13	13398-13403	PBR28	_	
85-14	13404-13406	VT	_	
85-15	13407-13414	between	_	
85-16	13415-13418	the	_	
85-17	13419-13426	alcohol	_	
85-18	13427-13436	dependent	_	
85-19	13437-13440	and	_	
85-20	13441-13448	healthy	_	
85-21	13449-13456	control	_	
85-22	13457-13463	groups	_	
85-23	13463-13464	,	_	
85-24	13465-13466	a	_	
85-25	13467-13472	model	_	
85-26	13473-13476	was	_	
85-27	13477-13488	constructed	_	
85-28	13489-13493	with	_	
85-29	13494-13500	rs6971	_	
85-30	13501-13509	genotype	_	
85-31	13510-13512	as	_	
85-32	13513-13514	a	_	
85-33	13515-13520	fixed	_	
85-34	13521-13527	factor	_	
85-35	13527-13528	,	_	
85-36	13529-13534	group	_	
85-37	13535-13537	as	_	
85-38	13538-13539	a	_	
85-39	13540-13556	between-subjects	_	
85-40	13557-13563	factor	_	
85-41	13564-13567	and	_	
85-42	13568-13574	region	_	
85-43	13575-13577	as	_	
85-44	13578-13579	a	_	
85-45	13580-13595	within-subjects	_	
85-46	13596-13602	factor	_	
85-47	13602-13603	.	_	

#Text=Post-hoc linear contrasts were generated to examine regional differences in [11C]PBR28 VT between alcohol dependent subjects and healthy controls.
86-1	13604-13612	Post-hoc	_	
86-2	13613-13619	linear	_	
86-3	13620-13629	contrasts	_	
86-4	13630-13634	were	_	
86-5	13635-13644	generated	_	
86-6	13645-13647	to	_	
86-7	13648-13655	examine	_	
86-8	13656-13664	regional	_	
86-9	13665-13676	differences	_	
86-10	13677-13679	in	_	
86-11	13680-13681	[	_	
86-12	13681-13684	11C	_	
86-13	13684-13685	]	_	
86-14	13685-13690	PBR28	_	
86-15	13691-13693	VT	_	
86-16	13694-13701	between	_	
86-17	13702-13709	alcohol	_	
86-18	13710-13719	dependent	_	
86-19	13720-13728	subjects	_	
86-20	13729-13732	and	_	
86-21	13733-13740	healthy	_	
86-22	13741-13749	controls	_	
86-23	13749-13750	.	_	

#Text=A power analysis using preliminary data before the study began determined a sample size of 30 subjects (15 in each group) to provide 80% probability of detecting significant differences in [11C]PBR28 VT between the two groups.
87-1	13751-13752	A	_	
87-2	13753-13758	power	_	
87-3	13759-13767	analysis	_	
87-4	13768-13773	using	_	
87-5	13774-13785	preliminary	_	
87-6	13786-13790	data	_	
87-7	13791-13797	before	_	
87-8	13798-13801	the	_	
87-9	13802-13807	study	_	
87-10	13808-13813	began	_	
87-11	13814-13824	determined	_	
87-12	13825-13826	a	_	
87-13	13827-13833	sample	_	
87-14	13834-13838	size	_	
87-15	13839-13841	of	_	
87-16	13842-13844	30	_	
87-17	13845-13853	subjects	_	
87-18	13854-13855	(	_	
87-19	13855-13857	15	_	
87-20	13858-13860	in	_	
87-21	13861-13865	each	_	
87-22	13866-13871	group	_	
87-23	13871-13872	)	_	
87-24	13873-13875	to	_	
87-25	13876-13883	provide	_	
87-26	13884-13887	80%	_	
87-27	13888-13899	probability	_	
87-28	13900-13902	of	_	
87-29	13903-13912	detecting	_	
87-30	13913-13924	significant	_	
87-31	13925-13936	differences	_	
87-32	13937-13939	in	_	
87-33	13940-13941	[	_	
87-34	13941-13944	11C	_	
87-35	13944-13945	]	_	
87-36	13945-13950	PBR28	_	
87-37	13951-13953	VT	_	
87-38	13954-13961	between	_	
87-39	13962-13965	the	_	
87-40	13966-13969	two	_	
87-41	13970-13976	groups	_	
87-42	13976-13977	.	_	

#Text=As an exploratory analysis, possible associations between [11C]PBR28 VT were examined for all regions with reported drinks per day over the previous month, Alcohol Dependence Scale score, and Alcohol Craving Questionnaire Score in each brain region.
88-1	13978-13980	As	_	
88-2	13981-13983	an	_	
88-3	13984-13995	exploratory	_	
88-4	13996-14004	analysis	_	
88-5	14004-14005	,	_	
88-6	14006-14014	possible	_	
88-7	14015-14027	associations	_	
88-8	14028-14035	between	_	
88-9	14036-14037	[	_	
88-10	14037-14040	11C	_	
88-11	14040-14041	]	_	
88-12	14041-14046	PBR28	_	
88-13	14047-14049	VT	_	
88-14	14050-14054	were	_	
88-15	14055-14063	examined	_	
88-16	14064-14067	for	_	
88-17	14068-14071	all	_	
88-18	14072-14079	regions	_	
88-19	14080-14084	with	_	
88-20	14085-14093	reported	_	
88-21	14094-14100	drinks	_	
88-22	14101-14104	per	_	
88-23	14105-14108	day	_	
88-24	14109-14113	over	_	
88-25	14114-14117	the	_	
88-26	14118-14126	previous	_	
88-27	14127-14132	month	_	
88-28	14132-14133	,	_	
88-29	14134-14141	Alcohol	_	
88-30	14142-14152	Dependence	_	
88-31	14153-14158	Scale	_	
88-32	14159-14164	score	_	
88-33	14164-14165	,	_	
88-34	14166-14169	and	_	
88-35	14170-14177	Alcohol	_	
88-36	14178-14185	Craving	_	
88-37	14186-14199	Questionnaire	_	
88-38	14200-14205	Score	_	
88-39	14206-14208	in	_	
88-40	14209-14213	each	_	
88-41	14214-14219	brain	_	
88-42	14220-14226	region	_	
88-43	14226-14227	.	_	

#Text=For this analysis, correction for rs6971 genotype was implemented by separating the subjects by genotype, and then creating a z-score for each variable (regional [11C]PBR28 VT, drinks per day over the previous month, Alcohol Dependence Scale score, and craving score) within each genotype group.
89-1	14228-14231	For	_	
89-2	14232-14236	this	_	
89-3	14237-14245	analysis	_	
89-4	14245-14246	,	_	
89-5	14247-14257	correction	_	
89-6	14258-14261	for	_	
89-7	14262-14268	rs6971	_	
89-8	14269-14277	genotype	_	
89-9	14278-14281	was	_	
89-10	14282-14293	implemented	_	
89-11	14294-14296	by	_	
89-12	14297-14307	separating	_	
89-13	14308-14311	the	_	
89-14	14312-14320	subjects	_	
89-15	14321-14323	by	_	
89-16	14324-14332	genotype	_	
89-17	14332-14333	,	_	
89-18	14334-14337	and	_	
89-19	14338-14342	then	_	
89-20	14343-14351	creating	_	
89-21	14352-14353	a	_	
89-22	14354-14361	z-score	_	
89-23	14362-14365	for	_	
89-24	14366-14370	each	_	
89-25	14371-14379	variable	_	
89-26	14380-14381	(	_	
89-27	14381-14389	regional	_	
89-28	14390-14391	[	_	
89-29	14391-14394	11C	_	
89-30	14394-14395	]	_	
89-31	14395-14400	PBR28	_	
89-32	14401-14403	VT	_	
89-33	14403-14404	,	_	
89-34	14405-14411	drinks	_	
89-35	14412-14415	per	_	
89-36	14416-14419	day	_	
89-37	14420-14424	over	_	
89-38	14425-14428	the	_	
89-39	14429-14437	previous	_	
89-40	14438-14443	month	_	
89-41	14443-14444	,	_	
89-42	14445-14452	Alcohol	_	
89-43	14453-14463	Dependence	_	
89-44	14464-14469	Scale	_	
89-45	14470-14475	score	_	
89-46	14475-14476	,	_	
89-47	14477-14480	and	_	
89-48	14481-14488	craving	_	
89-49	14489-14494	score	_	
89-50	14494-14495	)	_	
89-51	14496-14502	within	_	
89-52	14503-14507	each	_	
89-53	14508-14516	genotype	_	
89-54	14517-14522	group	_	
89-55	14522-14523	.	_	

#Text=Standard linear regression analysis techniques were then performed on these ‘standardized’ variables.
90-1	14524-14532	Standard	_	
90-2	14533-14539	linear	_	
90-3	14540-14550	regression	_	
90-4	14551-14559	analysis	_	
90-5	14560-14570	techniques	_	
90-6	14571-14575	were	_	
90-7	14576-14580	then	_	
90-8	14581-14590	performed	_	
90-9	14591-14593	on	_	
90-10	14594-14599	these	_	
90-11	14600-14601	‘	_	
90-12	14601-14613	standardized	_	
90-13	14613-14614	’	_	
90-14	14615-14624	variables	_	
90-15	14624-14625	.	_	

#Text=This procedure is analogous to previous reports that ‘correlated’ each variable with genotype and ran regression analysis on standardized residuals of this correlation, which effectively created a z-score by genotype.
91-1	14626-14630	This	_	
91-2	14631-14640	procedure	_	
91-3	14641-14643	is	_	
91-4	14644-14653	analogous	_	
91-5	14654-14656	to	_	
91-6	14657-14665	previous	_	
91-7	14666-14673	reports	_	
91-8	14674-14678	that	_	
91-9	14679-14680	‘	_	
91-10	14680-14690	correlated	_	
91-11	14690-14691	’	_	
91-12	14692-14696	each	_	
91-13	14697-14705	variable	_	
91-14	14706-14710	with	_	
91-15	14711-14719	genotype	_	
91-16	14720-14723	and	_	
91-17	14724-14727	ran	_	
91-18	14728-14738	regression	_	
91-19	14739-14747	analysis	_	
91-20	14748-14750	on	_	
91-21	14751-14763	standardized	_	
91-22	14764-14773	residuals	_	
91-23	14774-14776	of	_	
91-24	14777-14781	this	_	
91-25	14782-14793	correlation	_	
91-26	14793-14794	,	_	
91-27	14795-14800	which	_	
91-28	14801-14812	effectively	_	
91-29	14813-14820	created	_	
91-30	14821-14822	a	_	
91-31	14823-14830	z-score	_	
91-32	14831-14833	by	_	
91-33	14834-14842	genotype	_	
91-34	14842-14843	.	_	

#Text=The results of this analysis were not corrected for multiple comparisons due to the exploratory nature of these analyses.
92-1	14844-14847	The	_	
92-2	14848-14855	results	_	
92-3	14856-14858	of	_	
92-4	14859-14863	this	_	
92-5	14864-14872	analysis	_	
92-6	14873-14877	were	_	
92-7	14878-14881	not	_	
92-8	14882-14891	corrected	_	
92-9	14892-14895	for	_	
92-10	14896-14904	multiple	_	
92-11	14905-14916	comparisons	_	
92-12	14917-14920	due	_	
92-13	14921-14923	to	_	
92-14	14924-14927	the	_	
92-15	14928-14939	exploratory	_	
92-16	14940-14946	nature	_	
92-17	14947-14949	of	_	
92-18	14950-14955	these	_	
92-19	14956-14964	analyses	_	
92-20	14964-14965	.	_	

#Text=A linear mixed model approach was used to test the null hypothesis of no differences in fold-change of cytokine expression between alcohol dependent subjects and healthy controls.
93-1	14966-14967	A	_	
93-2	14968-14974	linear	_	
93-3	14975-14980	mixed	_	
93-4	14981-14986	model	_	
93-5	14987-14995	approach	_	
93-6	14996-14999	was	_	
93-7	15000-15004	used	_	
93-8	15005-15007	to	_	
93-9	15008-15012	test	_	
93-10	15013-15016	the	_	
93-11	15017-15021	null	_	
93-12	15022-15032	hypothesis	_	
93-13	15033-15035	of	_	
93-14	15036-15038	no	_	
93-15	15039-15050	differences	_	
93-16	15051-15053	in	_	
93-17	15054-15065	fold-change	_	
93-18	15066-15068	of	_	
93-19	15069-15077	cytokine	_	
93-20	15078-15088	expression	_	
93-21	15089-15096	between	_	
93-22	15097-15104	alcohol	_	
93-23	15105-15114	dependent	_	
93-24	15115-15123	subjects	_	
93-25	15124-15127	and	_	
93-26	15128-15135	healthy	_	
93-27	15136-15144	controls	_	
93-28	15144-15145	.	_	

#Text=Since different effects were expected for pro-inflammatory and anti-inflammatory cytokines, a separate model was constructed for each class of cytokines using group as a between-subjects factor and cytokine as a within-subjects factor.
94-1	15146-15151	Since	_	
94-2	15152-15161	different	_	
94-3	15162-15169	effects	_	
94-4	15170-15174	were	_	
94-5	15175-15183	expected	_	
94-6	15184-15187	for	_	
94-7	15188-15204	pro-inflammatory	_	
94-8	15205-15208	and	_	
94-9	15209-15226	anti-inflammatory	_	
94-10	15227-15236	cytokines	_	
94-11	15236-15237	,	_	
94-12	15238-15239	a	_	
94-13	15240-15248	separate	_	
94-14	15249-15254	model	_	
94-15	15255-15258	was	_	
94-16	15259-15270	constructed	_	
94-17	15271-15274	for	_	
94-18	15275-15279	each	_	
94-19	15280-15285	class	_	
94-20	15286-15288	of	_	
94-21	15289-15298	cytokines	_	
94-22	15299-15304	using	_	
94-23	15305-15310	group	_	
94-24	15311-15313	as	_	
94-25	15314-15315	a	_	
94-26	15316-15332	between-subjects	_	
94-27	15333-15339	factor	_	
94-28	15340-15343	and	_	
94-29	15344-15352	cytokine	_	
94-30	15353-15355	as	_	
94-31	15356-15357	a	_	
94-32	15358-15373	within-subjects	_	
94-33	15374-15380	factor	_	
94-34	15380-15381	.	_	

#Text=Post-hoc linear contrasts were generated to examine individual cytokines for differences between alcohol dependent subjects and healthy controls.
95-1	15382-15390	Post-hoc	_	
95-2	15391-15397	linear	_	
95-3	15398-15407	contrasts	_	
95-4	15408-15412	were	_	
95-5	15413-15422	generated	_	
95-6	15423-15425	to	_	
95-7	15426-15433	examine	_	
95-8	15434-15444	individual	_	
95-9	15445-15454	cytokines	_	
95-10	15455-15458	for	_	
95-11	15459-15470	differences	_	
95-12	15471-15478	between	_	
95-13	15479-15486	alcohol	_	
95-14	15487-15496	dependent	_	
95-15	15497-15505	subjects	_	
95-16	15506-15509	and	_	
95-17	15510-15517	healthy	_	
95-18	15518-15526	controls	_	
95-19	15526-15527	.	_	

#Text=Statistical analyses were all performed with R 3.1.1.
96-1	15528-15539	Statistical	_	
96-2	15540-15548	analyses	_	
96-3	15549-15553	were	_	
96-4	15554-15557	all	_	
96-5	15558-15567	performed	_	
96-6	15568-15572	with	_	
96-7	15573-15574	R	_	
96-8	15575-15580	3.1.1	_	
96-9	15580-15581	.	_	

#Text=Results
#Text=Individuals with alcohol dependence (n=15; duration of 22±10 years) reported drinking 6±3 drinks per day (range of 4-15 drinks per day) on 4-7 days a week.
97-1	15582-15589	Results	_	
97-2	15590-15601	Individuals	_	
97-3	15602-15606	with	_	
97-4	15607-15614	alcohol	_	
97-5	15615-15625	dependence	_	
97-6	15626-15627	(	_	
97-7	15627-15628	n	_	
97-8	15628-15629	=	_	
97-9	15629-15631	15	_	
97-10	15631-15632	;	_	
97-11	15633-15641	duration	_	
97-12	15642-15644	of	_	
97-13	15645-15647	22	_	
97-14	15647-15648	±	_	
97-15	15648-15650	10	_	
97-16	15651-15656	years	_	
97-17	15656-15657	)	_	
97-18	15658-15666	reported	_	
97-19	15667-15675	drinking	_	
97-20	15676-15677	6	_	
97-21	15677-15678	±	_	
97-22	15678-15679	3	_	
97-23	15680-15686	drinks	_	
97-24	15687-15690	per	_	
97-25	15691-15694	day	_	
97-26	15695-15696	(	_	
97-27	15696-15701	range	_	
97-28	15702-15704	of	_	
97-29	15705-15706	4	_	
97-30	15706-15707	-	_	
97-31	15707-15709	15	_	
97-32	15710-15716	drinks	_	
97-33	15717-15720	per	_	
97-34	15721-15724	day	_	
97-35	15724-15725	)	_	
97-36	15726-15728	on	_	
97-37	15729-15730	4	_	
97-38	15730-15731	-	_	
97-39	15731-15732	7	_	
97-40	15733-15737	days	_	
97-41	15738-15739	a	_	
97-42	15740-15744	week	_	
97-43	15744-15745	.	_	

#Text=Healthy controls (n=15) were matched for age, sex, and single nucleotide polymorphism (SNP) rs6971 genotype, which affects [11C]PBR28 affinity for the TSPO site.
98-1	15746-15753	Healthy	_	
98-2	15754-15762	controls	_	
98-3	15763-15764	(	_	
98-4	15764-15765	n	_	
98-5	15765-15766	=	_	
98-6	15766-15768	15	_	
98-7	15768-15769	)	_	
98-8	15770-15774	were	_	
98-9	15775-15782	matched	_	
98-10	15783-15786	for	_	
98-11	15787-15790	age	_	
98-12	15790-15791	,	_	
98-13	15792-15795	sex	_	
98-14	15795-15796	,	_	
98-15	15797-15800	and	_	
98-16	15801-15807	single	_	
98-17	15808-15818	nucleotide	_	
98-18	15819-15831	polymorphism	_	
98-19	15832-15833	(	_	
98-20	15833-15836	SNP	_	
98-21	15836-15837	)	_	
98-22	15838-15844	rs6971	_	
98-23	15845-15853	genotype	_	
98-24	15853-15854	,	_	
98-25	15855-15860	which	_	
98-26	15861-15868	affects	_	
98-27	15869-15870	[	_	
98-28	15870-15873	11C	_	
98-29	15873-15874	]	_	
98-30	15874-15879	PBR28	_	
98-31	15880-15888	affinity	_	
98-32	15889-15892	for	_	
98-33	15893-15896	the	_	
98-34	15897-15901	TSPO	_	
98-35	15902-15906	site	_	
98-36	15906-15907	.	_	

#Text=The average score on the Alcohol Dependence Scale was 8.3±5.6, and average alcohol craving evaluated with the Tiffany Scale was 23.3±12.6.
99-1	15908-15911	The	_	
99-2	15912-15919	average	_	
99-3	15920-15925	score	_	
99-4	15926-15928	on	_	
99-5	15929-15932	the	_	
99-6	15933-15940	Alcohol	_	
99-7	15941-15951	Dependence	_	
99-8	15952-15957	Scale	_	
99-9	15958-15961	was	_	
99-10	15962-15965	8.3	_	
99-11	15965-15966	±	_	
99-12	15966-15969	5.6	_	
99-13	15969-15970	,	_	
99-14	15971-15974	and	_	
99-15	15975-15982	average	_	
99-16	15983-15990	alcohol	_	
99-17	15991-15998	craving	_	
99-18	15999-16008	evaluated	_	
99-19	16009-16013	with	_	
99-20	16014-16017	the	_	
99-21	16018-16025	Tiffany	_	
99-22	16026-16031	Scale	_	
99-23	16032-16035	was	_	
99-24	16036-16040	23.3	_	
99-25	16040-16041	±	_	
99-26	16041-16045	12.6	_	
99-27	16045-16046	.	_	

#Text=Five alcohol dependent subjects (5±2 cigarettes/day) and four healthy controls (13±4 cigarettes/day) were cigarette smokers.
100-1	16047-16051	Five	_	
100-2	16052-16059	alcohol	_	
100-3	16060-16069	dependent	_	
100-4	16070-16078	subjects	_	
100-5	16079-16080	(	_	
100-6	16080-16081	5	_	
100-7	16081-16082	±	_	
100-8	16082-16083	2	_	
100-9	16084-16094	cigarettes	_	
100-10	16094-16095	/	_	
100-11	16095-16098	day	_	
100-12	16098-16099	)	_	
100-13	16100-16103	and	_	
100-14	16104-16108	four	_	
100-15	16109-16116	healthy	_	
100-16	16117-16125	controls	_	
100-17	16126-16127	(	_	
100-18	16127-16129	13	_	
100-19	16129-16130	±	_	
100-20	16130-16131	4	_	
100-21	16132-16142	cigarettes	_	
100-22	16142-16143	/	_	
100-23	16143-16146	day	_	
100-24	16146-16147	)	_	
100-25	16148-16152	were	_	
100-26	16153-16162	cigarette	_	
100-27	16163-16170	smokers	_	
100-28	16170-16171	.	_	

#Text=For [11C]PBR28 scans, there were no significant group differences (p<0.05) in injected radioactivity dose, injected mass, or fP (see Table 1).
101-1	16172-16175	For	_	
101-2	16176-16177	[	_	
101-3	16177-16180	11C	_	
101-4	16180-16181	]	_	
101-5	16181-16186	PBR28	_	
101-6	16187-16192	scans	_	
101-7	16192-16193	,	_	
101-8	16194-16199	there	_	
101-9	16200-16204	were	_	
101-10	16205-16207	no	_	
101-11	16208-16219	significant	_	
101-12	16220-16225	group	_	
101-13	16226-16237	differences	_	
101-14	16238-16239	(	_	
101-15	16239-16240	p	_	
101-16	16240-16241	<	_	
101-17	16241-16245	0.05	_	
101-18	16245-16246	)	_	
101-19	16247-16249	in	_	
101-20	16250-16258	injected	_	
101-21	16259-16272	radioactivity	_	
101-22	16273-16277	dose	_	
101-23	16277-16278	,	_	
101-24	16279-16287	injected	_	
101-25	16288-16292	mass	_	
101-26	16292-16293	,	_	
101-27	16294-16296	or	_	
101-28	16297-16299	fP	_	
101-29	16300-16301	(	_	
101-30	16301-16304	see	_	
101-31	16305-16310	Table	_	
101-32	16311-16312	1	_	
101-33	16312-16313	)	_	
101-34	16313-16314	.	_	

#Text=In contrast to our hypothesis, partial-volume corrected levels of activated microglia in regions of brain, quantified by [11C]PBR28 VT, were significantly lower in alcohol dependent individuals compared to healthy controls (F(1,26)=4.983, p=0.034; effect of genotype, F(1,26)=32.54, p<0.0001; interaction effect, F(1,26)=0.094, p=0.762). [11C]PBR28 VT values are shown in Figure 1 adjusted by the modeled genotype coefficient for visualization, and were 10% lower in alcohol dependent subjects compared to healthy controls averaged across regions, illustrated in Figure 2.
102-1	16315-16317	In	_	
102-2	16318-16326	contrast	_	
102-3	16327-16329	to	_	
102-4	16330-16333	our	_	
102-5	16334-16344	hypothesis	_	
102-6	16344-16345	,	_	
102-7	16346-16360	partial-volume	_	
102-8	16361-16370	corrected	_	
102-9	16371-16377	levels	_	
102-10	16378-16380	of	_	
102-11	16381-16390	activated	_	
102-12	16391-16400	microglia	_	
102-13	16401-16403	in	_	
102-14	16404-16411	regions	_	
102-15	16412-16414	of	_	
102-16	16415-16420	brain	_	
102-17	16420-16421	,	_	
102-18	16422-16432	quantified	_	
102-19	16433-16435	by	_	
102-20	16436-16437	[	_	
102-21	16437-16440	11C	_	
102-22	16440-16441	]	_	
102-23	16441-16446	PBR28	_	
102-24	16447-16449	VT	_	
102-25	16449-16450	,	_	
102-26	16451-16455	were	_	
102-27	16456-16469	significantly	_	
102-28	16470-16475	lower	_	
102-29	16476-16478	in	_	
102-30	16479-16486	alcohol	_	
102-31	16487-16496	dependent	_	
102-32	16497-16508	individuals	_	
102-33	16509-16517	compared	_	
102-34	16518-16520	to	_	
102-35	16521-16528	healthy	_	
102-36	16529-16537	controls	_	
102-37	16538-16539	(	_	
102-38	16539-16540	F	_	
102-39	16540-16541	(	_	
102-40	16541-16545	1,26	_	
102-41	16545-16546	)	_	
102-42	16546-16547	=	_	
102-43	16547-16552	4.983	_	
102-44	16552-16553	,	_	
102-45	16554-16555	p	_	
102-46	16555-16556	=	_	
102-47	16556-16561	0.034	_	
102-48	16561-16562	;	_	
102-49	16563-16569	effect	_	
102-50	16570-16572	of	_	
102-51	16573-16581	genotype	_	
102-52	16581-16582	,	_	
102-53	16583-16584	F	_	
102-54	16584-16585	(	_	
102-55	16585-16589	1,26	_	
102-56	16589-16590	)	_	
102-57	16590-16591	=	_	
102-58	16591-16596	32.54	_	
102-59	16596-16597	,	_	
102-60	16598-16599	p	_	
102-61	16599-16600	<	_	
102-62	16600-16606	0.0001	_	
102-63	16606-16607	;	_	
102-64	16608-16619	interaction	_	
102-65	16620-16626	effect	_	
102-66	16626-16627	,	_	
102-67	16628-16629	F	_	
102-68	16629-16630	(	_	
102-69	16630-16634	1,26	_	
102-70	16634-16635	)	_	
102-71	16635-16636	=	_	
102-72	16636-16641	0.094	_	
102-73	16641-16642	,	_	
102-74	16643-16644	p	_	
102-75	16644-16645	=	_	
102-76	16645-16650	0.762	_	
102-77	16650-16651	)	_	
102-78	16651-16652	.	_	
102-79	16653-16654	[	_	
102-80	16654-16657	11C	_	
102-81	16657-16658	]	_	
102-82	16658-16663	PBR28	_	
102-83	16664-16666	VT	_	
102-84	16667-16673	values	_	
102-85	16674-16677	are	_	
102-86	16678-16683	shown	_	
102-87	16684-16686	in	_	
102-88	16687-16693	Figure	_	
102-89	16694-16695	1	_	
102-90	16696-16704	adjusted	_	
102-91	16705-16707	by	_	
102-92	16708-16711	the	_	
102-93	16712-16719	modeled	_	
102-94	16720-16728	genotype	_	
102-95	16729-16740	coefficient	_	
102-96	16741-16744	for	_	
102-97	16745-16758	visualization	_	
102-98	16758-16759	,	_	
102-99	16760-16763	and	_	
102-100	16764-16768	were	_	
102-101	16769-16772	10%	_	
102-102	16773-16778	lower	_	
102-103	16779-16781	in	_	
102-104	16782-16789	alcohol	_	
102-105	16790-16799	dependent	_	
102-106	16800-16808	subjects	_	
102-107	16809-16817	compared	_	
102-108	16818-16820	to	_	
102-109	16821-16828	healthy	_	
102-110	16829-16837	controls	_	
102-111	16838-16846	averaged	_	
102-112	16847-16853	across	_	
102-113	16854-16861	regions	_	
102-114	16861-16862	,	_	
102-115	16863-16874	illustrated	_	
102-116	16875-16877	in	_	
102-117	16878-16884	Figure	_	
102-118	16885-16886	2	_	
102-119	16886-16887	.	_	

#Text=Post-hoc analysis revealed a significant effect of alcohol dependence in cerebellum (F(1,27)=5.000, p=0.034), with similar trends in frontal cortex (F(1,27)=4.183, p=0.051), striatum (F(1,27)=3.951, p=0.057), and hippocampus ((F(1,27)=2.941, p=0.098), shown in Supplementary Figure 1.
103-1	16888-16896	Post-hoc	_	
103-2	16897-16905	analysis	_	
103-3	16906-16914	revealed	_	
103-4	16915-16916	a	_	
103-5	16917-16928	significant	_	
103-6	16929-16935	effect	_	
103-7	16936-16938	of	_	
103-8	16939-16946	alcohol	_	
103-9	16947-16957	dependence	_	
103-10	16958-16960	in	_	
103-11	16961-16971	cerebellum	_	
103-12	16972-16973	(	_	
103-13	16973-16974	F	_	
103-14	16974-16975	(	_	
103-15	16975-16979	1,27	_	
103-16	16979-16980	)	_	
103-17	16980-16981	=	_	
103-18	16981-16986	5.000	_	
103-19	16986-16987	,	_	
103-20	16988-16989	p	_	
103-21	16989-16990	=	_	
103-22	16990-16995	0.034	_	
103-23	16995-16996	)	_	
103-24	16996-16997	,	_	
103-25	16998-17002	with	_	
103-26	17003-17010	similar	_	
103-27	17011-17017	trends	_	
103-28	17018-17020	in	_	
103-29	17021-17028	frontal	_	
103-30	17029-17035	cortex	_	
103-31	17036-17037	(	_	
103-32	17037-17038	F	_	
103-33	17038-17039	(	_	
103-34	17039-17043	1,27	_	
103-35	17043-17044	)	_	
103-36	17044-17045	=	_	
103-37	17045-17050	4.183	_	
103-38	17050-17051	,	_	
103-39	17052-17053	p	_	
103-40	17053-17054	=	_	
103-41	17054-17059	0.051	_	
103-42	17059-17060	)	_	
103-43	17060-17061	,	_	
103-44	17062-17070	striatum	_	
103-45	17071-17072	(	_	
103-46	17072-17073	F	_	
103-47	17073-17074	(	_	
103-48	17074-17078	1,27	_	
103-49	17078-17079	)	_	
103-50	17079-17080	=	_	
103-51	17080-17085	3.951	_	
103-52	17085-17086	,	_	
103-53	17087-17088	p	_	
103-54	17088-17089	=	_	
103-55	17089-17094	0.057	_	
103-56	17094-17095	)	_	
103-57	17095-17096	,	_	
103-58	17097-17100	and	_	
103-59	17101-17112	hippocampus	_	
103-60	17113-17114	(	_	
103-61	17114-17115	(	_	
103-62	17115-17116	F	_	
103-63	17116-17117	(	_	
103-64	17117-17121	1,27	_	
103-65	17121-17122	)	_	
103-66	17122-17123	=	_	
103-67	17123-17128	2.941	_	
103-68	17128-17129	,	_	
103-69	17130-17131	p	_	
103-70	17131-17132	=	_	
103-71	17132-17137	0.098	_	
103-72	17137-17138	)	_	
103-73	17138-17139	,	_	
103-74	17140-17145	shown	_	
103-75	17146-17148	in	_	
103-76	17149-17162	Supplementary	_	
103-77	17163-17169	Figure	_	
103-78	17170-17171	1	_	
103-79	17171-17172	.	_	

#Text=Partial volume correction (PVC) of PET data safeguards against tissue atrophy effects influencing PET outcome measures, but also introduces additional variability into the data.
104-1	17173-17180	Partial	_	
104-2	17181-17187	volume	_	
104-3	17188-17198	correction	_	
104-4	17199-17200	(	_	
104-5	17200-17203	PVC	_	
104-6	17203-17204	)	_	
104-7	17205-17207	of	_	
104-8	17208-17211	PET	_	
104-9	17212-17216	data	_	
104-10	17217-17227	safeguards	_	
104-11	17228-17235	against	_	
104-12	17236-17242	tissue	_	
104-13	17243-17250	atrophy	_	
104-14	17251-17258	effects	_	
104-15	17259-17270	influencing	_	
104-16	17271-17274	PET	_	
104-17	17275-17282	outcome	_	
104-18	17283-17291	measures	_	
104-19	17291-17292	,	_	
104-20	17293-17296	but	_	
104-21	17297-17301	also	_	
104-22	17302-17312	introduces	_	
104-23	17313-17323	additional	_	
104-24	17324-17335	variability	_	
104-25	17336-17340	into	_	
104-26	17341-17344	the	_	
104-27	17345-17349	data	_	
104-28	17349-17350	.	_	

#Text=To ensure that PVC did not bias our result, analysis of [11C]PBR28 data without this correction was also conducted.
105-1	17351-17353	To	_	
105-2	17354-17360	ensure	_	
105-3	17361-17365	that	_	
105-4	17366-17369	PVC	_	
105-5	17370-17373	did	_	
105-6	17374-17377	not	_	
105-7	17378-17382	bias	_	
105-8	17383-17386	our	_	
105-9	17387-17393	result	_	
105-10	17393-17394	,	_	
105-11	17395-17403	analysis	_	
105-12	17404-17406	of	_	
105-13	17407-17408	[	_	
105-14	17408-17411	11C	_	
105-15	17411-17412	]	_	
105-16	17412-17417	PBR28	_	
105-17	17418-17422	data	_	
105-18	17423-17430	without	_	
105-19	17431-17435	this	_	
105-20	17436-17446	correction	_	
105-21	17447-17450	was	_	
105-22	17451-17455	also	_	
105-23	17456-17465	conducted	_	
105-24	17465-17466	.	_	

#Text=This analysis yielded a strong main effect of significantly lower [11C]PBR28 VT in alcohol dependent patients compared to healthy controls (F(1,26)=6.681, p=0.016; effect of genotype, F(1,26)=44.98, p<0.0001; interaction effect, F(1,26)=0.039, p=0.845).
106-1	17467-17471	This	_	
106-2	17472-17480	analysis	_	
106-3	17481-17488	yielded	_	
106-4	17489-17490	a	_	
106-5	17491-17497	strong	_	
106-6	17498-17502	main	_	
106-7	17503-17509	effect	_	
106-8	17510-17512	of	_	
106-9	17513-17526	significantly	_	
106-10	17527-17532	lower	_	
106-11	17533-17534	[	_	
106-12	17534-17537	11C	_	
106-13	17537-17538	]	_	
106-14	17538-17543	PBR28	_	
106-15	17544-17546	VT	_	
106-16	17547-17549	in	_	
106-17	17550-17557	alcohol	_	
106-18	17558-17567	dependent	_	
106-19	17568-17576	patients	_	
106-20	17577-17585	compared	_	
106-21	17586-17588	to	_	
106-22	17589-17596	healthy	_	
106-23	17597-17605	controls	_	
106-24	17606-17607	(	_	
106-25	17607-17608	F	_	
106-26	17608-17609	(	_	
106-27	17609-17613	1,26	_	
106-28	17613-17614	)	_	
106-29	17614-17615	=	_	
106-30	17615-17620	6.681	_	
106-31	17620-17621	,	_	
106-32	17622-17623	p	_	
106-33	17623-17624	=	_	
106-34	17624-17629	0.016	_	
106-35	17629-17630	;	_	
106-36	17631-17637	effect	_	
106-37	17638-17640	of	_	
106-38	17641-17649	genotype	_	
106-39	17649-17650	,	_	
106-40	17651-17652	F	_	
106-41	17652-17653	(	_	
106-42	17653-17657	1,26	_	
106-43	17657-17658	)	_	
106-44	17658-17659	=	_	
106-45	17659-17664	44.98	_	
106-46	17664-17665	,	_	
106-47	17666-17667	p	_	
106-48	17667-17668	<	_	
106-49	17668-17674	0.0001	_	
106-50	17674-17675	;	_	
106-51	17676-17687	interaction	_	
106-52	17688-17694	effect	_	
106-53	17694-17695	,	_	
106-54	17696-17697	F	_	
106-55	17697-17698	(	_	
106-56	17698-17702	1,26	_	
106-57	17702-17703	)	_	
106-58	17703-17704	=	_	
106-59	17704-17709	0.039	_	
106-60	17709-17710	,	_	
106-61	17711-17712	p	_	
106-62	17712-17713	=	_	
106-63	17713-17718	0.845	_	
106-64	17718-17719	)	_	
106-65	17719-17720	.	_	

#Text=Post-hoc analysis revealed a significant effect of alcohol dependence in all regions (F(1,27)>4.249, p<0.049), shown in Supplementary Figure 2.
107-1	17721-17729	Post-hoc	_	
107-2	17730-17738	analysis	_	
107-3	17739-17747	revealed	_	
107-4	17748-17749	a	_	
107-5	17750-17761	significant	_	
107-6	17762-17768	effect	_	
107-7	17769-17771	of	_	
107-8	17772-17779	alcohol	_	
107-9	17780-17790	dependence	_	
107-10	17791-17793	in	_	
107-11	17794-17797	all	_	
107-12	17798-17805	regions	_	
107-13	17806-17807	(	_	
107-14	17807-17808	F	_	
107-15	17808-17809	(	_	
107-16	17809-17813	1,27	_	
107-17	17813-17814	)	_	
107-18	17814-17815	>	_	
107-19	17815-17820	4.249	_	
107-20	17820-17821	,	_	
107-21	17822-17823	p	_	
107-22	17823-17824	<	_	
107-23	17824-17829	0.049	_	
107-24	17829-17830	)	_	
107-25	17830-17831	,	_	
107-26	17832-17837	shown	_	
107-27	17838-17840	in	_	
107-28	17841-17854	Supplementary	_	
107-29	17855-17861	Figure	_	
107-30	17862-17863	2	_	
107-31	17863-17864	.	_	

#Text=Nonetheless, to be conservative, partial volume-corrected [11C]PBR28 VT is reported as the primary result to account for possible gray matter volume variations across subjects.
108-1	17865-17876	Nonetheless	_	
108-2	17876-17877	,	_	
108-3	17878-17880	to	_	
108-4	17881-17883	be	_	
108-5	17884-17896	conservative	_	
108-6	17896-17897	,	_	
108-7	17898-17905	partial	_	
108-8	17906-17922	volume-corrected	_	
108-9	17923-17924	[	_	
108-10	17924-17927	11C	_	
108-11	17927-17928	]	_	
108-12	17928-17933	PBR28	_	
108-13	17934-17936	VT	_	
108-14	17937-17939	is	_	
108-15	17940-17948	reported	_	
108-16	17949-17951	as	_	
108-17	17952-17955	the	_	
108-18	17956-17963	primary	_	
108-19	17964-17970	result	_	
108-20	17971-17973	to	_	
108-21	17974-17981	account	_	
108-22	17982-17985	for	_	
108-23	17986-17994	possible	_	
108-24	17995-17999	gray	_	
108-25	18000-18006	matter	_	
108-26	18007-18013	volume	_	
108-27	18014-18024	variations	_	
108-28	18025-18031	across	_	
108-29	18032-18040	subjects	_	
108-30	18040-18041	.	_	

#Text=As an exploratory analysis, we tested for relationships of levels of activated microglia with dependence severity, reported drinks per day during the previous month, and alcohol craving within the alcohol dependent group.
109-1	18042-18044	As	_	
109-2	18045-18047	an	_	
109-3	18048-18059	exploratory	_	
109-4	18060-18068	analysis	_	
109-5	18068-18069	,	_	
109-6	18070-18072	we	_	
109-7	18073-18079	tested	_	
109-8	18080-18083	for	_	
109-9	18084-18097	relationships	_	
109-10	18098-18100	of	_	
109-11	18101-18107	levels	_	
109-12	18108-18110	of	_	
109-13	18111-18120	activated	_	
109-14	18121-18130	microglia	_	
109-15	18131-18135	with	_	
109-16	18136-18146	dependence	_	
109-17	18147-18155	severity	_	
109-18	18155-18156	,	_	
109-19	18157-18165	reported	_	
109-20	18166-18172	drinks	_	
109-21	18173-18176	per	_	
109-22	18177-18180	day	_	
109-23	18181-18187	during	_	
109-24	18188-18191	the	_	
109-25	18192-18200	previous	_	
109-26	18201-18206	month	_	
109-27	18206-18207	,	_	
109-28	18208-18211	and	_	
109-29	18212-18219	alcohol	_	
109-30	18220-18227	craving	_	
109-31	18228-18234	within	_	
109-32	18235-18238	the	_	
109-33	18239-18246	alcohol	_	
109-34	18247-18256	dependent	_	
109-35	18257-18262	group	_	
109-36	18262-18263	.	_	

#Text=This analysis identified a significant negative relationship (uncorrected for multiple comparisons) between [11C]PBR28 VT and dependence severity, as assessed by the Alcohol Dependence Scale, in hippocampus (p=0.035) and striatum (p=0.035), with a similar trend in cerebellum (p=0.059; shown as a representative region in Figure 3A).
110-1	18264-18268	This	_	
110-2	18269-18277	analysis	_	
110-3	18278-18288	identified	_	
110-4	18289-18290	a	_	
110-5	18291-18302	significant	_	
110-6	18303-18311	negative	_	
110-7	18312-18324	relationship	_	
110-8	18325-18326	(	_	
110-9	18326-18337	uncorrected	_	
110-10	18338-18341	for	_	
110-11	18342-18350	multiple	_	
110-12	18351-18362	comparisons	_	
110-13	18362-18363	)	_	
110-14	18364-18371	between	_	
110-15	18372-18373	[	_	
110-16	18373-18376	11C	_	
110-17	18376-18377	]	_	
110-18	18377-18382	PBR28	_	
110-19	18383-18385	VT	_	
110-20	18386-18389	and	_	
110-21	18390-18400	dependence	_	
110-22	18401-18409	severity	_	
110-23	18409-18410	,	_	
110-24	18411-18413	as	_	
110-25	18414-18422	assessed	_	
110-26	18423-18425	by	_	
110-27	18426-18429	the	_	
110-28	18430-18437	Alcohol	_	
110-29	18438-18448	Dependence	_	
110-30	18449-18454	Scale	_	
110-31	18454-18455	,	_	
110-32	18456-18458	in	_	
110-33	18459-18470	hippocampus	_	
110-34	18471-18472	(	_	
110-35	18472-18473	p	_	
110-36	18473-18474	=	_	
110-37	18474-18479	0.035	_	
110-38	18479-18480	)	_	
110-39	18481-18484	and	_	
110-40	18485-18493	striatum	_	
110-41	18494-18495	(	_	
110-42	18495-18496	p	_	
110-43	18496-18497	=	_	
110-44	18497-18502	0.035	_	
110-45	18502-18503	)	_	
110-46	18503-18504	,	_	
110-47	18505-18509	with	_	
110-48	18510-18511	a	_	
110-49	18512-18519	similar	_	
110-50	18520-18525	trend	_	
110-51	18526-18528	in	_	
110-52	18529-18539	cerebellum	_	
110-53	18540-18541	(	_	
110-54	18541-18542	p	_	
110-55	18542-18543	=	_	
110-56	18543-18548	0.059	_	
110-57	18548-18549	;	_	
110-58	18550-18555	shown	_	
110-59	18556-18558	as	_	
110-60	18559-18560	a	_	
110-61	18561-18575	representative	_	
110-62	18576-18582	region	_	
110-63	18583-18585	in	_	
110-64	18586-18592	Figure	_	
110-65	18593-18595	3A	_	
110-66	18595-18596	)	_	
110-67	18596-18597	.	_	

#Text=These relationships indicated that more severe alcohol dependence was associated with lower levels of activated microglia.
111-1	18598-18603	These	_	
111-2	18604-18617	relationships	_	
111-3	18618-18627	indicated	_	
111-4	18628-18632	that	_	
111-5	18633-18637	more	_	
111-6	18638-18644	severe	_	
111-7	18645-18652	alcohol	_	
111-8	18653-18663	dependence	_	
111-9	18664-18667	was	_	
111-10	18668-18678	associated	_	
111-11	18679-18683	with	_	
111-12	18684-18689	lower	_	
111-13	18690-18696	levels	_	
111-14	18697-18699	of	_	
111-15	18700-18709	activated	_	
111-16	18710-18719	microglia	_	
111-17	18719-18720	.	_	

#Text=No significant relationships were found between reported drinks per day over the previous month (assessed with Timeline Followback; TLFB) or Alcohol Craving Questionnaire score with [11C]PBR28 VT using the entire alcohol dependent group.
112-1	18721-18723	No	_	
112-2	18724-18735	significant	_	
112-3	18736-18749	relationships	_	
112-4	18750-18754	were	_	
112-5	18755-18760	found	_	
112-6	18761-18768	between	_	
112-7	18769-18777	reported	_	
112-8	18778-18784	drinks	_	
112-9	18785-18788	per	_	
112-10	18789-18792	day	_	
112-11	18793-18797	over	_	
112-12	18798-18801	the	_	
112-13	18802-18810	previous	_	
112-14	18811-18816	month	_	
112-15	18817-18818	(	_	
112-16	18818-18826	assessed	_	
112-17	18827-18831	with	_	
112-18	18832-18840	Timeline	_	
112-19	18841-18851	Followback	_	
112-20	18851-18852	;	_	
112-21	18853-18857	TLFB	_	
112-22	18857-18858	)	_	
112-23	18859-18861	or	_	
112-24	18862-18869	Alcohol	_	
112-25	18870-18877	Craving	_	
112-26	18878-18891	Questionnaire	_	
112-27	18892-18897	score	_	
112-28	18898-18902	with	_	
112-29	18903-18904	[	_	
112-30	18904-18907	11C	_	
112-31	18907-18908	]	_	
112-32	18908-18913	PBR28	_	
112-33	18914-18916	VT	_	
112-34	18917-18922	using	_	
112-35	18923-18926	the	_	
112-36	18927-18933	entire	_	
112-37	18934-18941	alcohol	_	
112-38	18942-18951	dependent	_	
112-39	18952-18957	group	_	
112-40	18957-18958	.	_	

#Text=However, the heaviest drinker was a statistical outlier for this sample in reported drinks per day over the previous month (1.9 times the interquartile range greater than the third quartile).
113-1	18959-18966	However	_	
113-2	18966-18967	,	_	
113-3	18968-18971	the	_	
113-4	18972-18980	heaviest	_	
113-5	18981-18988	drinker	_	
113-6	18989-18992	was	_	
113-7	18993-18994	a	_	
113-8	18995-19006	statistical	_	
113-9	19007-19014	outlier	_	
113-10	19015-19018	for	_	
113-11	19019-19023	this	_	
113-12	19024-19030	sample	_	
113-13	19031-19033	in	_	
113-14	19034-19042	reported	_	
113-15	19043-19049	drinks	_	
113-16	19050-19053	per	_	
113-17	19054-19057	day	_	
113-18	19058-19062	over	_	
113-19	19063-19066	the	_	
113-20	19067-19075	previous	_	
113-21	19076-19081	month	_	
113-22	19082-19083	(	_	
113-23	19083-19086	1.9	_	
113-24	19087-19092	times	_	
113-25	19093-19096	the	_	
113-26	19097-19110	interquartile	_	
113-27	19111-19116	range	_	
113-28	19117-19124	greater	_	
113-29	19125-19129	than	_	
113-30	19130-19133	the	_	
113-31	19134-19139	third	_	
113-32	19140-19148	quartile	_	
113-33	19148-19149	)	_	
113-34	19149-19150	.	_	

#Text=Analyses omitting this subject indicated significant negative relationships between reported drinks per day over the previous month and [11C]PBR28 VT.
114-1	19151-19159	Analyses	_	
114-2	19160-19168	omitting	_	
114-3	19169-19173	this	_	
114-4	19174-19181	subject	_	
114-5	19182-19191	indicated	_	
114-6	19192-19203	significant	_	
114-7	19204-19212	negative	_	
114-8	19213-19226	relationships	_	
114-9	19227-19234	between	_	
114-10	19235-19243	reported	_	
114-11	19244-19250	drinks	_	
114-12	19251-19254	per	_	
114-13	19255-19258	day	_	
114-14	19259-19263	over	_	
114-15	19264-19267	the	_	
114-16	19268-19276	previous	_	
114-17	19277-19282	month	_	
114-18	19283-19286	and	_	
114-19	19287-19288	[	_	
114-20	19288-19291	11C	_	
114-21	19291-19292	]	_	
114-22	19292-19297	PBR28	_	
114-23	19298-19300	VT	_	
114-24	19300-19301	.	_	

#Text=This relationship was significant in cerebellum and striatum (both p<0.01, uncorrected; see Figure 3B for example of cerebellum) and in hippocampus (p=0.015), with a similar trend in frontal cortex (p=0.098).
115-1	19302-19306	This	_	
115-2	19307-19319	relationship	_	
115-3	19320-19323	was	_	
115-4	19324-19335	significant	_	
115-5	19336-19338	in	_	
115-6	19339-19349	cerebellum	_	
115-7	19350-19353	and	_	
115-8	19354-19362	striatum	_	
115-9	19363-19364	(	_	
115-10	19364-19368	both	_	
115-11	19369-19370	p	_	
115-12	19370-19371	<	_	
115-13	19371-19375	0.01	_	
115-14	19375-19376	,	_	
115-15	19377-19388	uncorrected	_	
115-16	19388-19389	;	_	
115-17	19390-19393	see	_	
115-18	19394-19400	Figure	_	
115-19	19401-19403	3B	_	
115-20	19404-19407	for	_	
115-21	19408-19415	example	_	
115-22	19416-19418	of	_	
115-23	19419-19429	cerebellum	_	
115-24	19429-19430	)	_	
115-25	19431-19434	and	_	
115-26	19435-19437	in	_	
115-27	19438-19449	hippocampus	_	
115-28	19450-19451	(	_	
115-29	19451-19452	p	_	
115-30	19452-19453	=	_	
115-31	19453-19458	0.015	_	
115-32	19458-19459	)	_	
115-33	19459-19460	,	_	
115-34	19461-19465	with	_	
115-35	19466-19467	a	_	
115-36	19468-19475	similar	_	
115-37	19476-19481	trend	_	
115-38	19482-19484	in	_	
115-39	19485-19492	frontal	_	
115-40	19493-19499	cortex	_	
115-41	19500-19501	(	_	
115-42	19501-19502	p	_	
115-43	19502-19503	=	_	
115-44	19503-19508	0.098	_	
115-45	19508-19509	)	_	
115-46	19509-19510	.	_	

#Text=A complete summary of these analyses is presented in Figure 3C.
116-1	19511-19512	A	_	
116-2	19513-19521	complete	_	
116-3	19522-19529	summary	_	
116-4	19530-19532	of	_	
116-5	19533-19538	these	_	
116-6	19539-19547	analyses	_	
116-7	19548-19550	is	_	
116-8	19551-19560	presented	_	
116-9	19561-19563	in	_	
116-10	19564-19570	Figure	_	
116-11	19571-19573	3C	_	
116-12	19573-19574	.	_	

#Text=Monocytes successfully derived from 9 alcohol dependent individuals and 8 controls were cultured and assayed for cytokine expression.
117-1	19575-19584	Monocytes	_	
117-2	19585-19597	successfully	_	
117-3	19598-19605	derived	_	
117-4	19606-19610	from	_	
117-5	19611-19612	9	_	
117-6	19613-19620	alcohol	_	
117-7	19621-19630	dependent	_	
117-8	19631-19642	individuals	_	
117-9	19643-19646	and	_	
117-10	19647-19648	8	_	
117-11	19649-19657	controls	_	
117-12	19658-19662	were	_	
117-13	19663-19671	cultured	_	
117-14	19672-19675	and	_	
117-15	19676-19683	assayed	_	
117-16	19684-19687	for	_	
117-17	19688-19696	cytokine	_	
117-18	19697-19707	expression	_	
117-19	19707-19708	.	_	

#Text=Stimulation of monocytes with LPS robustly increased measured cytokine expression relative to non-stimulated samples for all subjects, indicated by cytokine fold-change values significantly greater than 1 in Figures 4.
118-1	19709-19720	Stimulation	_	
118-2	19721-19723	of	_	
118-3	19724-19733	monocytes	_	
118-4	19734-19738	with	_	
118-5	19739-19742	LPS	_	
118-6	19743-19751	robustly	_	
118-7	19752-19761	increased	_	
118-8	19762-19770	measured	_	
118-9	19771-19779	cytokine	_	
118-10	19780-19790	expression	_	
118-11	19791-19799	relative	_	
118-12	19800-19802	to	_	
118-13	19803-19817	non-stimulated	_	
118-14	19818-19825	samples	_	
118-15	19826-19829	for	_	
118-16	19830-19833	all	_	
118-17	19834-19842	subjects	_	
118-18	19842-19843	,	_	
118-19	19844-19853	indicated	_	
118-20	19854-19856	by	_	
118-21	19857-19865	cytokine	_	
118-22	19866-19877	fold-change	_	
118-23	19878-19884	values	_	
118-24	19885-19898	significantly	_	
118-25	19899-19906	greater	_	
118-26	19907-19911	than	_	
118-27	19912-19913	1	_	
118-28	19914-19916	in	_	
118-29	19917-19924	Figures	_	
118-30	19925-19926	4	_	
118-31	19926-19927	.	_	

#Text=For pro-inflammatory cytokines, which promote inflammatory signaling including microglial activation, there was a trend of blunted LPS-induced fold-increase of cytokine expression for alcohol dependent subjects relative to healthy controls (F(1,14)=4.116, p=0.062).
119-1	19928-19931	For	_	
119-2	19932-19948	pro-inflammatory	_	
119-3	19949-19958	cytokines	_	
119-4	19958-19959	,	_	
119-5	19960-19965	which	_	
119-6	19966-19973	promote	_	
119-7	19974-19986	inflammatory	_	
119-8	19987-19996	signaling	_	
119-9	19997-20006	including	_	
119-10	20007-20017	microglial	_	
119-11	20018-20028	activation	_	
119-12	20028-20029	,	_	
119-13	20030-20035	there	_	
119-14	20036-20039	was	_	
119-15	20040-20041	a	_	
119-16	20042-20047	trend	_	
119-17	20048-20050	of	_	
119-18	20051-20058	blunted	_	
119-19	20059-20070	LPS-induced	_	
119-20	20071-20084	fold-increase	_	
119-21	20085-20087	of	_	
119-22	20088-20096	cytokine	_	
119-23	20097-20107	expression	_	
119-24	20108-20111	for	_	
119-25	20112-20119	alcohol	_	
119-26	20120-20129	dependent	_	
119-27	20130-20138	subjects	_	
119-28	20139-20147	relative	_	
119-29	20148-20150	to	_	
119-30	20151-20158	healthy	_	
119-31	20159-20167	controls	_	
119-32	20168-20169	(	_	
119-33	20169-20170	F	_	
119-34	20170-20171	(	_	
119-35	20171-20175	1,14	_	
119-36	20175-20176	)	_	
119-37	20176-20177	=	_	
119-38	20177-20182	4.116	_	
119-39	20182-20183	,	_	
119-40	20184-20185	p	_	
119-41	20185-20186	=	_	
119-42	20186-20191	0.062	_	
119-43	20191-20192	)	_	
119-44	20192-20193	.	_	

#Text=Post-hoc analysis revealed the effect to be significant for the cytokines IL-8 (p=0.031; Fig 4A) and IL-6 (p=0.043; Fig. 4B), while no significant differences were observed for IL-1β or TNF-α (Fig. 4C-D).
120-1	20194-20202	Post-hoc	_	
120-2	20203-20211	analysis	_	
120-3	20212-20220	revealed	_	
120-4	20221-20224	the	_	
120-5	20225-20231	effect	_	
120-6	20232-20234	to	_	
120-7	20235-20237	be	_	
120-8	20238-20249	significant	_	
120-9	20250-20253	for	_	
120-10	20254-20257	the	_	
120-11	20258-20267	cytokines	_	
120-12	20268-20270	IL	_	
120-13	20270-20271	-	_	
120-14	20271-20272	8	_	
120-15	20273-20274	(	_	
120-16	20274-20275	p	_	
120-17	20275-20276	=	_	
120-18	20276-20281	0.031	_	
120-19	20281-20282	;	_	
120-20	20283-20286	Fig	_	
120-21	20287-20289	4A	_	
120-22	20289-20290	)	_	
120-23	20291-20294	and	_	
120-24	20295-20297	IL	_	
120-25	20297-20298	-	_	
120-26	20298-20299	6	_	
120-27	20300-20301	(	_	
120-28	20301-20302	p	_	
120-29	20302-20303	=	_	
120-30	20303-20308	0.043	_	
120-31	20308-20309	;	_	
120-32	20310-20313	Fig	_	
120-33	20313-20314	.	_	
120-34	20315-20317	4B	_	
120-35	20317-20318	)	_	
120-36	20318-20319	,	_	
120-37	20320-20325	while	_	
120-38	20326-20328	no	_	
120-39	20329-20340	significant	_	
120-40	20341-20352	differences	_	
120-41	20353-20357	were	_	
120-42	20358-20366	observed	_	
120-43	20367-20370	for	_	
120-44	20371-20373	IL	_	
120-45	20373-20374	-	_	
120-46	20374-20376	1β	_	
120-47	20377-20379	or	_	
120-48	20380-20385	TNF-α	_	
120-49	20386-20387	(	_	
120-50	20387-20390	Fig	_	
120-51	20390-20391	.	_	
120-52	20392-20396	4C-D	_	
120-53	20396-20397	)	_	
120-54	20397-20398	.	_	

#Text=For anti-inflammatory cytokines, which suppress inflammatory signaling including microglial activation, LPS-induced fold-changes of IL-10 and IL-4 were not significantly different between alcohol dependent individuals and healthy controls (F(1,7)=2.355, p=0.169; Figure 4E-F).
121-1	20399-20402	For	_	
121-2	20403-20420	anti-inflammatory	_	
121-3	20421-20430	cytokines	_	
121-4	20430-20431	,	_	
121-5	20432-20437	which	_	
121-6	20438-20446	suppress	_	
121-7	20447-20459	inflammatory	_	
121-8	20460-20469	signaling	_	
121-9	20470-20479	including	_	
121-10	20480-20490	microglial	_	
121-11	20491-20501	activation	_	
121-12	20501-20502	,	_	
121-13	20503-20514	LPS-induced	_	
121-14	20515-20527	fold-changes	_	
121-15	20528-20530	of	_	
121-16	20531-20533	IL	_	
121-17	20533-20534	-	_	
121-18	20534-20536	10	_	
121-19	20537-20540	and	_	
121-20	20541-20543	IL	_	
121-21	20543-20544	-	_	
121-22	20544-20545	4	_	
121-23	20546-20550	were	_	
121-24	20551-20554	not	_	
121-25	20555-20568	significantly	_	
121-26	20569-20578	different	_	
121-27	20579-20586	between	_	
121-28	20587-20594	alcohol	_	
121-29	20595-20604	dependent	_	
121-30	20605-20616	individuals	_	
121-31	20617-20620	and	_	
121-32	20621-20628	healthy	_	
121-33	20629-20637	controls	_	
121-34	20638-20639	(	_	
121-35	20639-20640	F	_	
121-36	20640-20641	(	_	
121-37	20641-20644	1,7	_	
121-38	20644-20645	)	_	
121-39	20645-20646	=	_	
121-40	20646-20651	2.355	_	
121-41	20651-20652	,	_	
121-42	20653-20654	p	_	
121-43	20654-20655	=	_	
121-44	20655-20660	0.169	_	
121-45	20660-20661	;	_	
121-46	20662-20668	Figure	_	
121-47	20669-20673	4E-F	_	
121-48	20673-20674	)	_	
121-49	20674-20675	.	_	

#Text=No significant relationships between LPS-induced fold-changes in cytokine expression and alcohol use characteristics or levels of activated microglia in brain were observed.
122-1	20676-20678	No	_	
122-2	20679-20690	significant	_	
122-3	20691-20704	relationships	_	
122-4	20705-20712	between	_	
122-5	20713-20724	LPS-induced	_	
122-6	20725-20737	fold-changes	_	
122-7	20738-20740	in	_	
122-8	20741-20749	cytokine	_	
122-9	20750-20760	expression	_	
122-10	20761-20764	and	_	
122-11	20765-20772	alcohol	_	
122-12	20773-20776	use	_	
122-13	20777-20792	characteristics	_	
122-14	20793-20795	or	_	
122-15	20796-20802	levels	_	
122-16	20803-20805	of	_	
122-17	20806-20815	activated	_	
122-18	20816-20825	microglia	_	
122-19	20826-20828	in	_	
122-20	20829-20834	brain	_	
122-21	20835-20839	were	_	
122-22	20840-20848	observed	_	
122-23	20848-20849	.	_	

#Text=Discussion
#Text=The primary finding in this neuroimaging study is significantly lower levels of activated microglia in the brains of living alcohol dependent subjects compared to healthy controls as measured with [11C]PBR28 PET.
123-1	20850-20860	Discussion	_	
123-2	20861-20864	The	_	
123-3	20865-20872	primary	_	
123-4	20873-20880	finding	_	
123-5	20881-20883	in	_	
123-6	20884-20888	this	_	
123-7	20889-20901	neuroimaging	_	
123-8	20902-20907	study	_	
123-9	20908-20910	is	_	
123-10	20911-20924	significantly	_	
123-11	20925-20930	lower	_	
123-12	20931-20937	levels	_	
123-13	20938-20940	of	_	
123-14	20941-20950	activated	_	
123-15	20951-20960	microglia	_	
123-16	20961-20963	in	_	
123-17	20964-20967	the	_	
123-18	20968-20974	brains	_	
123-19	20975-20977	of	_	
123-20	20978-20984	living	_	
123-21	20985-20992	alcohol	_	
123-22	20993-21002	dependent	_	
123-23	21003-21011	subjects	_	
123-24	21012-21020	compared	_	
123-25	21021-21023	to	_	
123-26	21024-21031	healthy	_	
123-27	21032-21040	controls	_	
123-28	21041-21043	as	_	
123-29	21044-21052	measured	_	
123-30	21053-21057	with	_	
123-31	21058-21059	[	_	
123-32	21059-21062	11C	_	
123-33	21062-21063	]	_	
123-34	21063-21068	PBR28	_	
123-35	21069-21072	PET	_	
123-36	21072-21073	.	_	

#Text=Importantly, exploratory analyses suggest that lower [11C]PBR28 VT values are associated with greater alcohol dependence severity and more reported drinks per day over the previous month.
124-1	21074-21085	Importantly	_	
124-2	21085-21086	,	_	
124-3	21087-21098	exploratory	_	
124-4	21099-21107	analyses	_	
124-5	21108-21115	suggest	_	
124-6	21116-21120	that	_	
124-7	21121-21126	lower	_	
124-8	21127-21128	[	_	
124-9	21128-21131	11C	_	
124-10	21131-21132	]	_	
124-11	21132-21137	PBR28	_	
124-12	21138-21140	VT	_	
124-13	21141-21147	values	_	
124-14	21148-21151	are	_	
124-15	21152-21162	associated	_	
124-16	21163-21167	with	_	
124-17	21168-21175	greater	_	
124-18	21176-21183	alcohol	_	
124-19	21184-21194	dependence	_	
124-20	21195-21203	severity	_	
124-21	21204-21207	and	_	
124-22	21208-21212	more	_	
124-23	21213-21221	reported	_	
124-24	21222-21228	drinks	_	
124-25	21229-21232	per	_	
124-26	21233-21236	day	_	
124-27	21237-21241	over	_	
124-28	21242-21245	the	_	
124-29	21246-21254	previous	_	
124-30	21255-21260	month	_	
124-31	21260-21261	.	_	

#Text=This PET imaging study fills a crucial gap in the literature by measuring an in vivo brain marker of activated microglia levels in alcohol dependent subjects.
125-1	21262-21266	This	_	
125-2	21267-21270	PET	_	
125-3	21271-21278	imaging	_	
125-4	21279-21284	study	_	
125-5	21285-21290	fills	_	
125-6	21291-21292	a	_	
125-7	21293-21300	crucial	_	
125-8	21301-21304	gap	_	
125-9	21305-21307	in	_	
125-10	21308-21311	the	_	
125-11	21312-21322	literature	_	
125-12	21323-21325	by	_	
125-13	21326-21335	measuring	_	
125-14	21336-21338	an	_	
125-15	21339-21341	in	_	
125-16	21342-21346	vivo	_	
125-17	21347-21352	brain	_	
125-18	21353-21359	marker	_	
125-19	21360-21362	of	_	
125-20	21363-21372	activated	_	
125-21	21373-21382	microglia	_	
125-22	21383-21389	levels	_	
125-23	21390-21392	in	_	
125-24	21393-21400	alcohol	_	
125-25	21401-21410	dependent	_	
125-26	21411-21419	subjects	_	
125-27	21419-21420	.	_	

#Text=Additionally, peripheral monocytes from alcohol dependent subjects exhibit a blunted response for the pro-inflammatory cytokines IL-6 and IL-8 to LPS stimulus compared to healthy controls.
126-1	21421-21433	Additionally	_	
126-2	21433-21434	,	_	
126-3	21435-21445	peripheral	_	
126-4	21446-21455	monocytes	_	
126-5	21456-21460	from	_	
126-6	21461-21468	alcohol	_	
126-7	21469-21478	dependent	_	
126-8	21479-21487	subjects	_	
126-9	21488-21495	exhibit	_	
126-10	21496-21497	a	_	
126-11	21498-21505	blunted	_	
126-12	21506-21514	response	_	
126-13	21515-21518	for	_	
126-14	21519-21522	the	_	
126-15	21523-21539	pro-inflammatory	_	
126-16	21540-21549	cytokines	_	
126-17	21550-21552	IL	_	
126-18	21552-21553	-	_	
126-19	21553-21554	6	_	
126-20	21555-21558	and	_	
126-21	21559-21561	IL	_	
126-22	21561-21562	-	_	
126-23	21562-21563	8	_	
126-24	21564-21566	to	_	
126-25	21567-21570	LPS	_	
126-26	21571-21579	stimulus	_	
126-27	21580-21588	compared	_	
126-28	21589-21591	to	_	
126-29	21592-21599	healthy	_	
126-30	21600-21608	controls	_	
126-31	21608-21609	.	_	

#Text=Taken together, these findings suggest that alcohol dependence is associated with lower levels of activated microglia in the brain and a blunted immune response in the periphery.
127-1	21610-21615	Taken	_	
127-2	21616-21624	together	_	
127-3	21624-21625	,	_	
127-4	21626-21631	these	_	
127-5	21632-21640	findings	_	
127-6	21641-21648	suggest	_	
127-7	21649-21653	that	_	
127-8	21654-21661	alcohol	_	
127-9	21662-21672	dependence	_	
127-10	21673-21675	is	_	
127-11	21676-21686	associated	_	
127-12	21687-21691	with	_	
127-13	21692-21697	lower	_	
127-14	21698-21704	levels	_	
127-15	21705-21707	of	_	
127-16	21708-21717	activated	_	
127-17	21718-21727	microglia	_	
127-18	21728-21730	in	_	
127-19	21731-21734	the	_	
127-20	21735-21740	brain	_	
127-21	21741-21744	and	_	
127-22	21745-21746	a	_	
127-23	21747-21754	blunted	_	
127-24	21755-21761	immune	_	
127-25	21762-21770	response	_	
127-26	21771-21773	in	_	
127-27	21774-21777	the	_	
127-28	21778-21787	periphery	_	
127-29	21787-21788	.	_	

#Text=The main finding of lower activated microglia levels in alcohol dependent individuals compared to controls extends our current understanding of the influence of alcohol on the neuroimmune system.
128-1	21789-21792	The	_	
128-2	21793-21797	main	_	
128-3	21798-21805	finding	_	
128-4	21806-21808	of	_	
128-5	21809-21814	lower	_	
128-6	21815-21824	activated	_	
128-7	21825-21834	microglia	_	
128-8	21835-21841	levels	_	
128-9	21842-21844	in	_	
128-10	21845-21852	alcohol	_	
128-11	21853-21862	dependent	_	
128-12	21863-21874	individuals	_	
128-13	21875-21883	compared	_	
128-14	21884-21886	to	_	
128-15	21887-21895	controls	_	
128-16	21896-21903	extends	_	
128-17	21904-21907	our	_	
128-18	21908-21915	current	_	
128-19	21916-21929	understanding	_	
128-20	21930-21932	of	_	
128-21	21933-21936	the	_	
128-22	21937-21946	influence	_	
128-23	21947-21949	of	_	
128-24	21950-21957	alcohol	_	
128-25	21958-21960	on	_	
128-26	21961-21964	the	_	
128-27	21965-21976	neuroimmune	_	
128-28	21977-21983	system	_	
128-29	21983-21984	.	_	

#Text=A large body of preclinical literature converges on a profile of microglial activation following models of binge alcohol treatment in rodents.
129-1	21985-21986	A	_	
129-2	21987-21992	large	_	
129-3	21993-21997	body	_	
129-4	21998-22000	of	_	
129-5	22001-22012	preclinical	_	
129-6	22013-22023	literature	_	
129-7	22024-22033	converges	_	
129-8	22034-22036	on	_	
129-9	22037-22038	a	_	
129-10	22039-22046	profile	_	
129-11	22047-22049	of	_	
129-12	22050-22060	microglial	_	
129-13	22061-22071	activation	_	
129-14	22072-22081	following	_	
129-15	22082-22088	models	_	
129-16	22089-22091	of	_	
129-17	22092-22097	binge	_	
129-18	22098-22105	alcohol	_	
129-19	22106-22115	treatment	_	
129-20	22116-22118	in	_	
129-21	22119-22126	rodents	_	
129-22	22126-22127	.	_	

#Text=Specifically, recent studies provide evidence that an initial binge episode results in low or partial microglial activation, which ‘primes’ the microglia for greater activation following subsequent binge episodes.
130-1	22128-22140	Specifically	_	
130-2	22140-22141	,	_	
130-3	22142-22148	recent	_	
130-4	22149-22156	studies	_	
130-5	22157-22164	provide	_	
130-6	22165-22173	evidence	_	
130-7	22174-22178	that	_	
130-8	22179-22181	an	_	
130-9	22182-22189	initial	_	
130-10	22190-22195	binge	_	
130-11	22196-22203	episode	_	
130-12	22204-22211	results	_	
130-13	22212-22214	in	_	
130-14	22215-22218	low	_	
130-15	22219-22221	or	_	
130-16	22222-22229	partial	_	
130-17	22230-22240	microglial	_	
130-18	22241-22251	activation	_	
130-19	22251-22252	,	_	
130-20	22253-22258	which	_	
130-21	22259-22260	‘	_	
130-22	22260-22266	primes	_	
130-23	22266-22267	’	_	
130-24	22268-22271	the	_	
130-25	22272-22281	microglia	_	
130-26	22282-22285	for	_	
130-27	22286-22293	greater	_	
130-28	22294-22304	activation	_	
130-29	22305-22314	following	_	
130-30	22315-22325	subsequent	_	
130-31	22326-22331	binge	_	
130-32	22332-22340	episodes	_	
130-33	22340-22341	.	_	

#Text=‘Primed’ microglia may be associated with increased cell death and neurodegenerative disorders.
131-1	22342-22343	‘	_	
131-2	22343-22349	Primed	_	
131-3	22349-22350	’	_	
131-4	22351-22360	microglia	_	
131-5	22361-22364	may	_	
131-6	22365-22367	be	_	
131-7	22368-22378	associated	_	
131-8	22379-22383	with	_	
131-9	22384-22393	increased	_	
131-10	22394-22398	cell	_	
131-11	22399-22404	death	_	
131-12	22405-22408	and	_	
131-13	22409-22426	neurodegenerative	_	
131-14	22427-22436	disorders	_	
131-15	22436-22437	.	_	

#Text=However, rodent models of alcohol exposure have obvious limitations in modeling years of clinical alcohol dependence.
132-1	22438-22445	However	_	
132-2	22445-22446	,	_	
132-3	22447-22453	rodent	_	
132-4	22454-22460	models	_	
132-5	22461-22463	of	_	
132-6	22464-22471	alcohol	_	
132-7	22472-22480	exposure	_	
132-8	22481-22485	have	_	
132-9	22486-22493	obvious	_	
132-10	22494-22505	limitations	_	
132-11	22506-22508	in	_	
132-12	22509-22517	modeling	_	
132-13	22518-22523	years	_	
132-14	22524-22526	of	_	
132-15	22527-22535	clinical	_	
132-16	22536-22543	alcohol	_	
132-17	22544-22554	dependence	_	
132-18	22554-22555	.	_	

#Text=The present finding of low levels of activated microglia in alcohol dependence extends these preclinical findings to the clinical case of chronic alcohol use over a period of many years, and is consistent with a preliminary report from a separate imaging center of reduced [11C]PBR28 VT in the hippocampus of alcohol dependent patients.
133-1	22556-22559	The	_	
133-2	22560-22567	present	_	
133-3	22568-22575	finding	_	
133-4	22576-22578	of	_	
133-5	22579-22582	low	_	
133-6	22583-22589	levels	_	
133-7	22590-22592	of	_	
133-8	22593-22602	activated	_	
133-9	22603-22612	microglia	_	
133-10	22613-22615	in	_	
133-11	22616-22623	alcohol	_	
133-12	22624-22634	dependence	_	
133-13	22635-22642	extends	_	
133-14	22643-22648	these	_	
133-15	22649-22660	preclinical	_	
133-16	22661-22669	findings	_	
133-17	22670-22672	to	_	
133-18	22673-22676	the	_	
133-19	22677-22685	clinical	_	
133-20	22686-22690	case	_	
133-21	22691-22693	of	_	
133-22	22694-22701	chronic	_	
133-23	22702-22709	alcohol	_	
133-24	22710-22713	use	_	
133-25	22714-22718	over	_	
133-26	22719-22720	a	_	
133-27	22721-22727	period	_	
133-28	22728-22730	of	_	
133-29	22731-22735	many	_	
133-30	22736-22741	years	_	
133-31	22741-22742	,	_	
133-32	22743-22746	and	_	
133-33	22747-22749	is	_	
133-34	22750-22760	consistent	_	
133-35	22761-22765	with	_	
133-36	22766-22767	a	_	
133-37	22768-22779	preliminary	_	
133-38	22780-22786	report	_	
133-39	22787-22791	from	_	
133-40	22792-22793	a	_	
133-41	22794-22802	separate	_	
133-42	22803-22810	imaging	_	
133-43	22811-22817	center	_	
133-44	22818-22820	of	_	
133-45	22821-22828	reduced	_	
133-46	22829-22830	[	_	
133-47	22830-22833	11C	_	
133-48	22833-22834	]	_	
133-49	22834-22839	PBR28	_	
133-50	22840-22842	VT	_	
133-51	22843-22845	in	_	
133-52	22846-22849	the	_	
133-53	22850-22861	hippocampus	_	
133-54	22862-22864	of	_	
133-55	22865-22872	alcohol	_	
133-56	22873-22882	dependent	_	
133-57	22883-22891	patients	_	
133-58	22891-22892	.	_	

#Text=Indeed, the finding of negative associations of brain levels of activated microglia with both reported drinks per day over the previous month and alcohol dependence severity imply a close connection between chronic alcohol use and microglial levels.
134-1	22893-22899	Indeed	_	
134-2	22899-22900	,	_	
134-3	22901-22904	the	_	
134-4	22905-22912	finding	_	
134-5	22913-22915	of	_	
134-6	22916-22924	negative	_	
134-7	22925-22937	associations	_	
134-8	22938-22940	of	_	
134-9	22941-22946	brain	_	
134-10	22947-22953	levels	_	
134-11	22954-22956	of	_	
134-12	22957-22966	activated	_	
134-13	22967-22976	microglia	_	
134-14	22977-22981	with	_	
134-15	22982-22986	both	_	
134-16	22987-22995	reported	_	
134-17	22996-23002	drinks	_	
134-18	23003-23006	per	_	
134-19	23007-23010	day	_	
134-20	23011-23015	over	_	
134-21	23016-23019	the	_	
134-22	23020-23028	previous	_	
134-23	23029-23034	month	_	
134-24	23035-23038	and	_	
134-25	23039-23046	alcohol	_	
134-26	23047-23057	dependence	_	
134-27	23058-23066	severity	_	
134-28	23067-23072	imply	_	
134-29	23073-23074	a	_	
134-30	23075-23080	close	_	
134-31	23081-23091	connection	_	
134-32	23092-23099	between	_	
134-33	23100-23107	chronic	_	
134-34	23108-23115	alcohol	_	
134-35	23116-23119	use	_	
134-36	23120-23123	and	_	
134-37	23124-23134	microglial	_	
134-38	23135-23141	levels	_	
134-39	23141-23142	.	_	

#Text=Whether lower levels of activated microglia in brain contributed to or were merely a result of alcohol dependence is not known, however, this finding is consistent with the observation that individuals with alcohol dependence have increased susceptibility to liver disease, sepsis, and reduced host repair, possibly due to an inability to mount sufficient responses to inflammatory challenges.
135-1	23143-23150	Whether	_	
135-2	23151-23156	lower	_	
135-3	23157-23163	levels	_	
135-4	23164-23166	of	_	
135-5	23167-23176	activated	_	
135-6	23177-23186	microglia	_	
135-7	23187-23189	in	_	
135-8	23190-23195	brain	_	
135-9	23196-23207	contributed	_	
135-10	23208-23210	to	_	
135-11	23211-23213	or	_	
135-12	23214-23218	were	_	
135-13	23219-23225	merely	_	
135-14	23226-23227	a	_	
135-15	23228-23234	result	_	
135-16	23235-23237	of	_	
135-17	23238-23245	alcohol	_	
135-18	23246-23256	dependence	_	
135-19	23257-23259	is	_	
135-20	23260-23263	not	_	
135-21	23264-23269	known	_	
135-22	23269-23270	,	_	
135-23	23271-23278	however	_	
135-24	23278-23279	,	_	
135-25	23280-23284	this	_	
135-26	23285-23292	finding	_	
135-27	23293-23295	is	_	
135-28	23296-23306	consistent	_	
135-29	23307-23311	with	_	
135-30	23312-23315	the	_	
135-31	23316-23327	observation	_	
135-32	23328-23332	that	_	
135-33	23333-23344	individuals	_	
135-34	23345-23349	with	_	
135-35	23350-23357	alcohol	_	
135-36	23358-23368	dependence	_	
135-37	23369-23373	have	_	
135-38	23374-23383	increased	_	
135-39	23384-23398	susceptibility	_	
135-40	23399-23401	to	_	
135-41	23402-23407	liver	_	
135-42	23408-23415	disease	_	
135-43	23415-23416	,	_	
135-44	23417-23423	sepsis	_	
135-45	23423-23424	,	_	
135-46	23425-23428	and	_	
135-47	23429-23436	reduced	_	
135-48	23437-23441	host	_	
135-49	23442-23448	repair	_	
135-50	23448-23449	,	_	
135-51	23450-23458	possibly	_	
135-52	23459-23462	due	_	
135-53	23463-23465	to	_	
135-54	23466-23468	an	_	
135-55	23469-23478	inability	_	
135-56	23479-23481	to	_	
135-57	23482-23487	mount	_	
135-58	23488-23498	sufficient	_	
135-59	23499-23508	responses	_	
135-60	23509-23511	to	_	
135-61	23512-23524	inflammatory	_	
135-62	23525-23535	challenges	_	
135-63	23535-23536	.	_	

#Text=Such a hypothesis parallels emerging evidence of dystrophic microglia associated with advanced neurodegeneration.
136-1	23537-23541	Such	_	
136-2	23542-23543	a	_	
136-3	23544-23554	hypothesis	_	
136-4	23555-23564	parallels	_	
136-5	23565-23573	emerging	_	
136-6	23574-23582	evidence	_	
136-7	23583-23585	of	_	
136-8	23586-23596	dystrophic	_	
136-9	23597-23606	microglia	_	
136-10	23607-23617	associated	_	
136-11	23618-23622	with	_	
136-12	23623-23631	advanced	_	
136-13	23632-23649	neurodegeneration	_	
136-14	23649-23650	.	_	

#Text=Thus, we hypothesize that chronic activation of microglia from alcohol abuse eventually diminishes, or ‘burns out’, levels of activated microglia in brain.
#Text=[11C]PBR28 binds specifically to TSPO, which are overexpressed during microglial activation.
137-1	23651-23655	Thus	_	
137-2	23655-23656	,	_	
137-3	23657-23659	we	_	
137-4	23660-23671	hypothesize	_	
137-5	23672-23676	that	_	
137-6	23677-23684	chronic	_	
137-7	23685-23695	activation	_	
137-8	23696-23698	of	_	
137-9	23699-23708	microglia	_	
137-10	23709-23713	from	_	
137-11	23714-23721	alcohol	_	
137-12	23722-23727	abuse	_	
137-13	23728-23738	eventually	_	
137-14	23739-23749	diminishes	_	
137-15	23749-23750	,	_	
137-16	23751-23753	or	_	
137-17	23754-23755	‘	_	
137-18	23755-23760	burns	_	
137-19	23761-23764	out	_	
137-20	23764-23765	’	_	
137-21	23765-23766	,	_	
137-22	23767-23773	levels	_	
137-23	23774-23776	of	_	
137-24	23777-23786	activated	_	
137-25	23787-23796	microglia	_	
137-26	23797-23799	in	_	
137-27	23800-23805	brain	_	
137-28	23805-23806	.	_	
137-29	23807-23808	[	_	
137-30	23808-23811	11C	_	
137-31	23811-23812	]	_	
137-32	23812-23817	PBR28	_	
137-33	23818-23823	binds	_	
137-34	23824-23836	specifically	_	
137-35	23837-23839	to	_	
137-36	23840-23844	TSPO	_	
137-37	23844-23845	,	_	
137-38	23846-23851	which	_	
137-39	23852-23855	are	_	
137-40	23856-23869	overexpressed	_	
137-41	23870-23876	during	_	
137-42	23877-23887	microglial	_	
137-43	23888-23898	activation	_	
137-44	23898-23899	.	_	

#Text=TSPO are also expressed on astrocytes and with astrocyte activation, however, immunohistochemistry work from our lab indicated LPS-induced TSPO increases to result almost exclusively in activated microglia.
138-1	23900-23904	TSPO	_	
138-2	23905-23908	are	_	
138-3	23909-23913	also	_	
138-4	23914-23923	expressed	_	
138-5	23924-23926	on	_	
138-6	23927-23937	astrocytes	_	
138-7	23938-23941	and	_	
138-8	23942-23946	with	_	
138-9	23947-23956	astrocyte	_	
138-10	23957-23967	activation	_	
138-11	23967-23968	,	_	
138-12	23969-23976	however	_	
138-13	23976-23977	,	_	
138-14	23978-23998	immunohistochemistry	_	
138-15	23999-24003	work	_	
138-16	24004-24008	from	_	
138-17	24009-24012	our	_	
138-18	24013-24016	lab	_	
138-19	24017-24026	indicated	_	
138-20	24027-24038	LPS-induced	_	
138-21	24039-24043	TSPO	_	
138-22	24044-24053	increases	_	
138-23	24054-24056	to	_	
138-24	24057-24063	result	_	
138-25	24064-24070	almost	_	
138-26	24071-24082	exclusively	_	
138-27	24083-24085	in	_	
138-28	24086-24095	activated	_	
138-29	24096-24105	microglia	_	
138-30	24105-24106	.	_	

#Text=Therefore observed [11C]PBR28 signal is generally attributed to levels of activated microglia.
139-1	24107-24116	Therefore	_	
139-2	24117-24125	observed	_	
139-3	24126-24127	[	_	
139-4	24127-24130	11C	_	
139-5	24130-24131	]	_	
139-6	24131-24136	PBR28	_	
139-7	24137-24143	signal	_	
139-8	24144-24146	is	_	
139-9	24147-24156	generally	_	
139-10	24157-24167	attributed	_	
139-11	24168-24170	to	_	
139-12	24171-24177	levels	_	
139-13	24178-24180	of	_	
139-14	24181-24190	activated	_	
139-15	24191-24200	microglia	_	
139-16	24200-24201	.	_	

#Text=While this is a simple interpretation for increased TSPO levels, the data here indicating lower TSPO levels have a more difficult interpretation.
140-1	24202-24207	While	_	
140-2	24208-24212	this	_	
140-3	24213-24215	is	_	
140-4	24216-24217	a	_	
140-5	24218-24224	simple	_	
140-6	24225-24239	interpretation	_	
140-7	24240-24243	for	_	
140-8	24244-24253	increased	_	
140-9	24254-24258	TSPO	_	
140-10	24259-24265	levels	_	
140-11	24265-24266	,	_	
140-12	24267-24270	the	_	
140-13	24271-24275	data	_	
140-14	24276-24280	here	_	
140-15	24281-24291	indicating	_	
140-16	24292-24297	lower	_	
140-17	24298-24302	TSPO	_	
140-18	24303-24309	levels	_	
140-19	24310-24314	have	_	
140-20	24315-24316	a	_	
140-21	24317-24321	more	_	
140-22	24322-24331	difficult	_	
140-23	24332-24346	interpretation	_	
140-24	24346-24347	.	_	

#Text=TSPO expression is low in healthy brain, but specific [11C]PBR28 binding is still displaceable in normal humans.
141-1	24348-24352	TSPO	_	
141-2	24353-24363	expression	_	
141-3	24364-24366	is	_	
141-4	24367-24370	low	_	
141-5	24371-24373	in	_	
141-6	24374-24381	healthy	_	
141-7	24382-24387	brain	_	
141-8	24387-24388	,	_	
141-9	24389-24392	but	_	
141-10	24393-24401	specific	_	
141-11	24402-24403	[	_	
141-12	24403-24406	11C	_	
141-13	24406-24407	]	_	
141-14	24407-24412	PBR28	_	
141-15	24413-24420	binding	_	
141-16	24421-24423	is	_	
141-17	24424-24429	still	_	
141-18	24430-24442	displaceable	_	
141-19	24443-24445	in	_	
141-20	24446-24452	normal	_	
141-21	24453-24459	humans	_	
141-22	24459-24460	.	_	

#Text=Thus some baseline level of TSPO expression is present in the healthy brain.
142-1	24461-24465	Thus	_	
142-2	24466-24470	some	_	
142-3	24471-24479	baseline	_	
142-4	24480-24485	level	_	
142-5	24486-24488	of	_	
142-6	24489-24493	TSPO	_	
142-7	24494-24504	expression	_	
142-8	24505-24507	is	_	
142-9	24508-24515	present	_	
142-10	24516-24518	in	_	
142-11	24519-24522	the	_	
142-12	24523-24530	healthy	_	
142-13	24531-24536	brain	_	
142-14	24536-24537	.	_	

#Text=Additionally, pharmacological interventions can deplete microglia levels in healthy rodents and reduce TSPO levels in humans, raising the possibility of a dynamic range in baseline microglial levels.
143-1	24538-24550	Additionally	_	
143-2	24550-24551	,	_	
143-3	24552-24567	pharmacological	_	
143-4	24568-24581	interventions	_	
143-5	24582-24585	can	_	
143-6	24586-24593	deplete	_	
143-7	24594-24603	microglia	_	
143-8	24604-24610	levels	_	
143-9	24611-24613	in	_	
143-10	24614-24621	healthy	_	
143-11	24622-24629	rodents	_	
143-12	24630-24633	and	_	
143-13	24634-24640	reduce	_	
143-14	24641-24645	TSPO	_	
143-15	24646-24652	levels	_	
143-16	24653-24655	in	_	
143-17	24656-24662	humans	_	
143-18	24662-24663	,	_	
143-19	24664-24671	raising	_	
143-20	24672-24675	the	_	
143-21	24676-24687	possibility	_	
143-22	24688-24690	of	_	
143-23	24691-24692	a	_	
143-24	24693-24700	dynamic	_	
143-25	24701-24706	range	_	
143-26	24707-24709	in	_	
143-27	24710-24718	baseline	_	
143-28	24719-24729	microglial	_	
143-29	24730-24736	levels	_	
143-30	24736-24737	.	_	

#Text=Therefore, in this study we interpret lower TSPO levels as either diminished levels of activated microglia or possibly lower levels of TSPO in each cell.
144-1	24738-24747	Therefore	_	
144-2	24747-24748	,	_	
144-3	24749-24751	in	_	
144-4	24752-24756	this	_	
144-5	24757-24762	study	_	
144-6	24763-24765	we	_	
144-7	24766-24775	interpret	_	
144-8	24776-24781	lower	_	
144-9	24782-24786	TSPO	_	
144-10	24787-24793	levels	_	
144-11	24794-24796	as	_	
144-12	24797-24803	either	_	
144-13	24804-24814	diminished	_	
144-14	24815-24821	levels	_	
144-15	24822-24824	of	_	
144-16	24825-24834	activated	_	
144-17	24835-24844	microglia	_	
144-18	24845-24847	or	_	
144-19	24848-24856	possibly	_	
144-20	24857-24862	lower	_	
144-21	24863-24869	levels	_	
144-22	24870-24872	of	_	
144-23	24873-24877	TSPO	_	
144-24	24878-24880	in	_	
144-25	24881-24885	each	_	
144-26	24886-24890	cell	_	
144-27	24890-24891	.	_	

#Text=A further limitation in interpreting the source of [11C]PBR28 binding is the radioligand’s insensitivity to microglial phenotype (neuroprotective vs. neurodegenerative).
145-1	24892-24893	A	_	
145-2	24894-24901	further	_	
145-3	24902-24912	limitation	_	
145-4	24913-24915	in	_	
145-5	24916-24928	interpreting	_	
145-6	24929-24932	the	_	
145-7	24933-24939	source	_	
145-8	24940-24942	of	_	
145-9	24943-24944	[	_	
145-10	24944-24947	11C	_	
145-11	24947-24948	]	_	
145-12	24948-24953	PBR28	_	
145-13	24954-24961	binding	_	
145-14	24962-24964	is	_	
145-15	24965-24968	the	_	
145-16	24969-24980	radioligand	_	
145-17	24980-24981	’	_	
145-18	24981-24982	s	_	
145-19	24983-24996	insensitivity	_	
145-20	24997-24999	to	_	
145-21	25000-25010	microglial	_	
145-22	25011-25020	phenotype	_	
145-23	25021-25022	(	_	
145-24	25022-25037	neuroprotective	_	
145-25	25038-25040	vs	_	
145-26	25040-25041	.	_	
145-27	25042-25059	neurodegenerative	_	
145-28	25059-25060	)	_	
145-29	25060-25061	.	_	

#Text=There is strong evidence supporting an important role for microglial phenotype influencing alcohol associated neurodegeneration, and use of neuroimmune agents as interventions for alcohol use disorders has been postulated based on findings of microglial activation following alcohol exposure in rodent models.
146-1	25062-25067	There	_	
146-2	25068-25070	is	_	
146-3	25071-25077	strong	_	
146-4	25078-25086	evidence	_	
146-5	25087-25097	supporting	_	
146-6	25098-25100	an	_	
146-7	25101-25110	important	_	
146-8	25111-25115	role	_	
146-9	25116-25119	for	_	
146-10	25120-25130	microglial	_	
146-11	25131-25140	phenotype	_	
146-12	25141-25152	influencing	_	
146-13	25153-25160	alcohol	_	
146-14	25161-25171	associated	_	
146-15	25172-25189	neurodegeneration	_	
146-16	25189-25190	,	_	
146-17	25191-25194	and	_	
146-18	25195-25198	use	_	
146-19	25199-25201	of	_	
146-20	25202-25213	neuroimmune	_	
146-21	25214-25220	agents	_	
146-22	25221-25223	as	_	
146-23	25224-25237	interventions	_	
146-24	25238-25241	for	_	
146-25	25242-25249	alcohol	_	
146-26	25250-25253	use	_	
146-27	25254-25263	disorders	_	
146-28	25264-25267	has	_	
146-29	25268-25272	been	_	
146-30	25273-25283	postulated	_	
146-31	25284-25289	based	_	
146-32	25290-25292	on	_	
146-33	25293-25301	findings	_	
146-34	25302-25304	of	_	
146-35	25305-25315	microglial	_	
146-36	25316-25326	activation	_	
146-37	25327-25336	following	_	
146-38	25337-25344	alcohol	_	
146-39	25345-25353	exposure	_	
146-40	25354-25356	in	_	
146-41	25357-25363	rodent	_	
146-42	25364-25370	models	_	
146-43	25370-25371	.	_	

#Text=The present finding of diminished levels of activated microglia in alcohol dependence does not support the use of treatments suppressing inflammation for alcohol dependence, but provides evidence supporting the use of therapeutics promoting innate immune function as possible treatment options for alcohol dependence and promoting recovery.
147-1	25372-25375	The	_	
147-2	25376-25383	present	_	
147-3	25384-25391	finding	_	
147-4	25392-25394	of	_	
147-5	25395-25405	diminished	_	
147-6	25406-25412	levels	_	
147-7	25413-25415	of	_	
147-8	25416-25425	activated	_	
147-9	25426-25435	microglia	_	
147-10	25436-25438	in	_	
147-11	25439-25446	alcohol	_	
147-12	25447-25457	dependence	_	
147-13	25458-25462	does	_	
147-14	25463-25466	not	_	
147-15	25467-25474	support	_	
147-16	25475-25478	the	_	
147-17	25479-25482	use	_	
147-18	25483-25485	of	_	
147-19	25486-25496	treatments	_	
147-20	25497-25508	suppressing	_	
147-21	25509-25521	inflammation	_	
147-22	25522-25525	for	_	
147-23	25526-25533	alcohol	_	
147-24	25534-25544	dependence	_	
147-25	25544-25545	,	_	
147-26	25546-25549	but	_	
147-27	25550-25558	provides	_	
147-28	25559-25567	evidence	_	
147-29	25568-25578	supporting	_	
147-30	25579-25582	the	_	
147-31	25583-25586	use	_	
147-32	25587-25589	of	_	
147-33	25590-25602	therapeutics	_	
147-34	25603-25612	promoting	_	
147-35	25613-25619	innate	_	
147-36	25620-25626	immune	_	
147-37	25627-25635	function	_	
147-38	25636-25638	as	_	
147-39	25639-25647	possible	_	
147-40	25648-25657	treatment	_	
147-41	25658-25665	options	_	
147-42	25666-25669	for	_	
147-43	25670-25677	alcohol	_	
147-44	25678-25688	dependence	_	
147-45	25689-25692	and	_	
147-46	25693-25702	promoting	_	
147-47	25703-25711	recovery	_	
147-48	25711-25712	.	_	

#Text=Moreover, this study conclusively identifies TSPO-specific PET imaging as an important tool to aid in the development and evaluation of potential neuroimmune therapeutics.
148-1	25713-25721	Moreover	_	
148-2	25721-25722	,	_	
148-3	25723-25727	this	_	
148-4	25728-25733	study	_	
148-5	25734-25746	conclusively	_	
148-6	25747-25757	identifies	_	
148-7	25758-25771	TSPO-specific	_	
148-8	25772-25775	PET	_	
148-9	25776-25783	imaging	_	
148-10	25784-25786	as	_	
148-11	25787-25789	an	_	
148-12	25790-25799	important	_	
148-13	25800-25804	tool	_	
148-14	25805-25807	to	_	
148-15	25808-25811	aid	_	
148-16	25812-25814	in	_	
148-17	25815-25818	the	_	
148-18	25819-25830	development	_	
148-19	25831-25834	and	_	
148-20	25835-25845	evaluation	_	
148-21	25846-25848	of	_	
148-22	25849-25858	potential	_	
148-23	25859-25870	neuroimmune	_	
148-24	25871-25883	therapeutics	_	
148-25	25883-25884	.	_	

#Text=Lower [11C]PBR28 VT values were significantly associated with more reported drinks per day over the previous month and greater alcohol dependence severity.
149-1	25885-25890	Lower	_	
149-2	25891-25892	[	_	
149-3	25892-25895	11C	_	
149-4	25895-25896	]	_	
149-5	25896-25901	PBR28	_	
149-6	25902-25904	VT	_	
149-7	25905-25911	values	_	
149-8	25912-25916	were	_	
149-9	25917-25930	significantly	_	
149-10	25931-25941	associated	_	
149-11	25942-25946	with	_	
149-12	25947-25951	more	_	
149-13	25952-25960	reported	_	
149-14	25961-25967	drinks	_	
149-15	25968-25971	per	_	
149-16	25972-25975	day	_	
149-17	25976-25980	over	_	
149-18	25981-25984	the	_	
149-19	25985-25993	previous	_	
149-20	25994-25999	month	_	
149-21	26000-26003	and	_	
149-22	26004-26011	greater	_	
149-23	26012-26019	alcohol	_	
149-24	26020-26030	dependence	_	
149-25	26031-26039	severity	_	
149-26	26039-26040	.	_	

#Text=This supports the primary finding that lower levels of activated microglia are associated with alcohol dependence.
150-1	26041-26045	This	_	
150-2	26046-26054	supports	_	
150-3	26055-26058	the	_	
150-4	26059-26066	primary	_	
150-5	26067-26074	finding	_	
150-6	26075-26079	that	_	
150-7	26080-26085	lower	_	
150-8	26086-26092	levels	_	
150-9	26093-26095	of	_	
150-10	26096-26105	activated	_	
150-11	26106-26115	microglia	_	
150-12	26116-26119	are	_	
150-13	26120-26130	associated	_	
150-14	26131-26135	with	_	
150-15	26136-26143	alcohol	_	
150-16	26144-26154	dependence	_	
150-17	26154-26155	.	_	

#Text=Given this observation, possible relationships between [11C]PBR28 VT and time of last drink were also investigated.
151-1	26156-26161	Given	_	
151-2	26162-26166	this	_	
151-3	26167-26178	observation	_	
151-4	26178-26179	,	_	
151-5	26180-26188	possible	_	
151-6	26189-26202	relationships	_	
151-7	26203-26210	between	_	
151-8	26211-26212	[	_	
151-9	26212-26215	11C	_	
151-10	26215-26216	]	_	
151-11	26216-26221	PBR28	_	
151-12	26222-26224	VT	_	
151-13	26225-26228	and	_	
151-14	26229-26233	time	_	
151-15	26234-26236	of	_	
151-16	26237-26241	last	_	
151-17	26242-26247	drink	_	
151-18	26248-26252	were	_	
151-19	26253-26257	also	_	
151-20	26258-26270	investigated	_	
151-21	26270-26271	.	_	

#Text=There were no significant relationships (F(1,27)<0.083, p>0.778).
152-1	26272-26277	There	_	
152-2	26278-26282	were	_	
152-3	26283-26285	no	_	
152-4	26286-26297	significant	_	
152-5	26298-26311	relationships	_	
152-6	26312-26313	(	_	
152-7	26313-26314	F	_	
152-8	26314-26315	(	_	
152-9	26315-26319	1,27	_	
152-10	26319-26320	)	_	
152-11	26320-26321	<	_	
152-12	26321-26326	0.083	_	
152-13	26326-26327	,	_	
152-14	26328-26329	p	_	
152-15	26329-26330	>	_	
152-16	26330-26335	0.778	_	
152-17	26335-26336	)	_	
152-18	26336-26337	.	_	

#Text=Analysis excluding the subject imaged 24 days after their last drink yielded a trend of reduced [11C]PBR28 VT in alcohol dependence (F(1,25)=3.558, p=0.071; effect of genotype, F(1,25)=72.30, p<0.0001; interaction effect, F(1,25)=0.062, p=0.805), mirroring the findings incorporating the entire data set.
153-1	26338-26346	Analysis	_	
153-2	26347-26356	excluding	_	
153-3	26357-26360	the	_	
153-4	26361-26368	subject	_	
153-5	26369-26375	imaged	_	
153-6	26376-26378	24	_	
153-7	26379-26383	days	_	
153-8	26384-26389	after	_	
153-9	26390-26395	their	_	
153-10	26396-26400	last	_	
153-11	26401-26406	drink	_	
153-12	26407-26414	yielded	_	
153-13	26415-26416	a	_	
153-14	26417-26422	trend	_	
153-15	26423-26425	of	_	
153-16	26426-26433	reduced	_	
153-17	26434-26435	[	_	
153-18	26435-26438	11C	_	
153-19	26438-26439	]	_	
153-20	26439-26444	PBR28	_	
153-21	26445-26447	VT	_	
153-22	26448-26450	in	_	
153-23	26451-26458	alcohol	_	
153-24	26459-26469	dependence	_	
153-25	26470-26471	(	_	
153-26	26471-26472	F	_	
153-27	26472-26473	(	_	
153-28	26473-26477	1,25	_	
153-29	26477-26478	)	_	
153-30	26478-26479	=	_	
153-31	26479-26484	3.558	_	
153-32	26484-26485	,	_	
153-33	26486-26487	p	_	
153-34	26487-26488	=	_	
153-35	26488-26493	0.071	_	
153-36	26493-26494	;	_	
153-37	26495-26501	effect	_	
153-38	26502-26504	of	_	
153-39	26505-26513	genotype	_	
153-40	26513-26514	,	_	
153-41	26515-26516	F	_	
153-42	26516-26517	(	_	
153-43	26517-26521	1,25	_	
153-44	26521-26522	)	_	
153-45	26522-26523	=	_	
153-46	26523-26528	72.30	_	
153-47	26528-26529	,	_	
153-48	26530-26531	p	_	
153-49	26531-26532	<	_	
153-50	26532-26538	0.0001	_	
153-51	26538-26539	;	_	
153-52	26540-26551	interaction	_	
153-53	26552-26558	effect	_	
153-54	26558-26559	,	_	
153-55	26560-26561	F	_	
153-56	26561-26562	(	_	
153-57	26562-26566	1,25	_	
153-58	26566-26567	)	_	
153-59	26567-26568	=	_	
153-60	26568-26573	0.062	_	
153-61	26573-26574	,	_	
153-62	26575-26576	p	_	
153-63	26576-26577	=	_	
153-64	26577-26582	0.805	_	
153-65	26582-26583	)	_	
153-66	26583-26584	,	_	
153-67	26585-26594	mirroring	_	
153-68	26595-26598	the	_	
153-69	26599-26607	findings	_	
153-70	26608-26621	incorporating	_	
153-71	26622-26625	the	_	
153-72	26626-26632	entire	_	
153-73	26633-26637	data	_	
153-74	26638-26641	set	_	
153-75	26641-26642	.	_	

#Text=The modest average Alcohol Dependence Scale score (8.3±5.6) and exclusion from benzodiazepine treatment indicates that this population is most representative of moderate alcohol dependence.
154-1	26643-26646	The	_	
154-2	26647-26653	modest	_	
154-3	26654-26661	average	_	
154-4	26662-26669	Alcohol	_	
154-5	26670-26680	Dependence	_	
154-6	26681-26686	Scale	_	
154-7	26687-26692	score	_	
154-8	26693-26694	(	_	
154-9	26694-26697	8.3	_	
154-10	26697-26698	±	_	
154-11	26698-26701	5.6	_	
154-12	26701-26702	)	_	
154-13	26703-26706	and	_	
154-14	26707-26716	exclusion	_	
154-15	26717-26721	from	_	
154-16	26722-26736	benzodiazepine	_	
154-17	26737-26746	treatment	_	
154-18	26747-26756	indicates	_	
154-19	26757-26761	that	_	
154-20	26762-26766	this	_	
154-21	26767-26777	population	_	
154-22	26778-26780	is	_	
154-23	26781-26785	most	_	
154-24	26786-26800	representative	_	
154-25	26801-26803	of	_	
154-26	26804-26812	moderate	_	
154-27	26813-26820	alcohol	_	
154-28	26821-26831	dependence	_	
154-29	26831-26832	.	_	

#Text=Potential differences in levels of activated microglia after extended alcohol abstinence, the extent to which levels of activated microglia longitudinally may recover following abstinence, and the generalizability of this study to heavy alcohol dependence remain important lines of future research.
155-1	26833-26842	Potential	_	
155-2	26843-26854	differences	_	
155-3	26855-26857	in	_	
155-4	26858-26864	levels	_	
155-5	26865-26867	of	_	
155-6	26868-26877	activated	_	
155-7	26878-26887	microglia	_	
155-8	26888-26893	after	_	
155-9	26894-26902	extended	_	
155-10	26903-26910	alcohol	_	
155-11	26911-26921	abstinence	_	
155-12	26921-26922	,	_	
155-13	26923-26926	the	_	
155-14	26927-26933	extent	_	
155-15	26934-26936	to	_	
155-16	26937-26942	which	_	
155-17	26943-26949	levels	_	
155-18	26950-26952	of	_	
155-19	26953-26962	activated	_	
155-20	26963-26972	microglia	_	
155-21	26973-26987	longitudinally	_	
155-22	26988-26991	may	_	
155-23	26992-26999	recover	_	
155-24	27000-27009	following	_	
155-25	27010-27020	abstinence	_	
155-26	27020-27021	,	_	
155-27	27022-27025	and	_	
155-28	27026-27029	the	_	
155-29	27030-27046	generalizability	_	
155-30	27047-27049	of	_	
155-31	27050-27054	this	_	
155-32	27055-27060	study	_	
155-33	27061-27063	to	_	
155-34	27064-27069	heavy	_	
155-35	27070-27077	alcohol	_	
155-36	27078-27088	dependence	_	
155-37	27089-27095	remain	_	
155-38	27096-27105	important	_	
155-39	27106-27111	lines	_	
155-40	27112-27114	of	_	
155-41	27115-27121	future	_	
155-42	27122-27130	research	_	
155-43	27130-27131	.	_	

#Text=Previous imaging studies measuring TSPO levels in substance use disorders reported mixed findings.
156-1	27132-27140	Previous	_	
156-2	27141-27148	imaging	_	
156-3	27149-27156	studies	_	
156-4	27157-27166	measuring	_	
156-5	27167-27171	TSPO	_	
156-6	27172-27178	levels	_	
156-7	27179-27181	in	_	
156-8	27182-27191	substance	_	
156-9	27192-27195	use	_	
156-10	27196-27205	disorders	_	
156-11	27206-27214	reported	_	
156-12	27215-27220	mixed	_	
156-13	27221-27229	findings	_	
156-14	27229-27230	.	_	

#Text=One study imaging methamphetamine abusers with [11C]PK11195, a TSPO radiotracer less specific than [11C]PBR28, reported higher TSPO levels in midbrain, striatum, and orbitofrontal cortex compared to healthy controls, however, unconventional kinetic analysis methods limit interpretation of this work.
157-1	27231-27234	One	_	
157-2	27235-27240	study	_	
157-3	27241-27248	imaging	_	
157-4	27249-27264	methamphetamine	_	
157-5	27265-27272	abusers	_	
157-6	27273-27277	with	_	
157-7	27278-27279	[	_	
157-8	27279-27282	11C	_	
157-9	27282-27283	]	_	
157-10	27283-27290	PK11195	_	
157-11	27290-27291	,	_	
157-12	27292-27293	a	_	
157-13	27294-27298	TSPO	_	
157-14	27299-27310	radiotracer	_	
157-15	27311-27315	less	_	
157-16	27316-27324	specific	_	
157-17	27325-27329	than	_	
157-18	27330-27331	[	_	
157-19	27331-27334	11C	_	
157-20	27334-27335	]	_	
157-21	27335-27340	PBR28	_	
157-22	27340-27341	,	_	
157-23	27342-27350	reported	_	
157-24	27351-27357	higher	_	
157-25	27358-27362	TSPO	_	
157-26	27363-27369	levels	_	
157-27	27370-27372	in	_	
157-28	27373-27381	midbrain	_	
157-29	27381-27382	,	_	
157-30	27383-27391	striatum	_	
157-31	27391-27392	,	_	
157-32	27393-27396	and	_	
157-33	27397-27410	orbitofrontal	_	
157-34	27411-27417	cortex	_	
157-35	27418-27426	compared	_	
157-36	27427-27429	to	_	
157-37	27430-27437	healthy	_	
157-38	27438-27446	controls	_	
157-39	27446-27447	,	_	
157-40	27448-27455	however	_	
157-41	27455-27456	,	_	
157-42	27457-27471	unconventional	_	
157-43	27472-27479	kinetic	_	
157-44	27480-27488	analysis	_	
157-45	27489-27496	methods	_	
157-46	27497-27502	limit	_	
157-47	27503-27517	interpretation	_	
157-48	27518-27520	of	_	
157-49	27521-27525	this	_	
157-50	27526-27530	work	_	
157-51	27530-27531	.	_	

#Text=In contrast, no differences in TSPO levels measured with [11C]PBR28 were reported between cocaine abusers and healthy controls.
158-1	27532-27534	In	_	
158-2	27535-27543	contrast	_	
158-3	27543-27544	,	_	
158-4	27545-27547	no	_	
158-5	27548-27559	differences	_	
158-6	27560-27562	in	_	
158-7	27563-27567	TSPO	_	
158-8	27568-27574	levels	_	
158-9	27575-27583	measured	_	
158-10	27584-27588	with	_	
158-11	27589-27590	[	_	
158-12	27590-27593	11C	_	
158-13	27593-27594	]	_	
158-14	27594-27599	PBR28	_	
158-15	27600-27604	were	_	
158-16	27605-27613	reported	_	
158-17	27614-27621	between	_	
158-18	27622-27629	cocaine	_	
158-19	27630-27637	abusers	_	
158-20	27638-27641	and	_	
158-21	27642-27649	healthy	_	
158-22	27650-27658	controls	_	
158-23	27658-27659	.	_	

#Text=Thus the effects of substance use disorders on microglial activation may be drug specific.
159-1	27660-27664	Thus	_	
159-2	27665-27668	the	_	
159-3	27669-27676	effects	_	
159-4	27677-27679	of	_	
159-5	27680-27689	substance	_	
159-6	27690-27693	use	_	
159-7	27694-27703	disorders	_	
159-8	27704-27706	on	_	
159-9	27707-27717	microglial	_	
159-10	27718-27728	activation	_	
159-11	27729-27732	may	_	
159-12	27733-27735	be	_	
159-13	27736-27740	drug	_	
159-14	27741-27749	specific	_	
159-15	27749-27750	.	_	

#Text=With this in mind, smoking status was an important consideration in this work, as 5 alcohol dependent subjects and 4 healthy controls were tobacco smokers.
160-1	27751-27755	With	_	
160-2	27756-27760	this	_	
160-3	27761-27763	in	_	
160-4	27764-27768	mind	_	
160-5	27768-27769	,	_	
160-6	27770-27777	smoking	_	
160-7	27778-27784	status	_	
160-8	27785-27788	was	_	
160-9	27789-27791	an	_	
160-10	27792-27801	important	_	
160-11	27802-27815	consideration	_	
160-12	27816-27818	in	_	
160-13	27819-27823	this	_	
160-14	27824-27828	work	_	
160-15	27828-27829	,	_	
160-16	27830-27832	as	_	
160-17	27833-27834	5	_	
160-18	27835-27842	alcohol	_	
160-19	27843-27852	dependent	_	
160-20	27853-27861	subjects	_	
160-21	27862-27865	and	_	
160-22	27866-27867	4	_	
160-23	27868-27875	healthy	_	
160-24	27876-27884	controls	_	
160-25	27885-27889	were	_	
160-26	27890-27897	tobacco	_	
160-27	27898-27905	smokers	_	
160-28	27905-27906	.	_	

#Text=While there is evidence that nicotine itself may suppress microglial activation, tobacco smoke may lead to increased microglial activation.
161-1	27907-27912	While	_	
161-2	27913-27918	there	_	
161-3	27919-27921	is	_	
161-4	27922-27930	evidence	_	
161-5	27931-27935	that	_	
161-6	27936-27944	nicotine	_	
161-7	27945-27951	itself	_	
161-8	27952-27955	may	_	
161-9	27956-27964	suppress	_	
161-10	27965-27975	microglial	_	
161-11	27976-27986	activation	_	
161-12	27986-27987	,	_	
161-13	27988-27995	tobacco	_	
161-14	27996-28001	smoke	_	
161-15	28002-28005	may	_	
161-16	28006-28010	lead	_	
161-17	28011-28013	to	_	
161-18	28014-28023	increased	_	
161-19	28024-28034	microglial	_	
161-20	28035-28045	activation	_	
161-21	28045-28046	.	_	

#Text=It is not known currently how tobacco smoking may affect brain TSPO levels in vivo, as human imaging studies of neuroinflammation in tobacco smoking have not been reported.
162-1	28047-28049	It	_	
162-2	28050-28052	is	_	
162-3	28053-28056	not	_	
162-4	28057-28062	known	_	
162-5	28063-28072	currently	_	
162-6	28073-28076	how	_	
162-7	28077-28084	tobacco	_	
162-8	28085-28092	smoking	_	
162-9	28093-28096	may	_	
162-10	28097-28103	affect	_	
162-11	28104-28109	brain	_	
162-12	28110-28114	TSPO	_	
162-13	28115-28121	levels	_	
162-14	28122-28124	in	_	
162-15	28125-28129	vivo	_	
162-16	28129-28130	,	_	
162-17	28131-28133	as	_	
162-18	28134-28139	human	_	
162-19	28140-28147	imaging	_	
162-20	28148-28155	studies	_	
162-21	28156-28158	of	_	
162-22	28159-28176	neuroinflammation	_	
162-23	28177-28179	in	_	
162-24	28180-28187	tobacco	_	
162-25	28188-28195	smoking	_	
162-26	28196-28200	have	_	
162-27	28201-28204	not	_	
162-28	28205-28209	been	_	
162-29	28210-28218	reported	_	
162-30	28218-28219	.	_	

#Text=Thus, potential effects of tobacco smoking on measured TSPO levels were controlled for by matching for smoking status in the two study groups.
163-1	28220-28224	Thus	_	
163-2	28224-28225	,	_	
163-3	28226-28235	potential	_	
163-4	28236-28243	effects	_	
163-5	28244-28246	of	_	
163-6	28247-28254	tobacco	_	
163-7	28255-28262	smoking	_	
163-8	28263-28265	on	_	
163-9	28266-28274	measured	_	
163-10	28275-28279	TSPO	_	
163-11	28280-28286	levels	_	
163-12	28287-28291	were	_	
163-13	28292-28302	controlled	_	
163-14	28303-28306	for	_	
163-15	28307-28309	by	_	
163-16	28310-28318	matching	_	
163-17	28319-28322	for	_	
163-18	28323-28330	smoking	_	
163-19	28331-28337	status	_	
163-20	28338-28340	in	_	
163-21	28341-28344	the	_	
163-22	28345-28348	two	_	
163-23	28349-28354	study	_	
163-24	28355-28361	groups	_	
163-25	28361-28362	.	_	

#Text=The kinetic and statistical analysis methods of [11C]PBR28 PET data used here represent a major strength of this work.
164-1	28363-28366	The	_	
164-2	28367-28374	kinetic	_	
164-3	28375-28378	and	_	
164-4	28379-28390	statistical	_	
164-5	28391-28399	analysis	_	
164-6	28400-28407	methods	_	
164-7	28408-28410	of	_	
164-8	28411-28412	[	_	
164-9	28412-28415	11C	_	
164-10	28415-28416	]	_	
164-11	28416-28421	PBR28	_	
164-12	28422-28425	PET	_	
164-13	28426-28430	data	_	
164-14	28431-28435	used	_	
164-15	28436-28440	here	_	
164-16	28441-28450	represent	_	
164-17	28451-28452	a	_	
164-18	28453-28458	major	_	
164-19	28459-28467	strength	_	
164-20	28468-28470	of	_	
164-21	28471-28475	this	_	
164-22	28476-28480	work	_	
164-23	28480-28481	.	_	

#Text=Recent studies using TSPO-specific PET imaging have reported outcome measures of regional radioactivity concentrations normalized to whole brain radioactivity levels.
165-1	28482-28488	Recent	_	
165-2	28489-28496	studies	_	
165-3	28497-28502	using	_	
165-4	28503-28516	TSPO-specific	_	
165-5	28517-28520	PET	_	
165-6	28521-28528	imaging	_	
165-7	28529-28533	have	_	
165-8	28534-28542	reported	_	
165-9	28543-28550	outcome	_	
165-10	28551-28559	measures	_	
165-11	28560-28562	of	_	
165-12	28563-28571	regional	_	
165-13	28572-28585	radioactivity	_	
165-14	28586-28600	concentrations	_	
165-15	28601-28611	normalized	_	
165-16	28612-28614	to	_	
165-17	28615-28620	whole	_	
165-18	28621-28626	brain	_	
165-19	28627-28640	radioactivity	_	
165-20	28641-28647	levels	_	
165-21	28647-28648	.	_	

#Text=These approaches ignore the consensus use of VT as primary outcome measure for radioligands lacking a reference region that has been carefully validated to have no group differences in specific binding for a given pathology.
166-1	28649-28654	These	_	
166-2	28655-28665	approaches	_	
166-3	28666-28672	ignore	_	
166-4	28673-28676	the	_	
166-5	28677-28686	consensus	_	
166-6	28687-28690	use	_	
166-7	28691-28693	of	_	
166-8	28694-28696	VT	_	
166-9	28697-28699	as	_	
166-10	28700-28707	primary	_	
166-11	28708-28715	outcome	_	
166-12	28716-28723	measure	_	
166-13	28724-28727	for	_	
166-14	28728-28740	radioligands	_	
166-15	28741-28748	lacking	_	
166-16	28749-28750	a	_	
166-17	28751-28760	reference	_	
166-18	28761-28767	region	_	
166-19	28768-28772	that	_	
166-20	28773-28776	has	_	
166-21	28777-28781	been	_	
166-22	28782-28791	carefully	_	
166-23	28792-28801	validated	_	
166-24	28802-28804	to	_	
166-25	28805-28809	have	_	
166-26	28810-28812	no	_	
166-27	28813-28818	group	_	
166-28	28819-28830	differences	_	
166-29	28831-28833	in	_	
166-30	28834-28842	specific	_	
166-31	28843-28850	binding	_	
166-32	28851-28854	for	_	
166-33	28855-28856	a	_	
166-34	28857-28862	given	_	
166-35	28863-28872	pathology	_	
166-36	28872-28873	.	_	

#Text=Using normalized data severely limits the interpretation of whole brain normalization results to only test for differences in relative regional TSPO levels – effectively ignoring potential differences in absolute TSPO levels.
167-1	28874-28879	Using	_	
167-2	28880-28890	normalized	_	
167-3	28891-28895	data	_	
167-4	28896-28904	severely	_	
167-5	28905-28911	limits	_	
167-6	28912-28915	the	_	
167-7	28916-28930	interpretation	_	
167-8	28931-28933	of	_	
167-9	28934-28939	whole	_	
167-10	28940-28945	brain	_	
167-11	28946-28959	normalization	_	
167-12	28960-28967	results	_	
167-13	28968-28970	to	_	
167-14	28971-28975	only	_	
167-15	28976-28980	test	_	
167-16	28981-28984	for	_	
167-17	28985-28996	differences	_	
167-18	28997-28999	in	_	
167-19	29000-29008	relative	_	
167-20	29009-29017	regional	_	
167-21	29018-29022	TSPO	_	
167-22	29023-29029	levels	_	
167-23	29030-29031	–	_	
167-24	29032-29043	effectively	_	
167-25	29044-29052	ignoring	_	
167-26	29053-29062	potential	_	
167-27	29063-29074	differences	_	
167-28	29075-29077	in	_	
167-29	29078-29086	absolute	_	
167-30	29087-29091	TSPO	_	
167-31	29092-29098	levels	_	
167-32	29098-29099	.	_	

#Text=Further drawbacks of this method have been detailed elsewhere.
168-1	29100-29107	Further	_	
168-2	29108-29117	drawbacks	_	
168-3	29118-29120	of	_	
168-4	29121-29125	this	_	
168-5	29126-29132	method	_	
168-6	29133-29137	have	_	
168-7	29138-29142	been	_	
168-8	29143-29151	detailed	_	
168-9	29152-29161	elsewhere	_	
168-10	29161-29162	.	_	

#Text=In addition, the use of VT/fP as an alternative primary outcome measure to VT was investigated, but statistical analysis with this outcome yielded no significant effect of rs6971 genotype (effect of diagnosis, F(1,26)=1367, p=0.253; effect of genotype, F(1,26)=4.098, p=0.054; interaction effect, F(1,26)=0.234, p=0.633).
169-1	29163-29165	In	_	
169-2	29166-29174	addition	_	
169-3	29174-29175	,	_	
169-4	29176-29179	the	_	
169-5	29180-29183	use	_	
169-6	29184-29186	of	_	
169-7	29187-29189	VT	_	
169-8	29189-29190	/	_	
169-9	29190-29192	fP	_	
169-10	29193-29195	as	_	
169-11	29196-29198	an	_	
169-12	29199-29210	alternative	_	
169-13	29211-29218	primary	_	
169-14	29219-29226	outcome	_	
169-15	29227-29234	measure	_	
169-16	29235-29237	to	_	
169-17	29238-29240	VT	_	
169-18	29241-29244	was	_	
169-19	29245-29257	investigated	_	
169-20	29257-29258	,	_	
169-21	29259-29262	but	_	
169-22	29263-29274	statistical	_	
169-23	29275-29283	analysis	_	
169-24	29284-29288	with	_	
169-25	29289-29293	this	_	
169-26	29294-29301	outcome	_	
169-27	29302-29309	yielded	_	
169-28	29310-29312	no	_	
169-29	29313-29324	significant	_	
169-30	29325-29331	effect	_	
169-31	29332-29334	of	_	
169-32	29335-29341	rs6971	_	
169-33	29342-29350	genotype	_	
169-34	29351-29352	(	_	
169-35	29352-29358	effect	_	
169-36	29359-29361	of	_	
169-37	29362-29371	diagnosis	_	
169-38	29371-29372	,	_	
169-39	29373-29374	F	_	
169-40	29374-29375	(	_	
169-41	29375-29379	1,26	_	
169-42	29379-29380	)	_	
169-43	29380-29381	=	_	
169-44	29381-29385	1367	_	
169-45	29385-29386	,	_	
169-46	29387-29388	p	_	
169-47	29388-29389	=	_	
169-48	29389-29394	0.253	_	
169-49	29394-29395	;	_	
169-50	29396-29402	effect	_	
169-51	29403-29405	of	_	
169-52	29406-29414	genotype	_	
169-53	29414-29415	,	_	
169-54	29416-29417	F	_	
169-55	29417-29418	(	_	
169-56	29418-29422	1,26	_	
169-57	29422-29423	)	_	
169-58	29423-29424	=	_	
169-59	29424-29429	4.098	_	
169-60	29429-29430	,	_	
169-61	29431-29432	p	_	
169-62	29432-29433	=	_	
169-63	29433-29438	0.054	_	
169-64	29438-29439	;	_	
169-65	29440-29451	interaction	_	
169-66	29452-29458	effect	_	
169-67	29458-29459	,	_	
169-68	29460-29461	F	_	
169-69	29461-29462	(	_	
169-70	29462-29466	1,26	_	
169-71	29466-29467	)	_	
169-72	29467-29468	=	_	
169-73	29468-29473	0.234	_	
169-74	29473-29474	,	_	
169-75	29475-29476	p	_	
169-76	29476-29477	=	_	
169-77	29477-29482	0.633	_	
169-78	29482-29483	)	_	
169-79	29483-29484	.	_	

#Text=This finding provided evidence that the [11C]PBR28 fP measurement introduces excessive variability into the data, consistent with our center’s previous report of increased test-retest variability with VT/fP as an outcome measure for [11C]PBR28 PET imaging.
170-1	29485-29489	This	_	
170-2	29490-29497	finding	_	
170-3	29498-29506	provided	_	
170-4	29507-29515	evidence	_	
170-5	29516-29520	that	_	
170-6	29521-29524	the	_	
170-7	29525-29526	[	_	
170-8	29526-29529	11C	_	
170-9	29529-29530	]	_	
170-10	29530-29535	PBR28	_	
170-11	29536-29538	fP	_	
170-12	29539-29550	measurement	_	
170-13	29551-29561	introduces	_	
170-14	29562-29571	excessive	_	
170-15	29572-29583	variability	_	
170-16	29584-29588	into	_	
170-17	29589-29592	the	_	
170-18	29593-29597	data	_	
170-19	29597-29598	,	_	
170-20	29599-29609	consistent	_	
170-21	29610-29614	with	_	
170-22	29615-29618	our	_	
170-23	29619-29625	center	_	
170-24	29625-29626	’	_	
170-25	29626-29627	s	_	
170-26	29628-29636	previous	_	
170-27	29637-29643	report	_	
170-28	29644-29646	of	_	
170-29	29647-29656	increased	_	
170-30	29657-29668	test-retest	_	
170-31	29669-29680	variability	_	
170-32	29681-29685	with	_	
170-33	29686-29688	VT	_	
170-34	29688-29689	/	_	
170-35	29689-29691	fP	_	
170-36	29692-29694	as	_	
170-37	29695-29697	an	_	
170-38	29698-29705	outcome	_	
170-39	29706-29713	measure	_	
170-40	29714-29717	for	_	
170-41	29718-29719	[	_	
170-42	29719-29722	11C	_	
170-43	29722-29723	]	_	
170-44	29723-29728	PBR28	_	
170-45	29729-29732	PET	_	
170-46	29733-29740	imaging	_	
170-47	29740-29741	.	_	

#Text=We contend that the analysis of PET data using conventional kinetic modeling techniques with full arterial sampling and metabolite analysis represents the most appropriate method for direct measurement of activated microglia levels in vivo.
171-1	29742-29744	We	_	
171-2	29745-29752	contend	_	
171-3	29753-29757	that	_	
171-4	29758-29761	the	_	
171-5	29762-29770	analysis	_	
171-6	29771-29773	of	_	
171-7	29774-29777	PET	_	
171-8	29778-29782	data	_	
171-9	29783-29788	using	_	
171-10	29789-29801	conventional	_	
171-11	29802-29809	kinetic	_	
171-12	29810-29818	modeling	_	
171-13	29819-29829	techniques	_	
171-14	29830-29834	with	_	
171-15	29835-29839	full	_	
171-16	29840-29848	arterial	_	
171-17	29849-29857	sampling	_	
171-18	29858-29861	and	_	
171-19	29862-29872	metabolite	_	
171-20	29873-29881	analysis	_	
171-21	29882-29892	represents	_	
171-22	29893-29896	the	_	
171-23	29897-29901	most	_	
171-24	29902-29913	appropriate	_	
171-25	29914-29920	method	_	
171-26	29921-29924	for	_	
171-27	29925-29931	direct	_	
171-28	29932-29943	measurement	_	
171-29	29944-29946	of	_	
171-30	29947-29956	activated	_	
171-31	29957-29966	microglia	_	
171-32	29967-29973	levels	_	
171-33	29974-29976	in	_	
171-34	29977-29981	vivo	_	
171-35	29981-29982	.	_	

#Text=The selection of regions of interest and corrections for possible gray matter atrophy were critical considerations to this work.
172-1	29983-29986	The	_	
172-2	29987-29996	selection	_	
172-3	29997-29999	of	_	
172-4	30000-30007	regions	_	
172-5	30008-30010	of	_	
172-6	30011-30019	interest	_	
172-7	30020-30023	and	_	
172-8	30024-30035	corrections	_	
172-9	30036-30039	for	_	
172-10	30040-30048	possible	_	
172-11	30049-30053	gray	_	
172-12	30054-30060	matter	_	
172-13	30061-30068	atrophy	_	
172-14	30069-30073	were	_	
172-15	30074-30082	critical	_	
172-16	30083-30097	considerations	_	
172-17	30098-30100	to	_	
172-18	30101-30105	this	_	
172-19	30106-30110	work	_	
172-20	30110-30111	.	_	

#Text=Four large, non-adjacent regions of interest heavily implicated in the biology of alcohol neurodegeneration were selected for analysis.
173-1	30112-30116	Four	_	
173-2	30117-30122	large	_	
173-3	30122-30123	,	_	
173-4	30124-30136	non-adjacent	_	
173-5	30137-30144	regions	_	
173-6	30145-30147	of	_	
173-7	30148-30156	interest	_	
173-8	30157-30164	heavily	_	
173-9	30165-30175	implicated	_	
173-10	30176-30178	in	_	
173-11	30179-30182	the	_	
173-12	30183-30190	biology	_	
173-13	30191-30193	of	_	
173-14	30194-30201	alcohol	_	
173-15	30202-30219	neurodegeneration	_	
173-16	30220-30224	were	_	
173-17	30225-30233	selected	_	
173-18	30234-30237	for	_	
173-19	30238-30246	analysis	_	
173-20	30246-30247	.	_	

#Text=The frontal-striatal-cerebellar network and limbic system are brain regions affected the earliest and most severely in alcohol-related neurodegeneration, providing strong support motivating the selection of the a priori ROIs of frontal cortex, striatum, cerebellum, and hippocampus.
174-1	30248-30251	The	_	
174-2	30252-30279	frontal-striatal-cerebellar	_	
174-3	30280-30287	network	_	
174-4	30288-30291	and	_	
174-5	30292-30298	limbic	_	
174-6	30299-30305	system	_	
174-7	30306-30309	are	_	
174-8	30310-30315	brain	_	
174-9	30316-30323	regions	_	
174-10	30324-30332	affected	_	
174-11	30333-30336	the	_	
174-12	30337-30345	earliest	_	
174-13	30346-30349	and	_	
174-14	30350-30354	most	_	
174-15	30355-30363	severely	_	
174-16	30364-30366	in	_	
174-17	30367-30382	alcohol-related	_	
174-18	30383-30400	neurodegeneration	_	
174-19	30400-30401	,	_	
174-20	30402-30411	providing	_	
174-21	30412-30418	strong	_	
174-22	30419-30426	support	_	
174-23	30427-30437	motivating	_	
174-24	30438-30441	the	_	
174-25	30442-30451	selection	_	
174-26	30452-30454	of	_	
174-27	30455-30458	the	_	
174-28	30459-30460	a	_	
174-29	30461-30467	priori	_	
174-30	30468-30472	ROIs	_	
174-31	30473-30475	of	_	
174-32	30476-30483	frontal	_	
174-33	30484-30490	cortex	_	
174-34	30490-30491	,	_	
174-35	30492-30500	striatum	_	
174-36	30500-30501	,	_	
174-37	30502-30512	cerebellum	_	
174-38	30512-30513	,	_	
174-39	30514-30517	and	_	
174-40	30518-30529	hippocampus	_	
174-41	30529-30530	.	_	

#Text=This approach was chosen to provide some regional specificity without excessively increasing variance in the linear mixed model by introducing many regions of different sizes with different variance.
175-1	30531-30535	This	_	
175-2	30536-30544	approach	_	
175-3	30545-30548	was	_	
175-4	30549-30555	chosen	_	
175-5	30556-30558	to	_	
175-6	30559-30566	provide	_	
175-7	30567-30571	some	_	
175-8	30572-30580	regional	_	
175-9	30581-30592	specificity	_	
175-10	30593-30600	without	_	
175-11	30601-30612	excessively	_	
175-12	30613-30623	increasing	_	
175-13	30624-30632	variance	_	
175-14	30633-30635	in	_	
175-15	30636-30639	the	_	
175-16	30640-30646	linear	_	
175-17	30647-30652	mixed	_	
175-18	30653-30658	model	_	
175-19	30659-30661	by	_	
175-20	30662-30673	introducing	_	
175-21	30674-30678	many	_	
175-22	30679-30686	regions	_	
175-23	30687-30689	of	_	
175-24	30690-30699	different	_	
175-25	30700-30705	sizes	_	
175-26	30706-30710	with	_	
175-27	30711-30720	different	_	
175-28	30721-30729	variance	_	
175-29	30729-30730	.	_	

#Text=For the interested reader, [11C]PBR28 VT values for additional brain regions, including whole brain average, are included in Supplementary Table 1.
176-1	30731-30734	For	_	
176-2	30735-30738	the	_	
176-3	30739-30749	interested	_	
176-4	30750-30756	reader	_	
176-5	30756-30757	,	_	
176-6	30758-30759	[	_	
176-7	30759-30762	11C	_	
176-8	30762-30763	]	_	
176-9	30763-30768	PBR28	_	
176-10	30769-30771	VT	_	
176-11	30772-30778	values	_	
176-12	30779-30782	for	_	
176-13	30783-30793	additional	_	
176-14	30794-30799	brain	_	
176-15	30800-30807	regions	_	
176-16	30807-30808	,	_	
176-17	30809-30818	including	_	
176-18	30819-30824	whole	_	
176-19	30825-30830	brain	_	
176-20	30831-30838	average	_	
176-21	30838-30839	,	_	
176-22	30840-30843	are	_	
176-23	30844-30852	included	_	
176-24	30853-30855	in	_	
176-25	30856-30869	Supplementary	_	
176-26	30870-30875	Table	_	
176-27	30876-30877	1	_	
176-28	30877-30878	.	_	

#Text=Notably, the 10% reduction in [11C]PBR28 VT for alcohol dependent patients compared to healthy controls is consistent across all regions.
177-1	30879-30886	Notably	_	
177-2	30886-30887	,	_	
177-3	30888-30891	the	_	
177-4	30892-30895	10%	_	
177-5	30896-30905	reduction	_	
177-6	30906-30908	in	_	
177-7	30909-30910	[	_	
177-8	30910-30913	11C	_	
177-9	30913-30914	]	_	
177-10	30914-30919	PBR28	_	
177-11	30920-30922	VT	_	
177-12	30923-30926	for	_	
177-13	30927-30934	alcohol	_	
177-14	30935-30944	dependent	_	
177-15	30945-30953	patients	_	
177-16	30954-30962	compared	_	
177-17	30963-30965	to	_	
177-18	30966-30973	healthy	_	
177-19	30974-30982	controls	_	
177-20	30983-30985	is	_	
177-21	30986-30996	consistent	_	
177-22	30997-31003	across	_	
177-23	31004-31007	all	_	
177-24	31008-31015	regions	_	
177-25	31015-31016	.	_	

#Text=Additionally, a partial volume correction was implemented to adjust for possible individual differences in normalized gray matter volume.
178-1	31017-31029	Additionally	_	
178-2	31029-31030	,	_	
178-3	31031-31032	a	_	
178-4	31033-31040	partial	_	
178-5	31041-31047	volume	_	
178-6	31048-31058	correction	_	
178-7	31059-31062	was	_	
178-8	31063-31074	implemented	_	
178-9	31075-31077	to	_	
178-10	31078-31084	adjust	_	
178-11	31085-31088	for	_	
178-12	31089-31097	possible	_	
178-13	31098-31108	individual	_	
178-14	31109-31120	differences	_	
178-15	31121-31123	in	_	
178-16	31124-31134	normalized	_	
178-17	31135-31139	gray	_	
178-18	31140-31146	matter	_	
178-19	31147-31153	volume	_	
178-20	31153-31154	.	_	

#Text=For the regions analyzed, alcohol dependent subjects exhibited 9.6±20.8% less regional gray matter volume than healthy controls as estimated by our center’s automated segmentation and registration techniques.
179-1	31155-31158	For	_	
179-2	31159-31162	the	_	
179-3	31163-31170	regions	_	
179-4	31171-31179	analyzed	_	
179-5	31179-31180	,	_	
179-6	31181-31188	alcohol	_	
179-7	31189-31198	dependent	_	
179-8	31199-31207	subjects	_	
179-9	31208-31217	exhibited	_	
179-10	31218-31221	9.6	_	
179-11	31221-31222	±	_	
179-12	31222-31227	20.8%	_	
179-13	31228-31232	less	_	
179-14	31233-31241	regional	_	
179-15	31242-31246	gray	_	
179-16	31247-31253	matter	_	
179-17	31254-31260	volume	_	
179-18	31261-31265	than	_	
179-19	31266-31273	healthy	_	
179-20	31274-31282	controls	_	
179-21	31283-31285	as	_	
179-22	31286-31295	estimated	_	
179-23	31296-31298	by	_	
179-24	31299-31302	our	_	
179-25	31303-31309	center	_	
179-26	31309-31310	’	_	
179-27	31310-31311	s	_	
179-28	31312-31321	automated	_	
179-29	31322-31334	segmentation	_	
179-30	31335-31338	and	_	
179-31	31339-31351	registration	_	
179-32	31352-31362	techniques	_	
179-33	31362-31363	.	_	

#Text=These differences were greatest in frontal cortex and cerebellum, the regions most associated with tissue atrophy in alcohol dependence, thus we believe possible gray matter atrophy to be a critical consideration for this work.
180-1	31364-31369	These	_	
180-2	31370-31381	differences	_	
180-3	31382-31386	were	_	
180-4	31387-31395	greatest	_	
180-5	31396-31398	in	_	
180-6	31399-31406	frontal	_	
180-7	31407-31413	cortex	_	
180-8	31414-31417	and	_	
180-9	31418-31428	cerebellum	_	
180-10	31428-31429	,	_	
180-11	31430-31433	the	_	
180-12	31434-31441	regions	_	
180-13	31442-31446	most	_	
180-14	31447-31457	associated	_	
180-15	31458-31462	with	_	
180-16	31463-31469	tissue	_	
180-17	31470-31477	atrophy	_	
180-18	31478-31480	in	_	
180-19	31481-31488	alcohol	_	
180-20	31489-31499	dependence	_	
180-21	31499-31500	,	_	
180-22	31501-31505	thus	_	
180-23	31506-31508	we	_	
180-24	31509-31516	believe	_	
180-25	31517-31525	possible	_	
180-26	31526-31530	gray	_	
180-27	31531-31537	matter	_	
180-28	31538-31545	atrophy	_	
180-29	31546-31548	to	_	
180-30	31549-31551	be	_	
180-31	31552-31553	a	_	
180-32	31554-31562	critical	_	
180-33	31563-31576	consideration	_	
180-34	31577-31580	for	_	
180-35	31581-31585	this	_	
180-36	31586-31590	work	_	
180-37	31590-31591	.	_	

#Text=However, analysis of PET data without partial volume correction yielded a stronger main effect of diagnosis (F(1,26)=6.681) than the partial volume-corrected data (F(1,26)=4.983).
181-1	31592-31599	However	_	
181-2	31599-31600	,	_	
181-3	31601-31609	analysis	_	
181-4	31610-31612	of	_	
181-5	31613-31616	PET	_	
181-6	31617-31621	data	_	
181-7	31622-31629	without	_	
181-8	31630-31637	partial	_	
181-9	31638-31644	volume	_	
181-10	31645-31655	correction	_	
181-11	31656-31663	yielded	_	
181-12	31664-31665	a	_	
181-13	31666-31674	stronger	_	
181-14	31675-31679	main	_	
181-15	31680-31686	effect	_	
181-16	31687-31689	of	_	
181-17	31690-31699	diagnosis	_	
181-18	31700-31701	(	_	
181-19	31701-31702	F	_	
181-20	31702-31703	(	_	
181-21	31703-31707	1,26	_	
181-22	31707-31708	)	_	
181-23	31708-31709	=	_	
181-24	31709-31714	6.681	_	
181-25	31714-31715	)	_	
181-26	31716-31720	than	_	
181-27	31721-31724	the	_	
181-28	31725-31732	partial	_	
181-29	31733-31749	volume-corrected	_	
181-30	31750-31754	data	_	
181-31	31755-31756	(	_	
181-32	31756-31757	F	_	
181-33	31757-31758	(	_	
181-34	31758-31762	1,26	_	
181-35	31762-31763	)	_	
181-36	31763-31764	=	_	
181-37	31764-31769	4.983	_	
181-38	31769-31770	)	_	
181-39	31770-31771	.	_	

#Text=We hypothesize that the partial volume correction likely introduced additional variability into the brain data, yet, this correction was considered critical to account for possible tissue atrophy in alcohol dependence.
182-1	31772-31774	We	_	
182-2	31775-31786	hypothesize	_	
182-3	31787-31791	that	_	
182-4	31792-31795	the	_	
182-5	31796-31803	partial	_	
182-6	31804-31810	volume	_	
182-7	31811-31821	correction	_	
182-8	31822-31828	likely	_	
182-9	31829-31839	introduced	_	
182-10	31840-31850	additional	_	
182-11	31851-31862	variability	_	
182-12	31863-31867	into	_	
182-13	31868-31871	the	_	
182-14	31872-31877	brain	_	
182-15	31878-31882	data	_	
182-16	31882-31883	,	_	
182-17	31884-31887	yet	_	
182-18	31887-31888	,	_	
182-19	31889-31893	this	_	
182-20	31894-31904	correction	_	
182-21	31905-31908	was	_	
182-22	31909-31919	considered	_	
182-23	31920-31928	critical	_	
182-24	31929-31931	to	_	
182-25	31932-31939	account	_	
182-26	31940-31943	for	_	
182-27	31944-31952	possible	_	
182-28	31953-31959	tissue	_	
182-29	31960-31967	atrophy	_	
182-30	31968-31970	in	_	
182-31	31971-31978	alcohol	_	
182-32	31979-31989	dependence	_	
182-33	31989-31990	.	_	

#Text=Therefore, partial volume-corrected [11C]PBR28 VT was reported as the preferred outcome measure.
183-1	31991-32000	Therefore	_	
183-2	32000-32001	,	_	
183-3	32002-32009	partial	_	
183-4	32010-32026	volume-corrected	_	
183-5	32027-32028	[	_	
183-6	32028-32031	11C	_	
183-7	32031-32032	]	_	
183-8	32032-32037	PBR28	_	
183-9	32038-32040	VT	_	
183-10	32041-32044	was	_	
183-11	32045-32053	reported	_	
183-12	32054-32056	as	_	
183-13	32057-32060	the	_	
183-14	32061-32070	preferred	_	
183-15	32071-32078	outcome	_	
183-16	32079-32086	measure	_	
183-17	32086-32087	.	_	

#Text=The cytokine response of peripheral monocytes to LPS stimulation was examined to complement measurements of TSPO brain levels.
184-1	32088-32091	The	_	
184-2	32092-32100	cytokine	_	
184-3	32101-32109	response	_	
184-4	32110-32112	of	_	
184-5	32113-32123	peripheral	_	
184-6	32124-32133	monocytes	_	
184-7	32134-32136	to	_	
184-8	32137-32140	LPS	_	
184-9	32141-32152	stimulation	_	
184-10	32153-32156	was	_	
184-11	32157-32165	examined	_	
184-12	32166-32168	to	_	
184-13	32169-32179	complement	_	
184-14	32180-32192	measurements	_	
184-15	32193-32195	of	_	
184-16	32196-32200	TSPO	_	
184-17	32201-32206	brain	_	
184-18	32207-32213	levels	_	
184-19	32213-32214	.	_	

#Text=These data suggest that LPS stimulation of monocytes elicits a significantly less pro-inflammatory response in alcohol dependent subjects compared to healthy controls.
185-1	32215-32220	These	_	
185-2	32221-32225	data	_	
185-3	32226-32233	suggest	_	
185-4	32234-32238	that	_	
185-5	32239-32242	LPS	_	
185-6	32243-32254	stimulation	_	
185-7	32255-32257	of	_	
185-8	32258-32267	monocytes	_	
185-9	32268-32275	elicits	_	
185-10	32276-32277	a	_	
185-11	32278-32291	significantly	_	
185-12	32292-32296	less	_	
185-13	32297-32313	pro-inflammatory	_	
185-14	32314-32322	response	_	
185-15	32323-32325	in	_	
185-16	32326-32333	alcohol	_	
185-17	32334-32343	dependent	_	
185-18	32344-32352	subjects	_	
185-19	32353-32361	compared	_	
185-20	32362-32364	to	_	
185-21	32365-32372	healthy	_	
185-22	32373-32381	controls	_	
185-23	32381-32382	.	_	

#Text=Given the high variability in both sample groups and small sample size which likely precluded detection of significant differences, post-hoc analyses were conducted on these data, revealing significantly lower LPS-simulated cytokine response for IL-8 and IL-6 (see Figure 4A-B).
186-1	32383-32388	Given	_	
186-2	32389-32392	the	_	
186-3	32393-32397	high	_	
186-4	32398-32409	variability	_	
186-5	32410-32412	in	_	
186-6	32413-32417	both	_	
186-7	32418-32424	sample	_	
186-8	32425-32431	groups	_	
186-9	32432-32435	and	_	
186-10	32436-32441	small	_	
186-11	32442-32448	sample	_	
186-12	32449-32453	size	_	
186-13	32454-32459	which	_	
186-14	32460-32466	likely	_	
186-15	32467-32476	precluded	_	
186-16	32477-32486	detection	_	
186-17	32487-32489	of	_	
186-18	32490-32501	significant	_	
186-19	32502-32513	differences	_	
186-20	32513-32514	,	_	
186-21	32515-32523	post-hoc	_	
186-22	32524-32532	analyses	_	
186-23	32533-32537	were	_	
186-24	32538-32547	conducted	_	
186-25	32548-32550	on	_	
186-26	32551-32556	these	_	
186-27	32557-32561	data	_	
186-28	32561-32562	,	_	
186-29	32563-32572	revealing	_	
186-30	32573-32586	significantly	_	
186-31	32587-32592	lower	_	
186-32	32593-32606	LPS-simulated	_	
186-33	32607-32615	cytokine	_	
186-34	32616-32624	response	_	
186-35	32625-32628	for	_	
186-36	32629-32631	IL	_	
186-37	32631-32632	-	_	
186-38	32632-32633	8	_	
186-39	32634-32637	and	_	
186-40	32638-32640	IL	_	
186-41	32640-32641	-	_	
186-42	32641-32642	6	_	
186-43	32643-32644	(	_	
186-44	32644-32647	see	_	
186-45	32648-32654	Figure	_	
186-46	32655-32659	4A-B	_	
186-47	32659-32660	)	_	
186-48	32660-32661	.	_	

#Text=Indeed, further assessment of the data indicates a pattern of lower pro-inflammatory IL-1β response in alcohol dependent subjects compared to healthy controls (see Fig. 4C).
187-1	32662-32668	Indeed	_	
187-2	32668-32669	,	_	
187-3	32670-32677	further	_	
187-4	32678-32688	assessment	_	
187-5	32689-32691	of	_	
187-6	32692-32695	the	_	
187-7	32696-32700	data	_	
187-8	32701-32710	indicates	_	
187-9	32711-32712	a	_	
187-10	32713-32720	pattern	_	
187-11	32721-32723	of	_	
187-12	32724-32729	lower	_	
187-13	32730-32746	pro-inflammatory	_	
187-14	32747-32749	IL	_	
187-15	32749-32750	-	_	
187-16	32750-32752	1β	_	
187-17	32753-32761	response	_	
187-18	32762-32764	in	_	
187-19	32765-32772	alcohol	_	
187-20	32773-32782	dependent	_	
187-21	32783-32791	subjects	_	
187-22	32792-32800	compared	_	
187-23	32801-32803	to	_	
187-24	32804-32811	healthy	_	
187-25	32812-32820	controls	_	
187-26	32821-32822	(	_	
187-27	32822-32825	see	_	
187-28	32826-32829	Fig	_	
187-29	32829-32830	.	_	
187-30	32831-32833	4C	_	
187-31	32833-32834	)	_	
187-32	32834-32835	.	_	

#Text=In contrast, the anti-inflammatory IL-10 cytokine expression suggests an opposite pattern of greater response to LPS stimulation in alcohol dependent subject compared to healthy controls (Fig. 4E).
188-1	32836-32838	In	_	
188-2	32839-32847	contrast	_	
188-3	32847-32848	,	_	
188-4	32849-32852	the	_	
188-5	32853-32870	anti-inflammatory	_	
188-6	32871-32873	IL	_	
188-7	32873-32874	-	_	
188-8	32874-32876	10	_	
188-9	32877-32885	cytokine	_	
188-10	32886-32896	expression	_	
188-11	32897-32905	suggests	_	
188-12	32906-32908	an	_	
188-13	32909-32917	opposite	_	
188-14	32918-32925	pattern	_	
188-15	32926-32928	of	_	
188-16	32929-32936	greater	_	
188-17	32937-32945	response	_	
188-18	32946-32948	to	_	
188-19	32949-32952	LPS	_	
188-20	32953-32964	stimulation	_	
188-21	32965-32967	in	_	
188-22	32968-32975	alcohol	_	
188-23	32976-32985	dependent	_	
188-24	32986-32993	subject	_	
188-25	32994-33002	compared	_	
188-26	33003-33005	to	_	
188-27	33006-33013	healthy	_	
188-28	33014-33022	controls	_	
188-29	33023-33024	(	_	
188-30	33024-33027	Fig	_	
188-31	33027-33028	.	_	
188-32	33029-33031	4E	_	
188-33	33031-33032	)	_	
188-34	33032-33033	.	_	

#Text=The finding of lower pro-inflammatory response to LPS challenge in alcohol dependence is consistent with previous reports of lower LPS-stimulated response of IL-1β, IL-12, and TNF-α in alcohol dependent subjects.
189-1	33034-33037	The	_	
189-2	33038-33045	finding	_	
189-3	33046-33048	of	_	
189-4	33049-33054	lower	_	
189-5	33055-33071	pro-inflammatory	_	
189-6	33072-33080	response	_	
189-7	33081-33083	to	_	
189-8	33084-33087	LPS	_	
189-9	33088-33097	challenge	_	
189-10	33098-33100	in	_	
189-11	33101-33108	alcohol	_	
189-12	33109-33119	dependence	_	
189-13	33120-33122	is	_	
189-14	33123-33133	consistent	_	
189-15	33134-33138	with	_	
189-16	33139-33147	previous	_	
189-17	33148-33155	reports	_	
189-18	33156-33158	of	_	
189-19	33159-33164	lower	_	
189-20	33165-33179	LPS-stimulated	_	
189-21	33180-33188	response	_	
189-22	33189-33191	of	_	
189-23	33192-33194	IL	_	
189-24	33194-33195	-	_	
189-25	33195-33197	1β	_	
189-26	33197-33198	,	_	
189-27	33199-33201	IL	_	
189-28	33201-33202	-	_	
189-29	33202-33204	12	_	
189-30	33204-33205	,	_	
189-31	33206-33209	and	_	
189-32	33210-33215	TNF-α	_	
189-33	33216-33218	in	_	
189-34	33219-33226	alcohol	_	
189-35	33227-33236	dependent	_	
189-36	33237-33245	subjects	_	
189-37	33245-33246	.	_	

#Text=Interestingly, these previously reported findings were driven by significantly greater spontaneous (e.g. non-stimulated) cytokine levels in alcohol dependent subjects relative to controls, however, excessive experimental and physiological variability in this measurement limits the interpretation of this finding.
190-1	33247-33260	Interestingly	_	
190-2	33260-33261	,	_	
190-3	33262-33267	these	_	
190-4	33268-33278	previously	_	
190-5	33279-33287	reported	_	
190-6	33288-33296	findings	_	
190-7	33297-33301	were	_	
190-8	33302-33308	driven	_	
190-9	33309-33311	by	_	
190-10	33312-33325	significantly	_	
190-11	33326-33333	greater	_	
190-12	33334-33345	spontaneous	_	
190-13	33346-33347	(	_	
190-14	33347-33350	e.g	_	
190-15	33350-33351	.	_	
190-16	33352-33366	non-stimulated	_	
190-17	33366-33367	)	_	
190-18	33368-33376	cytokine	_	
190-19	33377-33383	levels	_	
190-20	33384-33386	in	_	
190-21	33387-33394	alcohol	_	
190-22	33395-33404	dependent	_	
190-23	33405-33413	subjects	_	
190-24	33414-33422	relative	_	
190-25	33423-33425	to	_	
190-26	33426-33434	controls	_	
190-27	33434-33435	,	_	
190-28	33436-33443	however	_	
190-29	33443-33444	,	_	
190-30	33445-33454	excessive	_	
190-31	33455-33467	experimental	_	
190-32	33468-33471	and	_	
190-33	33472-33485	physiological	_	
190-34	33486-33497	variability	_	
190-35	33498-33500	in	_	
190-36	33501-33505	this	_	
190-37	33506-33517	measurement	_	
190-38	33518-33524	limits	_	
190-39	33525-33528	the	_	
190-40	33529-33543	interpretation	_	
190-41	33544-33546	of	_	
190-42	33547-33551	this	_	
190-43	33552-33559	finding	_	
190-44	33559-33560	.	_	

#Text=Consistent with previous reports , no direct relationship between activated microglia levels in brain and cytokine measures was observed.
191-1	33561-33571	Consistent	_	
191-2	33572-33576	with	_	
191-3	33577-33585	previous	_	
191-4	33586-33593	reports	_	
191-5	33594-33595	,	_	
191-6	33596-33598	no	_	
191-7	33599-33605	direct	_	
191-8	33606-33618	relationship	_	
191-9	33619-33626	between	_	
191-10	33627-33636	activated	_	
191-11	33637-33646	microglia	_	
191-12	33647-33653	levels	_	
191-13	33654-33656	in	_	
191-14	33657-33662	brain	_	
191-15	33663-33666	and	_	
191-16	33667-33675	cytokine	_	
191-17	33676-33684	measures	_	
191-18	33685-33688	was	_	
191-19	33689-33697	observed	_	
191-20	33697-33698	.	_	

#Text=Therefore we are unable to comment on the extent to which the altered neuronal and peripheral immune profiles in alcohol dependence are directly related.
192-1	33699-33708	Therefore	_	
192-2	33709-33711	we	_	
192-3	33712-33715	are	_	
192-4	33716-33722	unable	_	
192-5	33723-33725	to	_	
192-6	33726-33733	comment	_	
192-7	33734-33736	on	_	
192-8	33737-33740	the	_	
192-9	33741-33747	extent	_	
192-10	33748-33750	to	_	
192-11	33751-33756	which	_	
192-12	33757-33760	the	_	
192-13	33761-33768	altered	_	
192-14	33769-33777	neuronal	_	
192-15	33778-33781	and	_	
192-16	33782-33792	peripheral	_	
192-17	33793-33799	immune	_	
192-18	33800-33808	profiles	_	
192-19	33809-33811	in	_	
192-20	33812-33819	alcohol	_	
192-21	33820-33830	dependence	_	
192-22	33831-33834	are	_	
192-23	33835-33843	directly	_	
192-24	33844-33851	related	_	
192-25	33851-33852	.	_	

#Text=In conclusion, this work demonstrates an association of alcohol dependence with lower activated microglia levels in brain and blunted pro-inflammatory cytokine response from peripheral monocytes.
193-1	33853-33855	In	_	
193-2	33856-33866	conclusion	_	
193-3	33866-33867	,	_	
193-4	33868-33872	this	_	
193-5	33873-33877	work	_	
193-6	33878-33890	demonstrates	_	
193-7	33891-33893	an	_	
193-8	33894-33905	association	_	
193-9	33906-33908	of	_	
193-10	33909-33916	alcohol	_	
193-11	33917-33927	dependence	_	
193-12	33928-33932	with	_	
193-13	33933-33938	lower	_	
193-14	33939-33948	activated	_	
193-15	33949-33958	microglia	_	
193-16	33959-33965	levels	_	
193-17	33966-33968	in	_	
193-18	33969-33974	brain	_	
193-19	33975-33978	and	_	
193-20	33979-33986	blunted	_	
193-21	33987-34003	pro-inflammatory	_	
193-22	34004-34012	cytokine	_	
193-23	34013-34021	response	_	
193-24	34022-34026	from	_	
193-25	34027-34037	peripheral	_	
193-26	34038-34047	monocytes	_	
193-27	34047-34048	.	_	

#Text=These findings support a view of a dysregulated innate immune system in alcohol dependence, which could be a potential target for future therapeutic development.
194-1	34049-34054	These	_	
194-2	34055-34063	findings	_	
194-3	34064-34071	support	_	
194-4	34072-34073	a	_	
194-5	34074-34078	view	_	
194-6	34079-34081	of	_	
194-7	34082-34083	a	_	
194-8	34084-34096	dysregulated	_	
194-9	34097-34103	innate	_	
194-10	34104-34110	immune	_	
194-11	34111-34117	system	_	
194-12	34118-34120	in	_	
194-13	34121-34128	alcohol	_	
194-14	34129-34139	dependence	_	
194-15	34139-34140	,	_	
194-16	34141-34146	which	_	
194-17	34147-34152	could	_	
194-18	34153-34155	be	_	
194-19	34156-34157	a	_	
194-20	34158-34167	potential	_	
194-21	34168-34174	target	_	
194-22	34175-34178	for	_	
194-23	34179-34185	future	_	
194-24	34186-34197	therapeutic	_	
194-25	34198-34209	development	_	
194-26	34209-34210	.	_	

#Text=Supplementary Material
#Text=Conflict of Interest
#Text=Dr.
195-1	34211-34224	Supplementary	_	
195-2	34225-34233	Material	_	
195-3	34234-34242	Conflict	_	
195-4	34243-34245	of	_	
195-5	34246-34254	Interest	_	
195-6	34255-34257	Dr	_	
195-7	34257-34258	.	_	

#Text=Hannestad reports the following: He was a full-time employee of UCB Pharma at the time this study was planned and conducted.
196-1	34259-34268	Hannestad	_	
196-2	34269-34276	reports	_	
196-3	34277-34280	the	_	
196-4	34281-34290	following	_	
196-5	34290-34291	:	_	
196-6	34292-34294	He	_	
196-7	34295-34298	was	_	
196-8	34299-34300	a	_	
196-9	34301-34310	full-time	_	
196-10	34311-34319	employee	_	
196-11	34320-34322	of	_	
196-12	34323-34326	UCB	_	
196-13	34327-34333	Pharma	_	
196-14	34334-34336	at	_	
196-15	34337-34340	the	_	
196-16	34341-34345	time	_	
196-17	34346-34350	this	_	
196-18	34351-34356	study	_	
196-19	34357-34360	was	_	
196-20	34361-34368	planned	_	
196-21	34369-34372	and	_	
196-22	34373-34382	conducted	_	
196-23	34382-34383	.	_	

#Text=Dr.
197-1	34384-34386	Dr	_	
197-2	34386-34387	.	_	

#Text=O’Connor reports the following: Genentech, EMD Serono – speaking honoraria; NeuroPhage Pharmaceuticals, Scitemex – consulting.
198-1	34388-34389	O	_	
198-2	34389-34390	’	_	
198-3	34390-34396	Connor	_	
198-4	34397-34404	reports	_	
198-5	34405-34408	the	_	
198-6	34409-34418	following	_	
198-7	34418-34419	:	_	
198-8	34420-34429	Genentech	_	
198-9	34429-34430	,	_	
198-10	34431-34434	EMD	_	
198-11	34435-34441	Serono	_	
198-12	34442-34443	–	_	
198-13	34444-34452	speaking	_	
198-14	34453-34462	honoraria	_	
198-15	34462-34463	;	_	
198-16	34464-34474	NeuroPhage	_	
198-17	34475-34490	Pharmaceuticals	_	
198-18	34490-34491	,	_	
198-19	34492-34500	Scitemex	_	
198-20	34501-34502	–	_	
198-21	34503-34513	consulting	_	
198-22	34513-34514	.	_	

#Text=Although not directly relevant to the reported work, Dr.
199-1	34515-34523	Although	_	
199-2	34524-34527	not	_	
199-3	34528-34536	directly	_	
199-4	34537-34545	relevant	_	
199-5	34546-34548	to	_	
199-6	34549-34552	the	_	
199-7	34553-34561	reported	_	
199-8	34562-34566	work	_	
199-9	34566-34567	,	_	
199-10	34568-34570	Dr	_	
199-11	34570-34571	.	_	

#Text=O’Malley reports the following: donated study medications: AstraZeneca, Pfizer; consultant or advisory board member – Alkermes, Cerecor, Opiant; Scientific Review Group, Hazelden Betty Ford Foundation; member of the American Society of Clinical Pharmacology Alcohol Clinical Trials Initiative supported by Ethypharm, Lilly, Lundbeck, Otsuka, Pfizer, Arbor Pharmaceuticals, Indivior.
200-1	34572-34573	O	_	
200-2	34573-34574	’	_	
200-3	34574-34580	Malley	_	
200-4	34581-34588	reports	_	
200-5	34589-34592	the	_	
200-6	34593-34602	following	_	
200-7	34602-34603	:	_	
200-8	34604-34611	donated	_	
200-9	34612-34617	study	_	
200-10	34618-34629	medications	_	
200-11	34629-34630	:	_	
200-12	34631-34642	AstraZeneca	_	
200-13	34642-34643	,	_	
200-14	34644-34650	Pfizer	_	
200-15	34650-34651	;	_	
200-16	34652-34662	consultant	_	
200-17	34663-34665	or	_	
200-18	34666-34674	advisory	_	
200-19	34675-34680	board	_	
200-20	34681-34687	member	_	
200-21	34688-34689	–	_	
200-22	34690-34698	Alkermes	_	
200-23	34698-34699	,	_	
200-24	34700-34707	Cerecor	_	
200-25	34707-34708	,	_	
200-26	34709-34715	Opiant	_	
200-27	34715-34716	;	_	
200-28	34717-34727	Scientific	_	
200-29	34728-34734	Review	_	
200-30	34735-34740	Group	_	
200-31	34740-34741	,	_	
200-32	34742-34750	Hazelden	_	
200-33	34751-34756	Betty	_	
200-34	34757-34761	Ford	_	
200-35	34762-34772	Foundation	_	
200-36	34772-34773	;	_	
200-37	34774-34780	member	_	
200-38	34781-34783	of	_	
200-39	34784-34787	the	_	
200-40	34788-34796	American	_	
200-41	34797-34804	Society	_	
200-42	34805-34807	of	_	
200-43	34808-34816	Clinical	_	
200-44	34817-34829	Pharmacology	_	
200-45	34830-34837	Alcohol	_	
200-46	34838-34846	Clinical	_	
200-47	34847-34853	Trials	_	
200-48	34854-34864	Initiative	_	
200-49	34865-34874	supported	_	
200-50	34875-34877	by	_	
200-51	34878-34887	Ethypharm	_	
200-52	34887-34888	,	_	
200-53	34889-34894	Lilly	_	
200-54	34894-34895	,	_	
200-55	34896-34904	Lundbeck	_	
200-56	34904-34905	,	_	
200-57	34906-34912	Otsuka	_	
200-58	34912-34913	,	_	
200-59	34914-34920	Pfizer	_	
200-60	34920-34921	,	_	
200-61	34922-34927	Arbor	_	
200-62	34928-34943	Pharmaceuticals	_	
200-63	34943-34944	,	_	
200-64	34945-34953	Indivior	_	
200-65	34953-34954	.	_	

#Text=All other authors have no conflict of interest to report.
201-1	34955-34958	All	_	
201-2	34959-34964	other	_	
201-3	34965-34972	authors	_	
201-4	34973-34977	have	_	
201-5	34978-34980	no	_	
201-6	34981-34989	conflict	_	
201-7	34990-34992	of	_	
201-8	34993-35001	interest	_	
201-9	35002-35004	to	_	
201-10	35005-35011	report	_	
201-11	35011-35012	.	_	

#Text=References
#Text=
#Text=Alcohol, host defence and society
#Text=A recent perspective on alcohol, immunity, and host defense
#Text=Neurocircuitry in alcoholism: a substrate of disruption and repair
#Text=Mechanisms of neuroimmune gene induction in alcoholism
#Text=MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway
#Text=The origin and cell lineage of microglia: new concepts
#Text=Microglia: gatekeepers of central nervous system immunology
#Text=Hematopoietic origin of pathological grooming in Hoxb8 mutant mice
#Text=Systemic infection and delirium: when cytokines and acetylcholine collide
#Text=Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
#Text=Inflammation, glutamate, and glia in depression: a literature review
#Text=Transcriptional control of maladaptive and protective responses in alcoholics: a role of the NF-kappaB system
#Text=The function of microglia, either neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro
#Text=Microglia: active sensor and versatile effector cells in the normal and pathologic brain
#Text=Microglial activation is not equivalent to neuroinflammation in alcohol-induced neurodegeneration: The importance of microglia phenotype
#Text=Neuroinflammation, neurodegeneration, and depression
#Text=Microglia and neuroinflammation: a pathological perspective
#Text=Opportunities for the development of neuroimmune therapies in addiction
#Text=Imaging robust microglial activation after lipopolysaccharide administration in humans with PET
#Text=Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders
#Text=Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain
#Text=The 18 kDa translocator protein, microglia and neuroinflammation
#Text=Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands
#Text=In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease
#Text=Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis
#Text=11C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas
#Text=Increased In Vivo Expression of an Inflammatory Marker in Temporal Lobe Epilepsy
#Text=High mobility group box 1/Toll-like receptor danger signaling increases brain neuroimmune activation in alcohol dependence
#Text=Increased MCP-1 and microglia in various regions of the human alcoholic brain
#Text=Striatal and forebrain nuclei volumes: Contribution to motor function and working memory deficits in alcoholism
#Text=Decreased volume of the brain reward system in alcoholism
#Text=Alcohol and adult hippocampal neurogenesis: promiscuous drug, wanton effects
#Text=Microglia and neurodegeneration: the role of systemic inflammation
#Text=Exploring the full spectrum of macrophage activation
#Text=The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes
#Text=Moderate alcohol intake in humans attenuates monocyte inflammatory responses: inhibition of nuclear regulatory factor kappa B and induction of interleukin 10
#Text=The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study
#Text=An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28
#Text=Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers
#Text=Alcohol dependence syndrome: measurement and validation
#Text=Alcohol craving questionnaire: ACQ-Now: background and administration manual
#Text=Timeline follow-back
#Text=Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT
#Text=Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction
#Text=Consensus nomenclature for in vivo imaging of reversibly binding radioligands
#Text=Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain
#Text=Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage
#Text=Effects of chronic ethanol intake and its withdrawal on the expression and phosphorylation of the CREB gene transcription factor in rat cortex
#Text=NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activation and neurodegeneration
#Text=Increased receptor for advanced glycation end product expression in the human alcoholic prefrontal cortex is linked to adolescent drinking
#Text=Activated microglia are implicated in cognitive deficits, neuronal death, and successful recovery following intermittent ethanol exposure
#Text=Prior Binge Ethanol Exposure Potentiates the Microglial Response in a Model of Alcohol-Induced Neurodegeneration
#Text=Neuro-inflammation induced in the hippocampus of ‘binge drinking’rats may be mediated by elevated extracellular glutamate content
#Text=Microglial priming in neurodegenerative disease
#Text=Hippocampal microglial dysfunction in alcohol dependence: a [C-11]PBR28 positron emission tomography (PET) study
#Text=Microglial Pathology
#Text=Determination of [11C]PBR28 binding potential in vivo: a first human TSPO blocking study
#Text=Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair
#Text=Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging
#Text=Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates
#Text=Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain
#Text=Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease
#Text=Methamphetamine causes microglial activation in the brains of human abusers
#Text=Comment on Analyses and Conclusions of “Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [11C]PBR28 PET Brain Imaging Study”
#Text=Cocaine abuse in humans is not associated with increased microglial activation: an 18-kDa translocator protein positron emission tomography imaging study with [11C]PBR28
#Text=Nicotine inhibits microglial proliferation and is neuroprotective in global ischemia rats
#Text=Inflammation and oxidative stress induced by cigarette smoke in Lewis Rats
#Text=Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [11C]PBR28 PET Brain Imaging Study
#Text=Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV
#Text=Evidence for brain glial activation in chronic pain patients
#Text=Alcohol: effects on neurobehavioral functions and the brain
#Text=Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients
#Text=Cortical gray matter loss in treatment-naive alcohol dependent individuals
#Text=Production of inflammatory cytokines by peripheral blood monocytes in chronic alcoholism: relationship with ethanol intake and liver disease
#Text=Role of inflammatory pathways, blood mononuclear cells, and gut-derived bacterial products in alcohol dependence
#Text=Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes
#Text=Levels of activated microglia are lower in alcohol dependent subjects (n=15; open green circles) compared to healthy controls (n=15; closed blue diamonds).
202-1	35013-35023	References	_	
202-2	35025-35032	Alcohol	_	
202-3	35032-35033	,	_	
202-4	35034-35038	host	_	
202-5	35039-35046	defence	_	
202-6	35047-35050	and	_	
202-7	35051-35058	society	_	
202-8	35059-35060	A	_	
202-9	35061-35067	recent	_	
202-10	35068-35079	perspective	_	
202-11	35080-35082	on	_	
202-12	35083-35090	alcohol	_	
202-13	35090-35091	,	_	
202-14	35092-35100	immunity	_	
202-15	35100-35101	,	_	
202-16	35102-35105	and	_	
202-17	35106-35110	host	_	
202-18	35111-35118	defense	_	
202-19	35119-35133	Neurocircuitry	_	
202-20	35134-35136	in	_	
202-21	35137-35147	alcoholism	_	
202-22	35147-35148	:	_	
202-23	35149-35150	a	_	
202-24	35151-35160	substrate	_	
202-25	35161-35163	of	_	
202-26	35164-35174	disruption	_	
202-27	35175-35178	and	_	
202-28	35179-35185	repair	_	
202-29	35186-35196	Mechanisms	_	
202-30	35197-35199	of	_	
202-31	35200-35211	neuroimmune	_	
202-32	35212-35216	gene	_	
202-33	35217-35226	induction	_	
202-34	35227-35229	in	_	
202-35	35230-35240	alcoholism	_	
202-36	35241-35249	MicroRNA	_	
202-37	35249-35250	-	_	
202-38	35250-35253	124	_	
202-39	35254-35262	promotes	_	
202-40	35263-35272	microglia	_	
202-41	35273-35283	quiescence	_	
202-42	35284-35287	and	_	
202-43	35288-35298	suppresses	_	
202-44	35299-35302	EAE	_	
202-45	35303-35305	by	_	
202-46	35306-35318	deactivating	_	
202-47	35319-35330	macrophages	_	
202-48	35331-35334	via	_	
202-49	35335-35338	the	_	
202-50	35339-35340	C	_	
202-51	35340-35341	/	_	
202-52	35341-35353	EBP-alpha-PU	_	
202-53	35353-35355	.1	_	
202-54	35356-35363	pathway	_	
202-55	35364-35367	The	_	
202-56	35368-35374	origin	_	
202-57	35375-35378	and	_	
202-58	35379-35383	cell	_	
202-59	35384-35391	lineage	_	
202-60	35392-35394	of	_	
202-61	35395-35404	microglia	_	
202-62	35404-35405	:	_	
202-63	35406-35409	new	_	
202-64	35410-35418	concepts	_	
202-65	35419-35428	Microglia	_	
202-66	35428-35429	:	_	
202-67	35430-35441	gatekeepers	_	
202-68	35442-35444	of	_	
202-69	35445-35452	central	_	
202-70	35453-35460	nervous	_	
202-71	35461-35467	system	_	
202-72	35468-35478	immunology	_	
202-73	35479-35492	Hematopoietic	_	
202-74	35493-35499	origin	_	
202-75	35500-35502	of	_	
202-76	35503-35515	pathological	_	
202-77	35516-35524	grooming	_	
202-78	35525-35527	in	_	
202-79	35528-35533	Hoxb8	_	
202-80	35534-35540	mutant	_	
202-81	35541-35545	mice	_	
202-82	35546-35554	Systemic	_	
202-83	35555-35564	infection	_	
202-84	35565-35568	and	_	
202-85	35569-35577	delirium	_	
202-86	35577-35578	:	_	
202-87	35579-35583	when	_	
202-88	35584-35593	cytokines	_	
202-89	35594-35597	and	_	
202-90	35598-35611	acetylcholine	_	
202-91	35612-35619	collide	_	
202-92	35620-35638	Microglia-mediated	_	
202-93	35639-35652	neurotoxicity	_	
202-94	35652-35653	:	_	
202-95	35654-35664	uncovering	_	
202-96	35665-35668	the	_	
202-97	35669-35678	molecular	_	
202-98	35679-35689	mechanisms	_	
202-99	35690-35702	Inflammation	_	
202-100	35702-35703	,	_	
202-101	35704-35713	glutamate	_	
202-102	35713-35714	,	_	
202-103	35715-35718	and	_	
202-104	35719-35723	glia	_	
202-105	35724-35726	in	_	
202-106	35727-35737	depression	_	
202-107	35737-35738	:	_	
202-108	35739-35740	a	_	
202-109	35741-35751	literature	_	
202-110	35752-35758	review	_	
202-111	35759-35774	Transcriptional	_	
202-112	35775-35782	control	_	
202-113	35783-35785	of	_	
202-114	35786-35797	maladaptive	_	
202-115	35798-35801	and	_	
202-116	35802-35812	protective	_	
202-117	35813-35822	responses	_	
202-118	35823-35825	in	_	
202-119	35826-35836	alcoholics	_	
202-120	35836-35837	:	_	
202-121	35838-35839	a	_	
202-122	35840-35844	role	_	
202-123	35845-35847	of	_	
202-124	35848-35851	the	_	
202-125	35852-35861	NF-kappaB	_	
202-126	35862-35868	system	_	
202-127	35869-35872	The	_	
202-128	35873-35881	function	_	
202-129	35882-35884	of	_	
202-130	35885-35894	microglia	_	
202-131	35894-35895	,	_	
202-132	35896-35902	either	_	
202-133	35903-35918	neuroprotection	_	
202-134	35919-35921	or	_	
202-135	35922-35935	neurotoxicity	_	
202-136	35935-35936	,	_	
202-137	35937-35939	is	_	
202-138	35940-35950	determined	_	
202-139	35951-35953	by	_	
202-140	35954-35957	the	_	
202-141	35958-35969	equilibrium	_	
202-142	35970-35975	among	_	
202-143	35976-35983	factors	_	
202-144	35984-35992	released	_	
202-145	35993-35997	from	_	
202-146	35998-36007	activated	_	
202-147	36008-36017	microglia	_	
202-148	36018-36020	in	_	
202-149	36021-36026	vitro	_	
202-150	36027-36036	Microglia	_	
202-151	36036-36037	:	_	
202-152	36038-36044	active	_	
202-153	36045-36051	sensor	_	
202-154	36052-36055	and	_	
202-155	36056-36065	versatile	_	
202-156	36066-36074	effector	_	
202-157	36075-36080	cells	_	
202-158	36081-36083	in	_	
202-159	36084-36087	the	_	
202-160	36088-36094	normal	_	
202-161	36095-36098	and	_	
202-162	36099-36109	pathologic	_	
202-163	36110-36115	brain	_	
202-164	36116-36126	Microglial	_	
202-165	36127-36137	activation	_	
202-166	36138-36140	is	_	
202-167	36141-36144	not	_	
202-168	36145-36155	equivalent	_	
202-169	36156-36158	to	_	
202-170	36159-36176	neuroinflammation	_	
202-171	36177-36179	in	_	
202-172	36180-36195	alcohol-induced	_	
202-173	36196-36213	neurodegeneration	_	
202-174	36213-36214	:	_	
202-175	36215-36218	The	_	
202-176	36219-36229	importance	_	
202-177	36230-36232	of	_	
202-178	36233-36242	microglia	_	
202-179	36243-36252	phenotype	_	
202-180	36253-36270	Neuroinflammation	_	
202-181	36270-36271	,	_	
202-182	36272-36289	neurodegeneration	_	
202-183	36289-36290	,	_	
202-184	36291-36294	and	_	
202-185	36295-36305	depression	_	
202-186	36306-36315	Microglia	_	
202-187	36316-36319	and	_	
202-188	36320-36337	neuroinflammation	_	
202-189	36337-36338	:	_	
202-190	36339-36340	a	_	
202-191	36341-36353	pathological	_	
202-192	36354-36365	perspective	_	
202-193	36366-36379	Opportunities	_	
202-194	36380-36383	for	_	
202-195	36384-36387	the	_	
202-196	36388-36399	development	_	
202-197	36400-36402	of	_	
202-198	36403-36414	neuroimmune	_	
202-199	36415-36424	therapies	_	
202-200	36425-36427	in	_	
202-201	36428-36437	addiction	_	
202-202	36438-36445	Imaging	_	
202-203	36446-36452	robust	_	
202-204	36453-36463	microglial	_	
202-205	36464-36474	activation	_	
202-206	36475-36480	after	_	
202-207	36481-36499	lipopolysaccharide	_	
202-208	36500-36514	administration	_	
202-209	36515-36517	in	_	
202-210	36518-36524	humans	_	
202-211	36525-36529	with	_	
202-212	36530-36533	PET	_	
202-213	36534-36546	Translocator	_	
202-214	36547-36554	protein	_	
202-215	36555-36556	(	_	
202-216	36556-36558	18	_	
202-217	36559-36562	kDa	_	
202-218	36562-36563	)	_	
202-219	36564-36565	(	_	
202-220	36565-36569	TSPO	_	
202-221	36569-36570	)	_	
202-222	36571-36573	as	_	
202-223	36574-36575	a	_	
202-224	36576-36587	therapeutic	_	
202-225	36588-36594	target	_	
202-226	36595-36598	for	_	
202-227	36599-36611	neurological	_	
202-228	36612-36615	and	_	
202-229	36616-36627	psychiatric	_	
202-230	36628-36637	disorders	_	
202-231	36638-36648	Expression	_	
202-232	36649-36651	of	_	
202-233	36652-36655	the	_	
202-234	36656-36668	translocator	_	
202-235	36669-36676	protein	_	
202-236	36677-36679	of	_	
202-237	36680-36682	18	_	
202-238	36683-36686	kDa	_	
202-239	36687-36689	by	_	
202-240	36690-36699	microglia	_	
202-241	36699-36700	,	_	
202-242	36701-36712	macrophages	_	
202-243	36713-36716	and	_	
202-244	36717-36727	astrocytes	_	
202-245	36728-36733	based	_	
202-246	36734-36736	on	_	
202-247	36737-36756	immunohistochemical	_	
202-248	36757-36769	localization	_	
202-249	36770-36772	in	_	
202-250	36773-36781	abnormal	_	
202-251	36782-36787	human	_	
202-252	36788-36793	brain	_	
202-253	36794-36797	The	_	
202-254	36798-36800	18	_	
202-255	36801-36804	kDa	_	
202-256	36805-36817	translocator	_	
202-257	36818-36825	protein	_	
202-258	36825-36826	,	_	
202-259	36827-36836	microglia	_	
202-260	36837-36840	and	_	
202-261	36841-36858	neuroinflammation	_	
202-262	36859-36866	Imaging	_	
202-263	36867-36872	brain	_	
202-264	36873-36883	microglial	_	
202-265	36884-36894	activation	_	
202-266	36895-36900	using	_	
202-267	36901-36909	positron	_	
202-268	36910-36918	emission	_	
202-269	36919-36929	tomography	_	
202-270	36930-36933	and	_	
202-271	36934-36946	translocator	_	
202-272	36947-36963	protein-specific	_	
202-273	36964-36976	radioligands	_	
202-274	36977-36979	In	_	
202-275	36980-36984	vivo	_	
202-276	36985-36996	radioligand	_	
202-277	36997-37004	binding	_	
202-278	37005-37007	to	_	
202-279	37008-37020	translocator	_	
202-280	37021-37028	protein	_	
202-281	37029-37039	correlates	_	
202-282	37040-37044	with	_	
202-283	37045-37053	severity	_	
202-284	37054-37056	of	_	
202-285	37057-37068	Alzheimer's	_	
202-286	37069-37076	disease	_	
202-287	37077-37089	Translocator	_	
202-288	37090-37097	Protein	_	
202-289	37098-37101	PET	_	
202-290	37102-37109	Imaging	_	
202-291	37110-37113	for	_	
202-292	37114-37119	Glial	_	
202-293	37120-37130	Activation	_	
202-294	37131-37133	in	_	
202-295	37134-37142	Multiple	_	
202-296	37143-37152	Sclerosis	_	
202-297	37153-37162	11C-PBR28	_	
202-298	37163-37170	imaging	_	
202-299	37171-37173	in	_	
202-300	37174-37182	multiple	_	
202-301	37183-37192	sclerosis	_	
202-302	37193-37201	patients	_	
202-303	37202-37205	and	_	
202-304	37206-37213	healthy	_	
202-305	37214-37222	controls	_	
202-306	37222-37223	:	_	
202-307	37224-37235	test-retest	_	
202-308	37236-37251	reproducibility	_	
202-309	37252-37255	and	_	
202-310	37256-37261	focal	_	
202-311	37262-37275	visualization	_	
202-312	37276-37278	of	_	
202-313	37279-37285	active	_	
202-314	37286-37291	white	_	
202-315	37292-37298	matter	_	
202-316	37299-37304	areas	_	
202-317	37305-37314	Increased	_	
202-318	37315-37317	In	_	
202-319	37318-37322	Vivo	_	
202-320	37323-37333	Expression	_	
202-321	37334-37336	of	_	
202-322	37337-37339	an	_	
202-323	37340-37352	Inflammatory	_	
202-324	37353-37359	Marker	_	
202-325	37360-37362	in	_	
202-326	37363-37371	Temporal	_	
202-327	37372-37376	Lobe	_	
202-328	37377-37385	Epilepsy	_	
202-329	37386-37390	High	_	
202-330	37391-37399	mobility	_	
202-331	37400-37405	group	_	
202-332	37406-37409	box	_	
202-333	37410-37411	1	_	
202-334	37411-37412	/	_	
202-335	37412-37421	Toll-like	_	
202-336	37422-37430	receptor	_	
202-337	37431-37437	danger	_	
202-338	37438-37447	signaling	_	
202-339	37448-37457	increases	_	
202-340	37458-37463	brain	_	
202-341	37464-37475	neuroimmune	_	
202-342	37476-37486	activation	_	
202-343	37487-37489	in	_	
202-344	37490-37497	alcohol	_	
202-345	37498-37508	dependence	_	
202-346	37509-37518	Increased	_	
202-347	37519-37522	MCP	_	
202-348	37522-37523	-	_	
202-349	37523-37524	1	_	
202-350	37525-37528	and	_	
202-351	37529-37538	microglia	_	
202-352	37539-37541	in	_	
202-353	37542-37549	various	_	
202-354	37550-37557	regions	_	
202-355	37558-37560	of	_	
202-356	37561-37564	the	_	
202-357	37565-37570	human	_	
202-358	37571-37580	alcoholic	_	
202-359	37581-37586	brain	_	
202-360	37587-37595	Striatal	_	
202-361	37596-37599	and	_	
202-362	37600-37609	forebrain	_	
202-363	37610-37616	nuclei	_	
202-364	37617-37624	volumes	_	
202-365	37624-37625	:	_	
202-366	37626-37638	Contribution	_	
202-367	37639-37641	to	_	
202-368	37642-37647	motor	_	
202-369	37648-37656	function	_	
202-370	37657-37660	and	_	
202-371	37661-37668	working	_	
202-372	37669-37675	memory	_	
202-373	37676-37684	deficits	_	
202-374	37685-37687	in	_	
202-375	37688-37698	alcoholism	_	
202-376	37699-37708	Decreased	_	
202-377	37709-37715	volume	_	
202-378	37716-37718	of	_	
202-379	37719-37722	the	_	
202-380	37723-37728	brain	_	
202-381	37729-37735	reward	_	
202-382	37736-37742	system	_	
202-383	37743-37745	in	_	
202-384	37746-37756	alcoholism	_	
202-385	37757-37764	Alcohol	_	
202-386	37765-37768	and	_	
202-387	37769-37774	adult	_	
202-388	37775-37786	hippocampal	_	
202-389	37787-37799	neurogenesis	_	
202-390	37799-37800	:	_	
202-391	37801-37812	promiscuous	_	
202-392	37813-37817	drug	_	
202-393	37817-37818	,	_	
202-394	37819-37825	wanton	_	
202-395	37826-37833	effects	_	
202-396	37834-37843	Microglia	_	
202-397	37844-37847	and	_	
202-398	37848-37865	neurodegeneration	_	
202-399	37865-37866	:	_	
202-400	37867-37870	the	_	
202-401	37871-37875	role	_	
202-402	37876-37878	of	_	
202-403	37879-37887	systemic	_	
202-404	37888-37900	inflammation	_	
202-405	37901-37910	Exploring	_	
202-406	37911-37914	the	_	
202-407	37915-37919	full	_	
202-408	37920-37928	spectrum	_	
202-409	37929-37931	of	_	
202-410	37932-37942	macrophage	_	
202-411	37943-37953	activation	_	
202-412	37954-37957	The	_	
202-413	37958-37966	opposite	_	
202-414	37967-37974	effects	_	
202-415	37975-37977	of	_	
202-416	37978-37983	acute	_	
202-417	37984-37987	and	_	
202-418	37988-37995	chronic	_	
202-419	37996-38003	alcohol	_	
202-420	38004-38006	on	_	
202-421	38007-38033	lipopolysaccharide-induced	_	
202-422	38034-38046	inflammation	_	
202-423	38047-38050	are	_	
202-424	38051-38057	linked	_	
202-425	38058-38060	to	_	
202-426	38061-38067	IRAK-M	_	
202-427	38068-38070	in	_	
202-428	38071-38076	human	_	
202-429	38077-38086	monocytes	_	
202-430	38087-38095	Moderate	_	
202-431	38096-38103	alcohol	_	
202-432	38104-38110	intake	_	
202-433	38111-38113	in	_	
202-434	38114-38120	humans	_	
202-435	38121-38131	attenuates	_	
202-436	38132-38140	monocyte	_	
202-437	38141-38153	inflammatory	_	
202-438	38154-38163	responses	_	
202-439	38163-38164	:	_	
202-440	38165-38175	inhibition	_	
202-441	38176-38178	of	_	
202-442	38179-38186	nuclear	_	
202-443	38187-38197	regulatory	_	
202-444	38198-38204	factor	_	
202-445	38205-38210	kappa	_	
202-446	38211-38212	B	_	
202-447	38213-38216	and	_	
202-448	38217-38226	induction	_	
202-449	38227-38229	of	_	
202-450	38230-38241	interleukin	_	
202-451	38242-38244	10	_	
202-452	38245-38248	The	_	
202-453	38249-38266	neuroinflammation	_	
202-454	38267-38273	marker	_	
202-455	38274-38286	translocator	_	
202-456	38287-38294	protein	_	
202-457	38295-38297	is	_	
202-458	38298-38301	not	_	
202-459	38302-38310	elevated	_	
202-460	38311-38313	in	_	
202-461	38314-38325	individuals	_	
202-462	38326-38330	with	_	
202-463	38331-38347	mild-to-moderate	_	
202-464	38348-38358	depression	_	
202-465	38358-38359	:	_	
202-466	38360-38361	A	_	
202-467	38362-38363	[	_	
202-468	38363-38366	11C	_	
202-469	38366-38367	]	_	
202-470	38367-38372	PBR28	_	
202-471	38373-38376	PET	_	
202-472	38377-38382	study	_	
202-473	38383-38385	An	_	
202-474	38386-38388	18	_	
202-475	38388-38389	-	_	
202-476	38389-38392	kDa	_	
202-477	38393-38405	translocator	_	
202-478	38406-38413	protein	_	
202-479	38414-38415	(	_	
202-480	38415-38419	TSPO	_	
202-481	38419-38420	)	_	
202-482	38421-38433	polymorphism	_	
202-483	38434-38442	explains	_	
202-484	38443-38454	differences	_	
202-485	38455-38457	in	_	
202-486	38458-38465	binding	_	
202-487	38466-38474	affinity	_	
202-488	38475-38477	of	_	
202-489	38478-38481	the	_	
202-490	38482-38485	PET	_	
202-491	38486-38497	radioligand	_	
202-492	38498-38503	PBR28	_	
202-493	38504-38511	Nuclear	_	
202-494	38512-38519	imaging	_	
202-495	38520-38522	of	_	
202-496	38523-38540	neuroinflammation	_	
202-497	38540-38541	:	_	
202-498	38542-38543	a	_	
202-499	38544-38557	comprehensive	_	
202-500	38558-38564	review	_	
202-501	38565-38567	of	_	
202-502	38568-38569	[	_	
202-503	38569-38572	11C	_	
202-504	38572-38573	]	_	
202-505	38573-38580	PK11195	_	
202-506	38581-38592	challengers	_	
202-507	38593-38600	Alcohol	_	
202-508	38601-38611	dependence	_	
202-509	38612-38620	syndrome	_	
202-510	38620-38621	:	_	
202-511	38622-38633	measurement	_	
202-512	38634-38637	and	_	
202-513	38638-38648	validation	_	
202-514	38649-38656	Alcohol	_	
202-515	38657-38664	craving	_	
202-516	38665-38678	questionnaire	_	
202-517	38678-38679	:	_	
202-518	38680-38687	ACQ-Now	_	
202-519	38687-38688	:	_	
202-520	38689-38699	background	_	
202-521	38700-38703	and	_	
202-522	38704-38718	administration	_	
202-523	38719-38725	manual	_	
202-524	38726-38734	Timeline	_	
202-525	38735-38746	follow-back	_	
202-526	38747-38753	Design	_	
202-527	38754-38756	of	_	
202-528	38757-38758	a	_	
202-529	38759-38778	motion-compensation	_	
202-530	38779-38783	OSEM	_	
202-531	38784-38793	list-mode	_	
202-532	38794-38803	algorithm	_	
202-533	38804-38807	for	_	
202-534	38808-38827	resolution-recovery	_	
202-535	38828-38842	reconstruction	_	
202-536	38843-38846	for	_	
202-537	38847-38850	the	_	
202-538	38851-38855	HRRT	_	
202-539	38856-38861	Brain	_	
202-540	38862-38875	incorporation	_	
202-541	38876-38878	of	_	
202-542	38879-38894	11C-arachidonic	_	
202-543	38895-38899	acid	_	
202-544	38899-38900	,	_	
202-545	38901-38906	blood	_	
202-546	38907-38913	volume	_	
202-547	38913-38914	,	_	
202-548	38915-38918	and	_	
202-549	38919-38924	blood	_	
202-550	38925-38929	flow	_	
202-551	38930-38932	in	_	
202-552	38933-38940	healthy	_	
202-553	38941-38946	aging	_	
202-554	38946-38947	:	_	
202-555	38948-38949	a	_	
202-556	38950-38955	study	_	
202-557	38956-38960	with	_	
202-558	38961-38975	partial-volume	_	
202-559	38976-38986	correction	_	
202-560	38987-38996	Consensus	_	
202-561	38997-39009	nomenclature	_	
202-562	39010-39013	for	_	
202-563	39014-39016	in	_	
202-564	39017-39021	vivo	_	
202-565	39022-39029	imaging	_	
202-566	39030-39032	of	_	
202-567	39033-39043	reversibly	_	
202-568	39044-39051	binding	_	
202-569	39052-39064	radioligands	_	
202-570	39065-39075	Linearized	_	
202-571	39076-39085	reference	_	
202-572	39086-39092	tissue	_	
202-573	39093-39103	parametric	_	
202-574	39104-39111	imaging	_	
202-575	39112-39119	methods	_	
202-576	39119-39120	:	_	
202-577	39121-39132	application	_	
202-578	39133-39135	to	_	
202-579	39136-39137	[	_	
202-580	39137-39140	11C	_	
202-581	39140-39141	]	_	
202-582	39141-39145	DASB	_	
202-583	39146-39154	positron	_	
202-584	39155-39163	emission	_	
202-585	39164-39174	tomography	_	
202-586	39175-39182	studies	_	
202-587	39183-39185	of	_	
202-588	39186-39189	the	_	
202-589	39190-39199	serotonin	_	
202-590	39200-39211	transporter	_	
202-591	39212-39214	in	_	
202-592	39215-39220	human	_	
202-593	39221-39226	brain	_	
202-594	39227-39234	Pivotal	_	
202-595	39235-39239	role	_	
202-596	39240-39242	of	_	
202-597	39243-39247	TLR4	_	
202-598	39248-39257	receptors	_	
202-599	39258-39260	in	_	
202-600	39261-39276	alcohol-induced	_	
202-601	39277-39294	neuroinflammation	_	
202-602	39295-39298	and	_	
202-603	39299-39304	brain	_	
202-604	39305-39311	damage	_	
202-605	39312-39319	Effects	_	
202-606	39320-39322	of	_	
202-607	39323-39330	chronic	_	
202-608	39331-39338	ethanol	_	
202-609	39339-39345	intake	_	
202-610	39346-39349	and	_	
202-611	39350-39353	its	_	
202-612	39354-39364	withdrawal	_	
202-613	39365-39367	on	_	
202-614	39368-39371	the	_	
202-615	39372-39382	expression	_	
202-616	39383-39386	and	_	
202-617	39387-39402	phosphorylation	_	
202-618	39403-39405	of	_	
202-619	39406-39409	the	_	
202-620	39410-39414	CREB	_	
202-621	39415-39419	gene	_	
202-622	39420-39433	transcription	_	
202-623	39434-39440	factor	_	
202-624	39441-39443	in	_	
202-625	39444-39447	rat	_	
202-626	39448-39454	cortex	_	
202-627	39455-39460	NADPH	_	
202-628	39461-39468	oxidase	_	
202-629	39469-39472	and	_	
202-630	39473-39481	reactive	_	
202-631	39482-39488	oxygen	_	
202-632	39489-39496	species	_	
202-633	39497-39507	contribute	_	
202-634	39508-39510	to	_	
202-635	39511-39526	alcohol-induced	_	
202-636	39527-39537	microglial	_	
202-637	39538-39548	activation	_	
202-638	39549-39552	and	_	
202-639	39553-39570	neurodegeneration	_	
202-640	39571-39580	Increased	_	
202-641	39581-39589	receptor	_	
202-642	39590-39593	for	_	
202-643	39594-39602	advanced	_	
202-644	39603-39612	glycation	_	
202-645	39613-39616	end	_	
202-646	39617-39624	product	_	
202-647	39625-39635	expression	_	
202-648	39636-39638	in	_	
202-649	39639-39642	the	_	
202-650	39643-39648	human	_	
202-651	39649-39658	alcoholic	_	
202-652	39659-39669	prefrontal	_	
202-653	39670-39676	cortex	_	
202-654	39677-39679	is	_	
202-655	39680-39686	linked	_	
202-656	39687-39689	to	_	
202-657	39690-39700	adolescent	_	
202-658	39701-39709	drinking	_	
202-659	39710-39719	Activated	_	
202-660	39720-39729	microglia	_	
202-661	39730-39733	are	_	
202-662	39734-39744	implicated	_	
202-663	39745-39747	in	_	
202-664	39748-39757	cognitive	_	
202-665	39758-39766	deficits	_	
202-666	39766-39767	,	_	
202-667	39768-39776	neuronal	_	
202-668	39777-39782	death	_	
202-669	39782-39783	,	_	
202-670	39784-39787	and	_	
202-671	39788-39798	successful	_	
202-672	39799-39807	recovery	_	
202-673	39808-39817	following	_	
202-674	39818-39830	intermittent	_	
202-675	39831-39838	ethanol	_	
202-676	39839-39847	exposure	_	
202-677	39848-39853	Prior	_	
202-678	39854-39859	Binge	_	
202-679	39860-39867	Ethanol	_	
202-680	39868-39876	Exposure	_	
202-681	39877-39888	Potentiates	_	
202-682	39889-39892	the	_	
202-683	39893-39903	Microglial	_	
202-684	39904-39912	Response	_	
202-685	39913-39915	in	_	
202-686	39916-39917	a	_	
202-687	39918-39923	Model	_	
202-688	39924-39926	of	_	
202-689	39927-39942	Alcohol-Induced	_	
202-690	39943-39960	Neurodegeneration	_	
202-691	39961-39979	Neuro-inflammation	_	
202-692	39980-39987	induced	_	
202-693	39988-39990	in	_	
202-694	39991-39994	the	_	
202-695	39995-40006	hippocampus	_	
202-696	40007-40009	of	_	
202-697	40010-40011	‘	_	
202-698	40011-40016	binge	_	
202-699	40017-40025	drinking	_	
202-700	40025-40026	’	_	
202-701	40026-40030	rats	_	
202-702	40031-40034	may	_	
202-703	40035-40037	be	_	
202-704	40038-40046	mediated	_	
202-705	40047-40049	by	_	
202-706	40050-40058	elevated	_	
202-707	40059-40072	extracellular	_	
202-708	40073-40082	glutamate	_	
202-709	40083-40090	content	_	
202-710	40091-40101	Microglial	_	
202-711	40102-40109	priming	_	
202-712	40110-40112	in	_	
202-713	40113-40130	neurodegenerative	_	
202-714	40131-40138	disease	_	
202-715	40139-40150	Hippocampal	_	
202-716	40151-40161	microglial	_	
202-717	40162-40173	dysfunction	_	
202-718	40174-40176	in	_	
202-719	40177-40184	alcohol	_	
202-720	40185-40195	dependence	_	
202-721	40195-40196	:	_	
202-722	40197-40198	a	_	
202-723	40199-40200	[	_	
202-724	40200-40201	C	_	
202-725	40201-40202	-	_	
202-726	40202-40204	11	_	
202-727	40204-40205	]	_	
202-728	40205-40210	PBR28	_	
202-729	40211-40219	positron	_	
202-730	40220-40228	emission	_	
202-731	40229-40239	tomography	_	
202-732	40240-40241	(	_	
202-733	40241-40244	PET	_	
202-734	40244-40245	)	_	
202-735	40246-40251	study	_	
202-736	40252-40262	Microglial	_	
202-737	40263-40272	Pathology	_	
202-738	40273-40286	Determination	_	
202-739	40287-40289	of	_	
202-740	40290-40291	[	_	
202-741	40291-40294	11C	_	
202-742	40294-40295	]	_	
202-743	40295-40300	PBR28	_	
202-744	40301-40308	binding	_	
202-745	40309-40318	potential	_	
202-746	40319-40321	in	_	
202-747	40322-40326	vivo	_	
202-748	40326-40327	:	_	
202-749	40328-40329	a	_	
202-750	40330-40335	first	_	
202-751	40336-40341	human	_	
202-752	40342-40346	TSPO	_	
202-753	40347-40355	blocking	_	
202-754	40356-40361	study	_	
202-755	40362-40374	Translocator	_	
202-756	40375-40382	protein	_	
202-757	40383-40385	18	_	
202-758	40386-40389	kDa	_	
202-759	40390-40391	(	_	
202-760	40391-40395	TSPO	_	
202-761	40395-40396	)	_	
202-762	40396-40397	:	_	
202-763	40398-40407	molecular	_	
202-764	40408-40414	sensor	_	
202-765	40415-40417	of	_	
202-766	40418-40423	brain	_	
202-767	40424-40430	injury	_	
202-768	40431-40434	and	_	
202-769	40435-40441	repair	_	
202-770	40442-40450	Reactive	_	
202-771	40451-40461	astrocytes	_	
202-772	40462-40473	overexpress	_	
202-773	40474-40478	TSPO	_	
202-774	40479-40482	and	_	
202-775	40483-40486	are	_	
202-776	40487-40495	detected	_	
202-777	40496-40498	by	_	
202-778	40499-40503	TSPO	_	
202-779	40504-40512	positron	_	
202-780	40513-40521	emission	_	
202-781	40522-40532	tomography	_	
202-782	40533-40540	imaging	_	
202-783	40541-40558	Endotoxin-induced	_	
202-784	40559-40567	systemic	_	
202-785	40568-40580	inflammation	_	
202-786	40581-40590	activates	_	
202-787	40591-40600	microglia	_	
202-788	40600-40601	:	_	
202-789	40602-40603	[	_	
202-790	40603-40606	11C	_	
202-791	40606-40607	]	_	
202-792	40607-40612	PBR28	_	
202-793	40613-40621	positron	_	
202-794	40622-40630	emission	_	
202-795	40631-40641	tomography	_	
202-796	40642-40644	in	_	
202-797	40645-40653	nonhuman	_	
202-798	40654-40662	primates	_	
202-799	40663-40681	Colony-Stimulating	_	
202-800	40682-40688	Factor	_	
202-801	40689-40690	1	_	
202-802	40691-40699	Receptor	_	
202-803	40700-40709	Signaling	_	
202-804	40710-40712	Is	_	
202-805	40713-40722	Necessary	_	
202-806	40723-40726	for	_	
202-807	40727-40736	Microglia	_	
202-808	40737-40746	Viability	_	
202-809	40746-40747	,	_	
202-810	40748-40757	Unmasking	_	
202-811	40758-40759	a	_	
202-812	40760-40769	Microglia	_	
202-813	40770-40780	Progenitor	_	
202-814	40781-40785	Cell	_	
202-815	40786-40788	in	_	
202-816	40789-40792	the	_	
202-817	40793-40798	Adult	_	
202-818	40799-40804	Brain	_	
202-819	40805-40811	Effect	_	
202-820	40812-40814	of	_	
202-821	40815-40818	the	_	
202-822	40819-40834	myeloperoxidase	_	
202-823	40835-40844	inhibitor	_	
202-824	40845-40852	AZD3241	_	
202-825	40853-40855	on	_	
202-826	40856-40865	microglia	_	
202-827	40865-40866	:	_	
202-828	40867-40868	a	_	
202-829	40869-40872	PET	_	
202-830	40873-40878	study	_	
202-831	40879-40881	in	_	
202-832	40882-40891	Parkinson	_	
202-833	40891-40892	’	_	
202-834	40892-40893	s	_	
202-835	40894-40901	disease	_	
202-836	40902-40917	Methamphetamine	_	
202-837	40918-40924	causes	_	
202-838	40925-40935	microglial	_	
202-839	40936-40946	activation	_	
202-840	40947-40949	in	_	
202-841	40950-40953	the	_	
202-842	40954-40960	brains	_	
202-843	40961-40963	of	_	
202-844	40964-40969	human	_	
202-845	40970-40977	abusers	_	
202-846	40978-40985	Comment	_	
202-847	40986-40988	on	_	
202-848	40989-40997	Analyses	_	
202-849	40998-41001	and	_	
202-850	41002-41013	Conclusions	_	
202-851	41014-41016	of	_	
202-852	41017-41018	“	_	
202-853	41018-41028	Microglial	_	
202-854	41029-41037	Activity	_	
202-855	41038-41040	in	_	
202-856	41041-41047	People	_	
202-857	41048-41050	at	_	
202-858	41051-41056	Ultra	_	
202-859	41057-41061	High	_	
202-860	41062-41066	Risk	_	
202-861	41067-41069	of	_	
202-862	41070-41079	Psychosis	_	
202-863	41080-41083	and	_	
202-864	41084-41086	in	_	
202-865	41087-41100	Schizophrenia	_	
202-866	41100-41101	:	_	
202-867	41102-41104	An	_	
202-868	41105-41106	[	_	
202-869	41106-41109	11C	_	
202-870	41109-41110	]	_	
202-871	41110-41115	PBR28	_	
202-872	41116-41119	PET	_	
202-873	41120-41125	Brain	_	
202-874	41126-41133	Imaging	_	
202-875	41134-41139	Study	_	
202-876	41139-41140	”	_	
202-877	41141-41148	Cocaine	_	
202-878	41149-41154	abuse	_	
202-879	41155-41157	in	_	
202-880	41158-41164	humans	_	
202-881	41165-41167	is	_	
202-882	41168-41171	not	_	
202-883	41172-41182	associated	_	
202-884	41183-41187	with	_	
202-885	41188-41197	increased	_	
202-886	41198-41208	microglial	_	
202-887	41209-41219	activation	_	
202-888	41219-41220	:	_	
202-889	41221-41223	an	_	
202-890	41224-41226	18	_	
202-891	41226-41227	-	_	
202-892	41227-41230	kDa	_	
202-893	41231-41243	translocator	_	
202-894	41244-41251	protein	_	
202-895	41252-41260	positron	_	
202-896	41261-41269	emission	_	
202-897	41270-41280	tomography	_	
202-898	41281-41288	imaging	_	
202-899	41289-41294	study	_	
202-900	41295-41299	with	_	
202-901	41300-41301	[	_	
202-902	41301-41304	11C	_	
202-903	41304-41305	]	_	
202-904	41305-41310	PBR28	_	
202-905	41311-41319	Nicotine	_	
202-906	41320-41328	inhibits	_	
202-907	41329-41339	microglial	_	
202-908	41340-41353	proliferation	_	
202-909	41354-41357	and	_	
202-910	41358-41360	is	_	
202-911	41361-41376	neuroprotective	_	
202-912	41377-41379	in	_	
202-913	41380-41386	global	_	
202-914	41387-41395	ischemia	_	
202-915	41396-41400	rats	_	
202-916	41401-41413	Inflammation	_	
202-917	41414-41417	and	_	
202-918	41418-41427	oxidative	_	
202-919	41428-41434	stress	_	
202-920	41435-41442	induced	_	
202-921	41443-41445	by	_	
202-922	41446-41455	cigarette	_	
202-923	41456-41461	smoke	_	
202-924	41462-41464	in	_	
202-925	41465-41470	Lewis	_	
202-926	41471-41475	Rats	_	
202-927	41476-41486	Microglial	_	
202-928	41487-41495	Activity	_	
202-929	41496-41498	in	_	
202-930	41499-41505	People	_	
202-931	41506-41508	at	_	
202-932	41509-41514	Ultra	_	
202-933	41515-41519	High	_	
202-934	41520-41524	Risk	_	
202-935	41525-41527	of	_	
202-936	41528-41537	Psychosis	_	
202-937	41538-41541	and	_	
202-938	41542-41544	in	_	
202-939	41545-41558	Schizophrenia	_	
202-940	41558-41559	:	_	
202-941	41560-41562	An	_	
202-942	41563-41564	[	_	
202-943	41564-41567	11C	_	
202-944	41567-41568	]	_	
202-945	41568-41573	PBR28	_	
202-946	41574-41577	PET	_	
202-947	41578-41583	Brain	_	
202-948	41584-41591	Imaging	_	
202-949	41592-41597	Study	_	
202-950	41598-41606	Regional	_	
202-951	41607-41612	brain	_	
202-952	41613-41625	distribution	_	
202-953	41626-41628	of	_	
202-954	41629-41641	translocator	_	
202-955	41642-41649	protein	_	
202-956	41650-41655	using	_	
202-957	41656-41657	[	_	
202-958	41657-41660	11C	_	
202-959	41660-41661	]	_	
202-960	41661-41664	DPA	_	
202-961	41664-41665	-	_	
202-962	41665-41668	713	_	
202-963	41669-41672	PET	_	
202-964	41673-41675	in	_	
202-965	41676-41687	individuals	_	
202-966	41688-41696	infected	_	
202-967	41697-41701	with	_	
202-968	41702-41705	HIV	_	
202-969	41706-41714	Evidence	_	
202-970	41715-41718	for	_	
202-971	41719-41724	brain	_	
202-972	41725-41730	glial	_	
202-973	41731-41741	activation	_	
202-974	41742-41744	in	_	
202-975	41745-41752	chronic	_	
202-976	41753-41757	pain	_	
202-977	41758-41766	patients	_	
202-978	41767-41774	Alcohol	_	
202-979	41774-41775	:	_	
202-980	41776-41783	effects	_	
202-981	41784-41786	on	_	
202-982	41787-41802	neurobehavioral	_	
202-983	41803-41812	functions	_	
202-984	41813-41816	and	_	
202-985	41817-41820	the	_	
202-986	41821-41826	brain	_	
202-987	41827-41833	Effect	_	
202-988	41834-41836	of	_	
202-989	41837-41842	brain	_	
202-990	41843-41852	structure	_	
202-991	41852-41853	,	_	
202-992	41854-41859	brain	_	
202-993	41860-41868	function	_	
202-994	41868-41869	,	_	
202-995	41870-41873	and	_	
202-996	41874-41879	brain	_	
202-997	41880-41892	connectivity	_	
202-998	41893-41895	on	_	
202-999	41896-41903	relapse	_	
202-1000	41904-41906	in	_	
202-1001	41907-41924	alcohol-dependent	_	
202-1002	41925-41933	patients	_	
202-1003	41934-41942	Cortical	_	
202-1004	41943-41947	gray	_	
202-1005	41948-41954	matter	_	
202-1006	41955-41959	loss	_	
202-1007	41960-41962	in	_	
202-1008	41963-41978	treatment-naive	_	
202-1009	41979-41986	alcohol	_	
202-1010	41987-41996	dependent	_	
202-1011	41997-42008	individuals	_	
202-1012	42009-42019	Production	_	
202-1013	42020-42022	of	_	
202-1014	42023-42035	inflammatory	_	
202-1015	42036-42045	cytokines	_	
202-1016	42046-42048	by	_	
202-1017	42049-42059	peripheral	_	
202-1018	42060-42065	blood	_	
202-1019	42066-42075	monocytes	_	
202-1020	42076-42078	in	_	
202-1021	42079-42086	chronic	_	
202-1022	42087-42097	alcoholism	_	
202-1023	42097-42098	:	_	
202-1024	42099-42111	relationship	_	
202-1025	42112-42116	with	_	
202-1026	42117-42124	ethanol	_	
202-1027	42125-42131	intake	_	
202-1028	42132-42135	and	_	
202-1029	42136-42141	liver	_	
202-1030	42142-42149	disease	_	
202-1031	42150-42154	Role	_	
202-1032	42155-42157	of	_	
202-1033	42158-42170	inflammatory	_	
202-1034	42171-42179	pathways	_	
202-1035	42179-42180	,	_	
202-1036	42181-42186	blood	_	
202-1037	42187-42198	mononuclear	_	
202-1038	42199-42204	cells	_	
202-1039	42204-42205	,	_	
202-1040	42206-42209	and	_	
202-1041	42210-42221	gut-derived	_	
202-1042	42222-42231	bacterial	_	
202-1043	42232-42240	products	_	
202-1044	42241-42243	in	_	
202-1045	42244-42251	alcohol	_	
202-1046	42252-42262	dependence	_	
202-1047	42263-42267	Role	_	
202-1048	42268-42270	of	_	
202-1049	42271-42283	translocator	_	
202-1050	42284-42291	protein	_	
202-1051	42292-42299	density	_	
202-1052	42299-42300	,	_	
202-1053	42301-42302	a	_	
202-1054	42303-42309	marker	_	
202-1055	42310-42312	of	_	
202-1056	42313-42330	neuroinflammation	_	
202-1057	42330-42331	,	_	
202-1058	42332-42334	in	_	
202-1059	42335-42338	the	_	
202-1060	42339-42344	brain	_	
202-1061	42345-42351	during	_	
202-1062	42352-42357	major	_	
202-1063	42358-42368	depressive	_	
202-1064	42369-42377	episodes	_	
202-1065	42378-42384	Levels	_	
202-1066	42385-42387	of	_	
202-1067	42388-42397	activated	_	
202-1068	42398-42407	microglia	_	
202-1069	42408-42411	are	_	
202-1070	42412-42417	lower	_	
202-1071	42418-42420	in	_	
202-1072	42421-42428	alcohol	_	
202-1073	42429-42438	dependent	_	
202-1074	42439-42447	subjects	_	
202-1075	42448-42449	(	_	
202-1076	42449-42450	n	_	
202-1077	42450-42451	=	_	
202-1078	42451-42453	15	_	
202-1079	42453-42454	;	_	
202-1080	42455-42459	open	_	
202-1081	42460-42465	green	_	
202-1082	42466-42473	circles	_	
202-1083	42473-42474	)	_	
202-1084	42475-42483	compared	_	
202-1085	42484-42486	to	_	
202-1086	42487-42494	healthy	_	
202-1087	42495-42503	controls	_	
202-1088	42504-42505	(	_	
202-1089	42505-42506	n	_	
202-1090	42506-42507	=	_	
202-1091	42507-42509	15	_	
202-1092	42509-42510	;	_	
202-1093	42511-42517	closed	_	
202-1094	42518-42522	blue	_	
202-1095	42523-42531	diamonds	_	
202-1096	42531-42532	)	_	
202-1097	42532-42533	.	_	

#Text=Partial-volume corrected [11C]PBR28 VT values were adjusted for rs6971 genotype for visualization purposes by adding the genotype coefficient determined by the mixed model to the measured [11C]PBR28 VT value for Medium-Affinity-Binders.
203-1	42534-42548	Partial-volume	_	
203-2	42549-42558	corrected	_	
203-3	42559-42560	[	_	
203-4	42560-42563	11C	_	
203-5	42563-42564	]	_	
203-6	42564-42569	PBR28	_	
203-7	42570-42572	VT	_	
203-8	42573-42579	values	_	
203-9	42580-42584	were	_	
203-10	42585-42593	adjusted	_	
203-11	42594-42597	for	_	
203-12	42598-42604	rs6971	_	
203-13	42605-42613	genotype	_	
203-14	42614-42617	for	_	
203-15	42618-42631	visualization	_	
203-16	42632-42640	purposes	_	
203-17	42641-42643	by	_	
203-18	42644-42650	adding	_	
203-19	42651-42654	the	_	
203-20	42655-42663	genotype	_	
203-21	42664-42675	coefficient	_	
203-22	42676-42686	determined	_	
203-23	42687-42689	by	_	
203-24	42690-42693	the	_	
203-25	42694-42699	mixed	_	
203-26	42700-42705	model	_	
203-27	42706-42708	to	_	
203-28	42709-42712	the	_	
203-29	42713-42721	measured	_	
203-30	42722-42723	[	_	
203-31	42723-42726	11C	_	
203-32	42726-42727	]	_	
203-33	42727-42732	PBR28	_	
203-34	42733-42735	VT	_	
203-35	42736-42741	value	_	
203-36	42742-42745	for	_	
203-37	42746-42769	Medium-Affinity-Binders	_	
203-38	42769-42770	.	_	

#Text=Regions shown include cerebellum (CB), frontal cortex (FC), hippocampus (HP), and striatum (ST).
204-1	42771-42778	Regions	_	
204-2	42779-42784	shown	_	
204-3	42785-42792	include	_	
204-4	42793-42803	cerebellum	_	
204-5	42804-42805	(	_	
204-6	42805-42807	CB	_	
204-7	42807-42808	)	_	
204-8	42808-42809	,	_	
204-9	42810-42817	frontal	_	
204-10	42818-42824	cortex	_	
204-11	42825-42826	(	_	
204-12	42826-42828	FC	_	
204-13	42828-42829	)	_	
204-14	42829-42830	,	_	
204-15	42831-42842	hippocampus	_	
204-16	42843-42844	(	_	
204-17	42844-42846	HP	_	
204-18	42846-42847	)	_	
204-19	42847-42848	,	_	
204-20	42849-42852	and	_	
204-21	42853-42861	striatum	_	
204-22	42862-42863	(	_	
204-23	42863-42865	ST	_	
204-24	42865-42866	)	_	
204-25	42866-42867	.	_	

#Text=Solid lines indicate group mean. * indicates p<0.05. ^ indicates 0.05<p<0.10.
205-1	42868-42873	Solid	_	
205-2	42874-42879	lines	_	
205-3	42880-42888	indicate	_	
205-4	42889-42894	group	_	
205-5	42895-42899	mean	_	
205-6	42899-42900	.	_	
205-7	42901-42902	*	_	
205-8	42903-42912	indicates	_	
205-9	42913-42914	p	_	
205-10	42914-42915	<	_	
205-11	42915-42919	0.05	_	
205-12	42919-42920	.	_	
205-13	42921-42922	^	_	
205-14	42923-42932	indicates	_	
205-15	42933-42937	0.05	_	
205-16	42937-42938	<	_	
205-17	42938-42939	p	_	
205-18	42939-42940	<	_	
205-19	42940-42944	0.10	_	
205-20	42944-42945	.	_	

#Text=Average levels of activated microglia are lower in alcohol dependent subjects (top) compared to healthy controls (middle) as illustrated by average parametric images of genotype-adjusted [11C]PBR28 VT values (scale shown on right in mL/cm3).
206-1	42946-42953	Average	_	
206-2	42954-42960	levels	_	
206-3	42961-42963	of	_	
206-4	42964-42973	activated	_	
206-5	42974-42983	microglia	_	
206-6	42984-42987	are	_	
206-7	42988-42993	lower	_	
206-8	42994-42996	in	_	
206-9	42997-43004	alcohol	_	
206-10	43005-43014	dependent	_	
206-11	43015-43023	subjects	_	
206-12	43024-43025	(	_	
206-13	43025-43028	top	_	
206-14	43028-43029	)	_	
206-15	43030-43038	compared	_	
206-16	43039-43041	to	_	
206-17	43042-43049	healthy	_	
206-18	43050-43058	controls	_	
206-19	43059-43060	(	_	
206-20	43060-43066	middle	_	
206-21	43066-43067	)	_	
206-22	43068-43070	as	_	
206-23	43071-43082	illustrated	_	
206-24	43083-43085	by	_	
206-25	43086-43093	average	_	
206-26	43094-43104	parametric	_	
206-27	43105-43111	images	_	
206-28	43112-43114	of	_	
206-29	43115-43132	genotype-adjusted	_	
206-30	43133-43134	[	_	
206-31	43134-43137	11C	_	
206-32	43137-43138	]	_	
206-33	43138-43143	PBR28	_	
206-34	43144-43146	VT	_	
206-35	43147-43153	values	_	
206-36	43154-43155	(	_	
206-37	43155-43160	scale	_	
206-38	43161-43166	shown	_	
206-39	43167-43169	on	_	
206-40	43170-43175	right	_	
206-41	43176-43178	in	_	
206-42	43179-43181	mL	_	
206-43	43181-43182	/	_	
206-44	43182-43185	cm3	_	
206-45	43185-43186	)	_	
206-46	43186-43187	.	_	

#Text=An MRI image is shown at bottom for anatomical reference.
207-1	43188-43190	An	_	
207-2	43191-43194	MRI	_	
207-3	43195-43200	image	_	
207-4	43201-43203	is	_	
207-5	43204-43209	shown	_	
207-6	43210-43212	at	_	
207-7	43213-43219	bottom	_	
207-8	43220-43223	for	_	
207-9	43224-43234	anatomical	_	
207-10	43235-43244	reference	_	
207-11	43244-43245	.	_	

#Text=Relationships between behavioral drinking characteristics and levels of activated microglia.
208-1	43246-43259	Relationships	_	
208-2	43260-43267	between	_	
208-3	43268-43278	behavioral	_	
208-4	43279-43287	drinking	_	
208-5	43288-43303	characteristics	_	
208-6	43304-43307	and	_	
208-7	43308-43314	levels	_	
208-8	43315-43317	of	_	
208-9	43318-43327	activated	_	
208-10	43328-43337	microglia	_	
208-11	43337-43338	.	_	

#Text=Figures A and B show the illustrative region of cerebellum for significant negative relationships found with Alcohol Dependence Scale (A, p=0.035) including all subjects, and drinks per day over the previous month reported with TLFB (B, p=0.015) when the heaviest drinking subject was omitted (distinguished by open symbol).
209-1	43339-43346	Figures	_	
209-2	43347-43348	A	_	
209-3	43349-43352	and	_	
209-4	43353-43354	B	_	
209-5	43355-43359	show	_	
209-6	43360-43363	the	_	
209-7	43364-43376	illustrative	_	
209-8	43377-43383	region	_	
209-9	43384-43386	of	_	
209-10	43387-43397	cerebellum	_	
209-11	43398-43401	for	_	
209-12	43402-43413	significant	_	
209-13	43414-43422	negative	_	
209-14	43423-43436	relationships	_	
209-15	43437-43442	found	_	
209-16	43443-43447	with	_	
209-17	43448-43455	Alcohol	_	
209-18	43456-43466	Dependence	_	
209-19	43467-43472	Scale	_	
209-20	43473-43474	(	_	
209-21	43474-43475	A	_	
209-22	43475-43476	,	_	
209-23	43477-43478	p	_	
209-24	43478-43479	=	_	
209-25	43479-43484	0.035	_	
209-26	43484-43485	)	_	
209-27	43486-43495	including	_	
209-28	43496-43499	all	_	
209-29	43500-43508	subjects	_	
209-30	43508-43509	,	_	
209-31	43510-43513	and	_	
209-32	43514-43520	drinks	_	
209-33	43521-43524	per	_	
209-34	43525-43528	day	_	
209-35	43529-43533	over	_	
209-36	43534-43537	the	_	
209-37	43538-43546	previous	_	
209-38	43547-43552	month	_	
209-39	43553-43561	reported	_	
209-40	43562-43566	with	_	
209-41	43567-43571	TLFB	_	
209-42	43572-43573	(	_	
209-43	43573-43574	B	_	
209-44	43574-43575	,	_	
209-45	43576-43577	p	_	
209-46	43577-43578	=	_	
209-47	43578-43583	0.015	_	
209-48	43583-43584	)	_	
209-49	43585-43589	when	_	
209-50	43590-43593	the	_	
209-51	43594-43602	heaviest	_	
209-52	43603-43611	drinking	_	
209-53	43612-43619	subject	_	
209-54	43620-43623	was	_	
209-55	43624-43631	omitted	_	
209-56	43632-43633	(	_	
209-57	43633-43646	distinguished	_	
209-58	43647-43649	by	_	
209-59	43650-43654	open	_	
209-60	43655-43661	symbol	_	
209-61	43661-43662	)	_	
209-62	43662-43663	.	_	

#Text=C summarizes the fitted slope, R2 value, and p-value are shown for each relationship investigated. * indicates p<0.05. ^ indicates 0.05<p<0.10.
210-1	43664-43665	C	_	
210-2	43666-43676	summarizes	_	
210-3	43677-43680	the	_	
210-4	43681-43687	fitted	_	
210-5	43688-43693	slope	_	
210-6	43693-43694	,	_	
210-7	43695-43697	R2	_	
210-8	43698-43703	value	_	
210-9	43703-43704	,	_	
210-10	43705-43708	and	_	
210-11	43709-43716	p-value	_	
210-12	43717-43720	are	_	
210-13	43721-43726	shown	_	
210-14	43727-43730	for	_	
210-15	43731-43735	each	_	
210-16	43736-43748	relationship	_	
210-17	43749-43761	investigated	_	
210-18	43761-43762	.	_	
210-19	43763-43764	*	_	
210-20	43765-43774	indicates	_	
210-21	43775-43776	p	_	
210-22	43776-43777	<	_	
210-23	43777-43781	0.05	_	
210-24	43781-43782	.	_	
210-25	43783-43784	^	_	
210-26	43785-43794	indicates	_	
210-27	43795-43799	0.05	_	
210-28	43799-43800	<	_	
210-29	43800-43801	p	_	
210-30	43801-43802	<	_	
210-31	43802-43806	0.10	_	
210-32	43806-43807	.	_	

#Text=Lipopolysaccharide (LPS) induced release of cytokines in alcohol dependent subjects (n=9; green solid bars) compared to healthy controls (n=8; blue hatched bars).
211-1	43808-43826	Lipopolysaccharide	_	
211-2	43827-43828	(	_	
211-3	43828-43831	LPS	_	
211-4	43831-43832	)	_	
211-5	43833-43840	induced	_	
211-6	43841-43848	release	_	
211-7	43849-43851	of	_	
211-8	43852-43861	cytokines	_	
211-9	43862-43864	in	_	
211-10	43865-43872	alcohol	_	
211-11	43873-43882	dependent	_	
211-12	43883-43891	subjects	_	
211-13	43892-43893	(	_	
211-14	43893-43894	n	_	
211-15	43894-43895	=	_	
211-16	43895-43896	9	_	
211-17	43896-43897	;	_	
211-18	43898-43903	green	_	
211-19	43904-43909	solid	_	
211-20	43910-43914	bars	_	
211-21	43914-43915	)	_	
211-22	43916-43924	compared	_	
211-23	43925-43927	to	_	
211-24	43928-43935	healthy	_	
211-25	43936-43944	controls	_	
211-26	43945-43946	(	_	
211-27	43946-43947	n	_	
211-28	43947-43948	=	_	
211-29	43948-43949	8	_	
211-30	43949-43950	;	_	
211-31	43951-43955	blue	_	
211-32	43956-43963	hatched	_	
211-33	43964-43968	bars	_	
211-34	43968-43969	)	_	
211-35	43969-43970	.	_	

#Text=The finding was significant for pro-inflammatory cytokines interleukin (IL)-8 (A; p=0.031) and IL-6 (B; p=0.043).
212-1	43971-43974	The	_	
212-2	43975-43982	finding	_	
212-3	43983-43986	was	_	
212-4	43987-43998	significant	_	
212-5	43999-44002	for	_	
212-6	44003-44019	pro-inflammatory	_	
212-7	44020-44029	cytokines	_	
212-8	44030-44041	interleukin	_	
212-9	44042-44043	(	_	
212-10	44043-44045	IL	_	
212-11	44045-44046	)	_	
212-12	44046-44047	-	_	
212-13	44047-44048	8	_	
212-14	44049-44050	(	_	
212-15	44050-44051	A	_	
212-16	44051-44052	;	_	
212-17	44053-44054	p	_	
212-18	44054-44055	=	_	
212-19	44055-44060	0.031	_	
212-20	44060-44061	)	_	
212-21	44062-44065	and	_	
212-22	44066-44068	IL	_	
212-23	44068-44069	-	_	
212-24	44069-44070	6	_	
212-25	44071-44072	(	_	
212-26	44072-44073	B	_	
212-27	44073-44074	;	_	
212-28	44075-44076	p	_	
212-29	44076-44077	=	_	
212-30	44077-44082	0.043	_	
212-31	44082-44083	)	_	
212-32	44083-44084	.	_	

#Text=Other pro-inflammatory cytokines examined include IL-1β (C) and tissue necrosis factor (TNF)-α (D).
213-1	44085-44090	Other	_	
213-2	44091-44107	pro-inflammatory	_	
213-3	44108-44117	cytokines	_	
213-4	44118-44126	examined	_	
213-5	44127-44134	include	_	
213-6	44135-44137	IL	_	
213-7	44137-44138	-	_	
213-8	44138-44140	1β	_	
213-9	44141-44142	(	_	
213-10	44142-44143	C	_	
213-11	44143-44144	)	_	
213-12	44145-44148	and	_	
213-13	44149-44155	tissue	_	
213-14	44156-44164	necrosis	_	
213-15	44165-44171	factor	_	
213-16	44172-44173	(	_	
213-17	44173-44176	TNF	_	
213-18	44176-44177	)	_	
213-19	44177-44178	-	_	
213-20	44178-44179	α	_	
213-21	44180-44181	(	_	
213-22	44181-44182	D	_	
213-23	44182-44183	)	_	
213-24	44183-44184	.	_	

#Text=Anti-inflammatory cytokines examined include interleukin (IL)-10 (E) and IL-4 (F).
214-1	44185-44202	Anti-inflammatory	_	
214-2	44203-44212	cytokines	_	
214-3	44213-44221	examined	_	
214-4	44222-44229	include	_	
214-5	44230-44241	interleukin	_	
214-6	44242-44243	(	_	
214-7	44243-44245	IL	_	
214-8	44245-44246	)	_	
214-9	44246-44247	-	_	
214-10	44247-44249	10	_	
214-11	44250-44251	(	_	
214-12	44251-44252	E	_	
214-13	44252-44253	)	_	
214-14	44254-44257	and	_	
214-15	44258-44260	IL	_	
214-16	44260-44261	-	_	
214-17	44261-44262	4	_	
214-18	44263-44264	(	_	
214-19	44264-44265	F	_	
214-20	44265-44266	)	_	
214-21	44266-44267	.	_	

#Text=Graphs show fold-change of cytokine expression of LPS-stimulated monocytes relative to non-stimulated monocytes.
215-1	44268-44274	Graphs	_	
215-2	44275-44279	show	_	
215-3	44280-44291	fold-change	_	
215-4	44292-44294	of	_	
215-5	44295-44303	cytokine	_	
215-6	44304-44314	expression	_	
215-7	44315-44317	of	_	
215-8	44318-44332	LPS-stimulated	_	
215-9	44333-44342	monocytes	_	
215-10	44343-44351	relative	_	
215-11	44352-44354	to	_	
215-12	44355-44369	non-stimulated	_	
215-13	44370-44379	monocytes	_	
215-14	44379-44380	.	_	

#Text=Error bars indicate standard error of the mean. * indicates p<0.05.
216-1	44381-44386	Error	_	
216-2	44387-44391	bars	_	
216-3	44392-44400	indicate	_	
216-4	44401-44409	standard	_	
216-5	44410-44415	error	_	
216-6	44416-44418	of	_	
216-7	44419-44422	the	_	
216-8	44423-44427	mean	_	
216-9	44427-44428	.	_	
216-10	44429-44430	*	_	
216-11	44431-44440	indicates	_	
216-12	44441-44442	p	_	
216-13	44442-44443	<	_	
216-14	44443-44447	0.05	_	
216-15	44447-44448	.	_	

#Text=Subject Demographics and Scanning Parameters
#Text=\tAlcohol Dependent n=15\tHealthy Control n=15\t \tAge\t39.9±9.7\t35.0±11.6\t \tSex\t11 M; 4F\t11 M; 4F\t \tDrinks per Day\t6±3\t1±1\t \tYears Alcohol Dependence\t22±10\tN/A\t \trs6971 Genotype\t8 HAB; 7 MAB\t8 HAB; 7 MAB\t \tInjected Dose (MBq)\t496±197\t609±123\t \tInjected Mass (μg)\t1.1±1.9\t2.3±2.5\t \tfP (%)\t2.7±1.1\t2.4±0.8
217-1	44449-44456	Subject	_	
217-2	44457-44469	Demographics	_	
217-3	44470-44473	and	_	
217-4	44474-44482	Scanning	_	
217-5	44483-44493	Parameters	_	
217-6	44495-44502	Alcohol	_	
217-7	44503-44512	Dependent	_	
217-8	44513-44514	n	_	
217-9	44514-44515	=	_	
217-10	44515-44517	15	_	
217-11	44518-44525	Healthy	_	
217-12	44526-44533	Control	_	
217-13	44534-44535	n	_	
217-14	44535-44536	=	_	
217-15	44536-44538	15	_	
217-16	44541-44544	Age	_	
217-17	44545-44549	39.9	_	
217-18	44549-44550	±	_	
217-19	44550-44553	9.7	_	
217-20	44554-44558	35.0	_	
217-21	44558-44559	±	_	
217-22	44559-44563	11.6	_	
217-23	44566-44569	Sex	_	
217-24	44570-44572	11	_	
217-25	44573-44574	M	_	
217-26	44574-44575	;	_	
217-27	44576-44578	4F	_	
217-28	44579-44581	11	_	
217-29	44582-44583	M	_	
217-30	44583-44584	;	_	
217-31	44585-44587	4F	_	
217-32	44590-44596	Drinks	_	
217-33	44597-44600	per	_	
217-34	44601-44604	Day	_	
217-35	44605-44606	6	_	
217-36	44606-44607	±	_	
217-37	44607-44608	3	_	
217-38	44609-44610	1	_	
217-39	44610-44611	±	_	
217-40	44611-44612	1	_	
217-41	44615-44620	Years	_	
217-42	44621-44628	Alcohol	_	
217-43	44629-44639	Dependence	_	
217-44	44640-44642	22	_	
217-45	44642-44643	±	_	
217-46	44643-44645	10	_	
217-47	44646-44647	N	_	
217-48	44647-44648	/	_	
217-49	44648-44649	A	_	
217-50	44652-44658	rs6971	_	
217-51	44659-44667	Genotype	_	
217-52	44668-44669	8	_	
217-53	44670-44673	HAB	_	
217-54	44673-44674	;	_	
217-55	44675-44676	7	_	
217-56	44677-44680	MAB	_	
217-57	44681-44682	8	_	
217-58	44683-44686	HAB	_	
217-59	44686-44687	;	_	
217-60	44688-44689	7	_	
217-61	44690-44693	MAB	_	
217-62	44696-44704	Injected	_	
217-63	44705-44709	Dose	_	
217-64	44710-44711	(	_	
217-65	44711-44714	MBq	_	
217-66	44714-44715	)	_	
217-67	44716-44719	496	_	
217-68	44719-44720	±	_	
217-69	44720-44723	197	_	
217-70	44724-44727	609	_	
217-71	44727-44728	±	_	
217-72	44728-44731	123	_	
217-73	44734-44742	Injected	_	
217-74	44743-44747	Mass	_	
217-75	44748-44749	(	_	
217-76	44749-44751	μg	_	
217-77	44751-44752	)	_	
217-78	44753-44756	1.1	_	
217-79	44756-44757	±	_	
217-80	44757-44760	1.9	_	
217-81	44761-44764	2.3	_	
217-82	44764-44765	±	_	
217-83	44765-44768	2.5	_	
217-84	44771-44773	fP	_	
217-85	44774-44775	(	_	
217-86	44775-44776	%	_	
217-87	44776-44777	)	_	
217-88	44778-44781	2.7	_	
217-89	44781-44782	±	_	
217-90	44782-44785	1.1	_	
217-91	44786-44789	2.4	_	
217-92	44789-44790	±	_	
217-93	44790-44793	0.8	_	
